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Abstract 
A major problem in prostate cancer is the high relapse rate post therapy. This is believed 
to be due to the presence of a small number of prostate cancer stem cells within a tumour. 
Tumour initiation, maintenance and spreading have been attributed to this subpopulation 
of tumour cells. 
Wnt activity and !-catenin signalling have been associated with different types of cancer 
and microarray data from our laboratory highlighted upregulation of members of the Wnt 
pathway in primary prostate cancer stem cells. Therefore, the aim of this study was to 
determine the consequences of !-catenin downregulation on prostate cancer stem cell fate 
and to identify whether aberrant Wnt signalling and !-catenin levels and location play a 
role in prostate tumour initiation, growth and dissemination. 
Our strategy was to develop and use lentiviral vectors containing short-hairpin RNAs to 
downregulate !-catenin in prostate cancer cell lines and primary, cultured cells. 
This work shows that PC-3 prostate cancer cells, infected with !-catenin-shRNA-
lentiviruses (PC-3v), displayed a significant downregulation of !-catenin at the protein 
level. These cells also exhibited reduced growth in vitro as well as a significantly lower 
invasiveness. In vivo, PC-3v cells showed slower tumour onset in immunocompromised 
mice. To assess Wnt activity in individual cells the localisation of !-catenin in prostate 
cancer cell lines and cultured primary cells was determined. Cells were stained for active, 
dephosphorylated !-catenin and various forms of phosphorylated !-catenin using 
immunofluorescence. Cultured, primary prostate cells were infected with a GFP 
containing lentivirus to establish an optimal infection protocol for primary cells. Primary 
cells were also infected with shRNA-containing viruses and changes in cell morphology 
were observed. 
This is the first study to examine the biological consequences of !-catenin downregulation 
by shRNAs in prostate cancer cell lines and prostate primary cells. 
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1. Introduction 
1.1 Prostate anatomy and prostatic disease 
1.1.1 Prostate development and morphology 
The prostate develops from the urogenital sinus (UGS), which consists of an endodermally 
derived epithelial layer and a mesodermally derived mesenchymal part. Initially, solid 
epithelial buds form as outgrowths of the UGS (Thomson and Marker, 2006). The 
development of the human and rodent prostate is characterised by branching 
morphogenesis, which is defined by epithelial invasion of the surrounding mesenchyme 
and by the elongation and branching of the developing ducts to form a complex secretory 
network. 
The prostate is a structurally complex exocrine gland of the male reproductive tract in 
mammals, which undergoes epithelial and mesenchymal (stromal) differentiation during 
development (Cunha et al., 2004). 
In early embryonic development, all vertebrates undergo an ambisexual period of sex 
differentiation where the gonads in both male and female organism are morphologically 
undifferentiated. The male genital tract develops from the Wolfian ducts and the UGS 
(Cunha et al., 1992). 
As early as the 1960s it was found that organogenesis depends on epithelial-mesenchymal 
interactions and the prostate is no exception from this rule. One of the very early 
discoveries of prostatic epithelial-mesenchymal interactions was made by Cunha in 1972. 
He showed that UGS mesenchyme (UGM), seminal vesicle mesenchyme (SVM), UGS 
epithelium (UGE) and seminal vesicle epithelium (SVE) were not able to develop 
normally if grown in isolation from each other in the presence of adult physiological 
levels of androgen. However, when the UGS compartments or the seminal vesicle 
compartments were co-cultured, normal development of the prostate and the seminal 
vesicle was observed, respectively (Cunha, 1972b). 
Growth and ductal branching are continuous processes, which extend from late foetal life 
into early adulthood (Cunha et al., 1992, Thomson and Marker, 2006) but development is 
most pronounced during the first half of gestation (Xue et al., 2001). 
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Androgenic effects on prostatic development are mediated by the androgen receptor (AR) 
through mesenchymal-epithelial interactions. It was shown that only urogenital 
mesenchyme, which expresses androgen receptor (AR), but not skin mesenchyme (no AR) 
can act as a mediator for the response of UGE to androgens and hence stimulate normal 
prostate development (Cunha, 1972a). 
In rodents, AR signals via an unidentified activating or repressing mesenchymal factor to 
the epithelium. Although studies showed controversial results, Sonic Hedgehog (Shh) 
seems to play a significant role in regulating branching morphogenesis, possibly by up-
regulating transcription in the epithelium (Donjacour and Cunha, 1993, Notini et al., 
2005), e.g. of transcription factor NKX3.1 (Bhatia-Gaur et al., 1999, Freestone et al., 
2003, Schneider et al., 2000, Tanaka et al., 2000) and the mesenchymal homeobox genes 
Hoxa13 and Hoxd13 to enhance prostatic duct formation (Podlasek et al., 1999, Warot et 
al., 1997). Mice with mutations or knockouts in these homeobox genes exhibit reduced 
size or missing of parts of the prostate and decreased branching morphogenesis (Podlasek 
et al., 1997, Podlasek et al., 1999, Warot et al., 1997). Budding and ductal branching are 
initiated after birth through epithelial–mesenchymal interactions. While Notch signalling 
can stimulate branching morphogenesis (Shou et al., 2001, Wang et al., 2004) it is 
inhibited by bone morphogenetic proteins BMP4 and BMP7, which are secreted by the 
mesenchyme (Grishina et al., 2005, Lamm et al., 2001). 
TGF! has also been shown to inhibit prostatic growth and decrease ductal tip number, 
leading to changes in branching pattern (Itoh et al., 1998, Tomlinson et al., 2004). 
Shh expression is maintained by the interaction of fibroblast growth factors FGF7 and 
FGF10, which bind to the epithelial FGF receptor 2 (Donjacour et al., 2003, Guo et al., 
1996, Huang et al., 2005, Sugimura et al., 1996). In addition, this process is regulated by a 
negative-feedback loop, as SHH is able to downregulate FGF expression (Wilhelm and 
Koopman, 2006). Furthermore, expression patterns of the developing prostate have 
implicated the importance of Activin A and Follistatin during prostate morphogenesis 
(Cancilla et al., 2001) as well as the polysaccharide component Hyaluronan and its 
receptor CD44 where it was shown that anti-CD44 antibodies were able to impair prostatic 
development (Gakunga et al., 1997, Marker et al., 2003). p63 is a key transcription factor 
which controls the differentiation of epithelial cells in the prostate and subsequently, 
smooth muscle cells form around the epithelium before lumen formation occurs (Kurita et 
al., 2004, Signoretti et al., 2000). 
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In rodents, Keratinocyte Growth Factor has been proposed as a mediator of androgens 
(Thomson et al., 1997). However, in the prostate, the androgen receptor is neither essential 
nor sufficient for the regulation of epithelial differentiation. Prior to and during bud 
formation, AR is initially only detected in the mesenchyme of the urogenital sinus, 
however it is undetectable in the developing buds (Cunha et al., 2004). 
Androgen production, which is crucial to prostate development, initiates during the 
ambisexual phase and continues until after birth. Then the androgen level falls and starts 
to increase again during puberty, when new prostate growth is initiated. Growth ceases 
once adulthood is reached but can be reinitiated in old age resulting in benign prostate 
hyperplasia (BPH) (Cunha et al., 1992).  
Most of our knowledge about prostate development is based on the rodent prostate (Figure 
1), which has been extensively studied. However, there are distinct differences between 
the rodent and human organ. One of the main morphological differences is that, rodent 
UGS forms 3-4 distinct prostatic lobes, which are absent in humans (Figures 1 and 2). 
 
Epithelial branching morphogenesis in the human prostate occurs within a solid mass of 
mesenchyme (stroma) and results in a compact, walnut-sized and - shaped organ (Figure 
2). Three zones can be identified in the human prostate, the central, transitional and 
peripheral zone which consist of three distinct sets of branching ducts (Thomson and 
Marker, 2006). 
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Figure 1: The rodent prostate 
Lobes of the adult rodent prostate (left), each with its own distinct shape. Hematoxilin and eosin 
(H&E) staining (insets, right) show histological appearance of anterior (AP), dorsolateral (DLP) and 
ventral prostate (VP) (Marker et al., 2003). 
 
 
Figure 2: The human prostate 
Zonal model of the human prostate and the differences between mouse and human prostate (Thomson 
and Marker, 2006). H&E staining of the murine prostatic duct shows that the epithelium is very 
closely linked to a smooth muscle compartment, whereas in the human prostate branched epithelial 
ducts are present which are surrounded by a solid mass of stroma. 
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Figure 3: The organisation of the prostate epithelium. 
Basal and secretory, luminal cells are illustrated in a cross-section of the prostate gland (Collins and 
Maitland, 2006). 
 
 
 
Figure 4: Schematic model of the prostate epithelium 
Proposed schematic model of the prostate epithelium containing tissue stem cells among the basal 
layer of cells. 
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In the developed prostate three phenotypically distinct epithelial cell types are present: 
Neuroendocrine, basal and luminal cells (Figures 3 and 4) (Matusik et al., 2008). One 
hypothesis suggests, that neuroendocrine cells originate from the neural crest and are 
therefore ectodermal, in contrast to basal and luminal cells which are related by a common 
endodermal precursor. However, in the other hypothesis, all three cell types share a 
common precursor and evidence for both hypotheses are still controversial (Aumuller et 
al., 1999, Marker et al., 2003, Matusik et al., 2008, Xue et al., 1998). 
Prostate epithelial cells can be identified by the distinct expression of certain cell surface 
markers. Basal cells express cytokeratins CK5 and CK14 as well as Cluster Designation 
molecule CD44 (Islam et al., 2004, Okada et al., 1992, Terpe et al., 1994) and mediate 
stromal attachment, while luminal cells express CK8 and CK18 together with Prostate 
specific antigen (PSA) and CD57 (Islam et al., 2004, Okada et al., 1992, Terpe et al., 
1994). 
Neuroendocrine cells are the least common cell type and secrete Chromogranin A, 
seratonin and neurophysin (Bonkhoff et al., 1994, Marker et al., 2003). Prostatic 
epithelium was shown to consist of two functional compartments, the luminal layer with 
fully differentiated epithelial cells showing a high apoptotic index and the basal layer with 
high proliferative capacity (De Marzo et al., 2007). This proliferative compartment is 
androgen-independent while the luminal compartment depends on androgen, in particular 
dihydrotestosterone (DHT), for survival (Foster et al., 2002, Schalken and van Leenders, 
2003). 
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1.1.2 Epidemiology of prostate cancer 
Prostate cancer is the most common cancer in males in Western countries (Figure 5) and 
incidence rates have continuingly increased over the last years (Jemal et al., 2008, Jemal et 
al., 2007, Jemal et al., 2004, Weir et al., 2003).  
Even though there are serum testing methods for prostate specific antigen (PSA) and 
improved surgical and other therapies in place, an effective cure still has to be found 
(Abate-Shen and Shen, 2000). Several risk factors have been associated with prostate 
cancer (Wigle et al., 2008). Incidence increases rapidly in men over 50 years of age and it 
peaks between 70 and 74 years (Figure 5). This makes age one of the main risk factors for 
developing prostate cancer. Prostate cancer cells have been found in most men by age 80 
according to post-mortem studies (Sakr et al., 1996). 
Due to geographic variation of incidence rates around the world, ethnicity is also 
suggested to affect the risk of developing prostate cancer. It was found that African 
Americans have a significantly higher risk than white Americans while Asian males have 
the overall lowest risk for prostate cancer (Parkin and Muir, 1992, Powell, 2007, Winter et 
al., 1999). Jones and Wenzel reported that it is 1.7 times more likely for African-American 
men to develop prostate cancer and 2-3 times more likely that these men die from the 
disease when compared to their white counterparts. A number of reasons like 
socioeconomic disparities as well as past experiences with the health-care system and 
cultural beliefs were suggested (Jones et al., 2005). These findings are backed up by data 
from UK studies where black Caribbean and black African men have a significantly 
higher risk of dying of prostate cancer (Jack et al., 2007). Asian men have a generally 
lower risk of developing the disease, however, migration studies showed that this risk can 
increase if these men move to or live in Western countries, suggesting a strong link with 
environmental risk factors (Winter et al., 1999). In a study which looked at the effects of 
race and ethnicity on PSA screening, it was found that black immigrants from the 
Caribbean were less likely to have regular, annual PSA screening performed than white 
Americans even though no difference was detected for initial screening incidence 
(Gonzalez et al., 2008) 
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Figure 5: Prostate cancer incidence 
The ten most common cancers in males in the UK, 2007 (top). Numbers of cases and age specific 
incidence rates for prostate cancer, UK, 2006 (bottom). Modified from Cancer Research UK1. 
                                                
1 http://info.cancerresearchuk.org/cancerstats (accessed 09/10/2010) 
Sarah Jakoby  PhD thesis 2010 
 22 
Within Europe the lowest rates of prostate cancer are found in south and east Europe while 
Scandinavia and northern European countries show higher rates2. Even though 
socioeconomic reasons are often suggested when looking at ethnicity and cancer-risk, 
Mouw et al. were not able to show a relation between a risk of developing prostate cancer 
and lower education levels in men in the USA (Mouw et al., 2008). 
In addition, several studies suggest that the diet in Western countries increases the risk of 
developing prostate cancer due to higher intake in alpha-linoleic acid which is contained 
in animal fat (Brouwer et al., 2004, Leitzmann et al., 2004). Amin et al. found that fish 
diets appear to reduce the risk of developing prostate cancer and at the same time, they 
were able to associate meat diets with a increased risk (Amin et al., 2008). In an analysis 
of 32 different studies van Platten et al. found that a low fat and/or vegan diet decreased 
PSA levels, however the usefulness of dietary supplements like lycopene remains 
controversial (Van Patten et al., 2008). Zlotta also pointed out the limitations when trying 
to pinpoint dietary factors to prostate cancer risk and evaluating the effectiveness of 
preventive measures (Zlotta, 2008). 
Reports that alcohol can also be considered a risk factor are controversial (Bagnardi et al., 
2001). However, in a recently performed metaanalysis, Middleton Fillmore et al. found 
that the number of drinks per day was positively associated with prostate cancer risk as 
heavier drinkers were more likely to develop the disease (Middleton Fillmore et al., 2009). 
In addition, the effects of smoking on the development of prostate cancer are still 
debatable. A recent study suggests that there is no association between smoking and 
advanced prostate cancer (Watters et al., 2009) 
In contrast to adult body mass or body growth, markers for delayed androgen action, such 
as delayed growth during puberty, have been assumed to decrease the risk for prostate 
cancer development (Giles et al., 2003a). Whitley et al. showed that anthropometric 
measurements in children were not strongly associated with adult cancer risk (Whitley et 
al., 2009). Obesity in general was found not to be a significant risk factor, however, when 
taking other clinical characteristics into account, such as PSA levels, obese men had a 
98 % increased risk (Freedland et al., 2008). 
Moreover, it was observed that, like in breast cancer, risk can increase for men with a 
history of prostate cancer among close relatives (Bruner et al., 2003). This is more 
pronounced in early-onset forms of the disease where patients are under 55 years old 
                                                
2http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/ (accessed 09/10/2010) 
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(Bratt, 2002, Bratt et al., 2002, Carter et al., 1992). Therefore it was suggested that men 
with a family history of prostate cancer might benefit from targeted prostate cancer testing 
and better risk assessment (McDowell et al., 2009). Zhang et al. also reported findings 
where a strong family risk was associated with developing other cancers after the 
treatment of the initial prostate tumour, such as bladder or colorectal cancers (Zhang et al., 
2009a). Genome-wide studies in the last years have highlighted genetic variants that cause 
a slight increase in prostate cancer risk but their contribution to a large proportion of cases 
is still under discussion (Amundadottir et al., 2006, Eeles et al., 2008, Haiman et al., 2007, 
Thomas et al., 2008, Zheng et al., 2007). 
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1.1.3 Prostate cancer development, treatment and therapeutic problems 
The majority of prostate tumours are adenocarcinomas and share common features of 
other epithelial tumours such as breast and colon cancer (Abate-Shen and Shen, 2000). 
Aberrant cell proliferation and differentiation in the prostate can lead to benign prostate 
hyperplasia (BPH, Figure 6), which later can result in malignant tumours (Hudson et al., 
2001). 
 
Figure 6: Schematic illustration of BPH3. 
Compared to normal prostate (left), benign (non-cancerous) cell proliferation causes the prostate to 
enlarge (right) from the middle part outwards. The upper part of the urethra is affected by this cell 
growth and patients experience reduced urinary flow (blue arrows). 
 
Prostate cancer is graded according to the Gleason score with 1 being normal tissue and 5 
the highest malignant grade (Gleason, 1966). A Gleason grade is assigned to each of the 
two most common areas of cancerous tissue. Both grades are added together to produce a 
Gleason score, e.g. 3+4, which is also used to define different stages of prostate cancer 
(Figures 7 and 8). 
In order to improve characterisation of low and high grade prostate tumours modifications 
to the Gleason system have been suggested (Epstein et al., 2006, Helpap and Egevad, 
2009). 
 
                                                
3 Modified from National Cancer Institute, http://www.cancer.gov (accessed on 09/10/2010). 
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Figure 7: The four stages of prostate cancer (CaP) development4. 
Stage I - Small, localised cancer inside the prostate gland with low Gleason score. Stage II - Cancer 
still located inside gland but more advanced than in stage I, a hard lump might be felt during rectal 
examination. The Gleason score can vary from 2-10. Stage III - cancer has broken through the outer 
layer of the prostate to nearby tissues, e.g. seminal vesicles. Stage IV - Metastases can be found in 
lymph nodes and/or bladder, rectum, bones, liver, or lungs. 
 
 
Figure 8: Gleason grading 
Gleason grading system for prostate adenocarcinoma as defined by differentiation pattern within a 
surgical specimen (Gleason, 1966). 
                                                
4 http://www.cancerhelp.org.uk/type/prostate-cancer/treatment/the-stages-of-prostate-cancer (accessed on 
17/03/2010) 
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De Marzo et al. suggested that prostate cancer could be caused by a combination of 
inflammation of the prostate gland and external elements such as dietary factors. They 
proposed a model where at the first stage towards the development of invasive prostate 
carcinoma, infiltration of inflammatory cells into the secretory cell layer occurs. This 
Proliferative Inflammatory Atrophy (PIA) is followed by Prostate Intraepithelial 
Neoplasia (PIN), which is a precancerous stage characterised by increased proliferation. 
The basal cell layer is still intact whereas it is lost in the invasive carcinoma stage (Figure 
9) (De Marzo et al., 2007). 
 
Figure 9: Development and progression of prostate adenocarcinoma 
(De Marzo et al., 2007) 
 
A number of inflammatory cytokines have been found in prostatic fluid of radical 
prostatectomy specimens which may be useful as prognostic or diagnostic markers in the 
future (Fujita et al., 2008). Furthermore, a number of anti-inflammatory drugs such as 
aspirin or nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) have been suggested 
as potential chemopreventive treatments (Bardia et al., 2009). 
 
Even though no single tumour suppressor gene, responsible for prostate cancer, has been 
found yet, a number of possible candidates have been discussed, including p53, RB and 
PTEN (Abate-Shen and Shen, 2000). 
As the growth of prostate tumours is androgen-dependent, the cancer is initially treated by 
androgen ablation, e.g. by using anti-androgenic drugs or surgical treatment like castration 
(Culig et al., 2005). Apart from radical prostatectomy5, external6 and internal radiotherapy 
(brachytherapy7) can also be used for therapy (MacRae et al., 2006). A number of viral 
                                                
5 http://www.cancerresearchuk.org (accessed 09/10/2010) 
6 http://www.cancerresearchuk.org (accessed 09/10/2010) 
7 http://www.cancerresearchuk.org (accessed 09/10/2010) 
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and cellular gene therapy strategies for the treatment of prostate cancer are currently under 
discussion (MacRae et al., 2006). However, at a later stage the tumours can become 
androgen-independent and often metastatic to bone (Thalmann et al., 2000), and therefore 
other therapeutic methods have to be found (Verhagen et al., 1992). 
It was proposed that the main problem with prostate cancer therapy is the lack of targeting 
the stem cell population that is thought to be tumour initiating and causes tumour growth 
(Collins et al., 2005, Collins and Maitland, 2006, Maitland et al., 2006). This could be an 
explanation for the reoccurrence of tumours, which were thought to be successfully treated 
by radiotherapy at an initial stage. Further supporting this is the fact that most stem cells 
highly express drug transporters such as the ABC transporter family and can therefore 
become resistant to chemotherapy very quickly (Dean et al., 2005). 
Taking everything into account, there is a large demand for new therapeutic methods to 
overcome the current lack of therapeutic measures for advanced stages of prostate cancer. 
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1.2 Stem cells and cancer stem cells 
1.2.1 Embryonic stem cells 
Embryonic stem cells (ES cells) have been in the focus of extensive research since their 
isolation from mice in 1981 and humans in 1998 (Evans and Kaufman, 1981, Thomson et 
al., 1998). ES cells can be isolated from the Inner Cell Mass (ICM) of a blastocyst (Figure 
10). In humans, the blastocyst stage is reached at 4 to 5 days post fertilisation. The 
blastocyst consists of the fluid-filled blastocoel, the trophoblast, a cell layer which 
surrounds the blastocoel, and the inner cell mass. ES cells are defined as undifferentiated 
cells which are able to give rise to all embryonic tissue (pluripotency) (Thomson et al., 
1998). 
 
 
Figure 10: Isolation of ES cells from ICM of the blastocyst8. 
 
Stem cells, by definition, can reproduce themselves, as well as produce daughter cells 
which then enter a pathway of differentiation. Once the daughter cells are designated for 
differentiation, they become progenitor cells (also called precursor or transit amplifying 
                                                
8 Modified from http://stemcells.nih.gov (accessed 09/10/2010) 
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cells), which proliferate before differentiation occurs, thus multiplying the amount of 
specialised cells (Ying et al., 2003). Stem cells can give rise to cells of all three germ 
layers (Figure 11). 
 
 
 
Figure 11: Pluripotency of embryonic stem cells 
Pluripotent stem cells from the ICM can give rise to cells of all three germ layers, ectoderm, 
mesoderm and endoderm.9 
 
1.2.2 Adult stem cells 
It was originally thought that adult stem cells only occur in tissue with a high turnover 
rate, however, it has become clear that most tissues contain stem cells. Adult stem cells 
(tissue specific stem cells), which are derived from ES cells, are multipotent or unipotent 
cells producing multiple types of specialised cells within their tissue or organ or only one 
type of specialised cell, respectively. Adult stem cells are thought to have an unlimited 
capacity for self-renewal and remain in an organism for life. However, they divide slowly 
                                                
9 Modified from http://stemcells.nih.gov (accessed on 09/10/2010) 
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while their progenitor cells produce the high number of differentiated cells needed for 
tissue growth and maintenance (Raff, 2003). 
Hematopoietic stem cells (HSC) were the first adult stem cells to be isolated (Spangrude 
et al., 1988) and a number of phenotypic markers have been used to isolate HSC from 
human fetal bone marrow (Baum et al., 1992). Commitment of stem cells to 
hematopoiesis can already be detected in the yolk sac, shortly after implantation. HSCs 
can differentiate into B and T lymphocytes as well as granulocytes, erythrocytes and mast 
cells (Huang and Auerbach, 1993). Isolated HCSs were able to reconstitute all blood cell 
types in lethally irradiated mice (Spangrude et al., 1988).  
 
 
Figure 12: Hematopoietic stem cell differentiation10. 
 
The development of the hematopoietic model was immensely important for the 
understanding of mammalian tissue development and maintenance (Raff, 2003). 
 
                                                
10 Modified from http://stemcells.nih.gov (accessed on 09/10/2010) 
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1.2.3 Isolation of cancer stem cells 
In recent years, stem-like cells have been isolated from a variety of cancers, such as acute 
myeloid leukaemia (AML), brain, breast, lung and prostate cancer (Table 1). 
Leukemic stem cells were detected in a population of CD34+CD38- cells and this 
subpopulation was shown to initiate human AML in NOD-SCID mice (Bonnet and Dick, 
1997). Singh et al. isolated CD133+ cells from human brain tumours, which display stem 
cell properties in vitro. The group subsequently demonstrated the ability of these cells to 
initiate tumour growth in a NOD-SCID mouse xenograft assay (Singh et al., 2003, Singh 
et al., 2004). Al-Haji and co-workers were able to identify tumorigenic cancer cells with 
CD44+CD24-/low expression from breast cancer patients. It was also shown that as few as 
100 cells of this phenotype formed tumours in mice (Al-Hajj et al., 2003). 
Bronchioaveolar stem cells, which expand in vitro and in vivo after oncogenic K-ras 
activation, were also recently identified (Kim et al., 2005a). Human prostate epithelial 
stem cells were isolated from basal cells by Collins at al. on their increased expression 
levels of "2-integrin (Collins et al., 2001). Later CD133 was identified to be a marker for 
human prostate epithelial stem cells. "2!1hi/CD133+ cells showed high proliferative 
potential in vitro and were also able to form fully differentiated acini of prostate-like 
structure in athymic nude mice (Richardson et al., 2004). 
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Breast   (Al-Hajj et al., 2003) 
CNS (Galli et al., 2004, Singh et al., 2003, Singh et al., 2004, Yuan et al., 
2004) 
Multiple Myeloma (Matsui et al., 2004) 
Melanoma  (Fang et al., 2005) 
Prostate  (Collins et al., 2005) 
HNSCC  (Prince et al., 2007) 
Colon (Dalerba et al., 2007, O'Brien et al., 2007, Ricci-Vitiani et al., 2007) 
Pancreas  (Li et al., 2007) 
Lung   (Kim et al., 2005a) 
Ovaries  (Zhang et al., 2008a) 
Cervix   (Feng et al., 2009) 
Bladder  (He et al., 2009) 
 
Table 1: Discovery of tissue and cancer stem cells 
 
 
1.2.4 Cancer stem cells in prostate cancer – targets for new therapies 
The problem of current cancer therapies is that they target the bulk of tumour cells. These 
cells are rapidly dividing and are therefore susceptible to chemotherapy. However, if the 
cancer stem cell hypothesis is true, the cancer stem cells will only divide sporadically and 
thus will not be destroyed by the anti-tumour drugs. This leads to inefficient eradication of 
the tumour and the possibility that it re-grows and subsequently forms metastasis. In 
addition, multiple drug resistance has been reported in both stem cells and cancer stem 
cells (Dean et al., 2005, Donnenberg and Donnenberg, 2005). Targeting of the cancer stem 
cell population and its subsequent manipulation to decrease or inhibit tumour growth has 
to be addressed in order to develop more effective drugs. 
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1.2.5 Signalling pathways in stem cells and cancer 
A variety of pathways that have been associated with stem cell self-renewal have 
previously been identified to be important for oncogenesis. Questions arise whether 
signalling pathways which normally regulate self-renewal in stem cells can cause tumours 
when dysregulated, and if stem cells themselves are the targets for cancer-causing 
mutations as hypothesised in the cancer stem cell hypothesis (Donnenberg and 
Donnenberg, 2005, Pardal et al., 2003, Reya et al., 2001). There are several reasons why 
the cancer stem cell hypothesis is a likely model for oncogenesis. Firstly, in a lot of 
tumours, only a small subset of cells are able to proliferate extensively (Reya et al., 2001). 
In addition, normal tissues, as well a tumours, are organised as mixed, heterogeneous 
populations of different cell types which have a large range of differentiation potentials 
and varying phenotypic appearance. It is possible, that the potential of cancers for 
mutagenic change is based on abnormal differentiation in stem cells (Reya et al., 2001). 
Furthermore, stem cells are, by definition, cells that persist in the organism for a long time 
if not for life. They are therefore more likely to accumulate the mutations, which might 
give rise to cancer. Secondly, the same signalling pathways are important for self-renewal 
of stem cells as well as tumourigenesis. Pathways which have been associated with both 
stem cell self-renewal and tumourigenesis include Oct-4, Hedgehog, Wnt, Notch and 
Bmi-1 (Reya et al., 2001). 
 
1.2.6 Oct-4, Hedgehog, Notch and Bmi-1 signalling 
Expression of the homeobox gene Oct-4 can determine the cell fate in a level-dependent 
manner. While little expression results in trophectoderm differentiation, intermediate 
levels maintain stem cells and highest levels lead to differentiation into ectoderm. If Oct-4 
expression is increased to 1.5-fold the potential of tumour formation is more than 80% as 
the amount of malignant cells is increased (Abate-Shen, 2003). 
A number of components of the Hedgehog pathway have also been associated with cancer 
development. Sonic hedgehog (SHH), for example, which is needed for normal cortical 
development and brain function in humans, induces basal cell carcinoma of the skin if 
overexpressed. Furthermore, loss of function in the two genes EXT-1 and EXT-2 resulting 
in decreased signalling in the Hh pathway, has been associated with benign bone tumours 
which frequently become malignant. Loss of function mutations in PTCH1, which 
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activates the pathway, result in a higher-than-average rate of a number of tumours, 
including cerebral medulloblastomas. In mice the occurrence of these tumours is further 
increased in p53-/- knockouts. Another component of the Hh signalling cascade which can 
be linked to a variety of cancers, including glioblastoma, endometrial and prostate cancer 
is SU(FU) (Mullor et al., 2002). During embryogenesis, testosterone-dependent SHH 
signalling is particularly important for the initiation of prostate development (Podlasek et 
al., 1999). 
Notch signalling controls inhibition of certain differentiation pathways in vertebrates and 
invertebrates by permitting cells only to enter specific differentiation pathways or to self-
renew. If constitutively activated, immortalised cell lines can be developed from 
hematopoietic cells which can give rise to myeloid or lymphoid cells (Varnum-Finney et 
al., 2000). Furthermore, Notch signalling is responsible for the maintenance of 
undifferentiated, proliferative crypt progenitor cells in the intestinal epithelium and has 
also been associated with the proliferation of adenoma cells. The pharmacological 
inhibition of the Notch pathway resulted in the conversion of the adenoma cells into 
differentiated, post-mitotic Goblet cells (van Es and Clevers, 2005). 
Another pathway suggesting a connection between stem cells and cancer is Bmi-1. It 
normally participates in hematopoietic development and is required for the maintenance of 
adult hematopoietic stem cells, but Bmi-1 can also be linked to acute myeloid leukaemia 
when dysregulated. Moreover, it was shown to be essential for self-renewal of leukaemia 
cells (Lessard and Sauvageau, 2003, Marx, 2003, Park et al., 2003). 
 
1.2.7 The Wnt signalling pathways 
The Wnt family of signalling molecules have been shown to regulate a number of 
different processes in animal development and have been demonstrated to control self-
renewal in a variety of adult tissues. Wnt was first identified as the drosophila homolog 
Wingless (Int in mouse) (Nusse et al., 1991). 
Since mutations in molecules involved in the Wnt-pathways can cause several hereditary 
diseases and mutations in adult tissues have been associated with a variety of cancers, Wnt 
signalling has been the focus of extensive research during the last years (Clevers, 2006, 
Gordon and Nusse, 2006, Klaus and Birchmeier, 2008, Nusse, 2005). Furthermore, they 
have been implicated to play an important role in tissue homeostasis in adult organisms 
(Nusse, 2005). 
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Wnt signalling molecules have been shown to have a number of different activities and 
downstream signalling pathways. One of the reasons for that is, that the Wnt family is not 
defined by functional properties but by amino acid sequence, which shows a characteristic 
cystein pattern and other conserved residues (Clevers, 2006, Gordon and Nusse, 2006, 
Klaus and Birchmeier, 2008, Nusse, 2005). 
So far, three different pathways, which can be activated through Wnt receptor activation 
have been studied: The PCP (planar cell polarity) pathway (Figure 13 a), the Wnt/Ca2+ 
pathway (Figure 13 b) and the canonical Wnt/!-catenin pathway (Figure 13 c) (Clevers, 
2006, Gordon and Nusse, 2006, Klaus and Birchmeier, 2008, Nusse, 2005). 
PCP has been defined as tissue polarization within the epithelium and PCP signalling is 
involved in vertebrate development, e.g. skin patterning and movement of mesenchymal 
cells during gastrulation. There are similarities of PCP signalling between vertebrates and 
Drosophila, where PCP has been extensively studied (Jenny and Mlodzik, 2006). 
The current model of Wnt-PCP-signalling, which does not involve !-catenin, uses two 
interlinking pathways with a presumed third one not involving Wnts as ligands (Figure 13 
a). Firstly, Wnt11 can bind to Frizzled-7, which leads to the activation of Dvl. Two 
domains of Dvl (PDZ and DEP) then mediate convergent extension (CE), a process 
defined as the regulation of body axis elongation during gastrulation (Keller et al., 1985), 
through RhoA and Rok. It is presumed that the main outcome of CE are changes in the 
actin cytoskeleton. Furthermore, an interaction between Dvl and Rac activates Jun 
N-terminal kinase (JNK), which leads to transcriptional changes of target genes. Secondly, 
Wnt5 binding to the Ror2 receptor can also more directly activate JNK. One of the target 
genes of JNK is papc, a protocadherin which is an important mediator of CE (Tada and 
Kai, 2009) (Figure 13 a). 
It has been noted that mutations in components of the canonical Wnt signalling pathway 
do not disrupt PCP. One of the reasons for this, apart from the lack of !-catenin 
involvement, might be the use of a different domain of Dvl in PCP signalling compared to 
canonical signalling (Mlodzik, 2002). 
In contrast to canonical Wnt/!-catenin signalling, which depends on the effects of so-
called axis inducing Wnts (like Wnt1 and Wnt3A), Wnt/Ca2+ signalling involves non axis 
inducing Wnts, predominantly Wnt5A. Similar to the PCP pathway, !-catenin is not 
required for Wnt/Ca2+ signalling. Instead, binding of Wnt5A to Fz leads to the release of 
intracellular Calcium through phospholipase C (PLC) and inositol-1,4,5-trisphosphate 
(IP3). Intracellular increase in Ca2+ leads to the activation of two Ca2+-sensitive enzymes, 
Sarah Jakoby  PhD thesis 2010 
 36 
protein kinase C (PKC) and Ca2+-calmodulin-dependent protein kinase II (CamKII) 
independently from !-catenin signalling. This results in a cellular response, modifying cell 
movement and adhesion (Kühl et al., 2000) (Figure 13 b ). 
Even though Wnt ligands can play a role in different pathways as illustrated above, 
research has focused on canonical or !-catenin dependent Wnt signalling because of the 
important role this pathway plays in the regulation of cell movement, proliferation, 
embryonic stem cell maintenance and various types of cancers (Takahashi-Yanaga and 
Kahn, 2010, Takebe and Ivy, 2010). Canonical Wnt signalling is defined by the 
cytoplasmic accumulation of !-catenin and its activity through subsequent nuclear 
translocation (Gordon and Nusse, 2006) (Figure 13 c). 
Upon activation of the pathway by secreted Wnt molecules, a receptor complex is formed, 
which consists of Frizzled (Fz) (Yang-Snyder et al., 1996) plus a low density lipoprotein 
receptor-related protein (LRP). Frizzled receptors belong to a family of seven 
transmembrane serpentine receptors with an extracellular N-terminal cystein-rich domain 
(CRD) (Bhanot et al., 1996). A single Wnt can bind multiple Frizzled and vice versa 
(Clevers, 2006). Both surface expression of Fz and LRP5/6 (Arrow in Drosophila) (Pinson 
et al., 2000, Tamai et al., 2000) is required to initiate Wnt signaling (Clevers, 2006). 
Wnt binding to the receptor complex results in inhibition of the !-catenin destruction 
complex. This happens when the receptor activation causes the cytoplasmic protein 
Dishevelled (DVL) to be activated and subsequently to dephosphorylate Axin. This 
decreases the capacity of Axin to form a complex with Adenomatous polyposis coli (APC) 
or !-catenin (CTNNB1) (Yardy and Brewster, 2006). Hypo-phosphorylated !-catenin can 
accumulate in the cytoplasm from where it translocates to the nucleus (Kobayashi et al., 
2000). !-catenin then interacts with T-cell specific transcription factor/ Lymphoid 
enhancer binding factor 1 family members (TCF/LEF) and regulates target gene 
expression (Gordon and Nusse, 2006, van de Wetering et al., 1996, van de Wetering et al., 
1991). 
!-catenin therefore exists in three pools within the cell: associated at the membrane with 
E-cadherin and "-catenin, in the cytoplasm and in the nucleus (Chesire and Isaacs, 2003). 
The complex composition of the !-catenin destruction complex is not clear yet but some 
core proteins in the complex have been identified which include glycogen synthase kinase 
3 ! (GSK3B), adenomatous polyposis coli (APC) and axin (AXIN1) (Fagotto et al., 1999). 
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Figure 13: The different Wnt signalling pathways 
a. Planar cell polarity b. Wnt/Ca2+ signalling c. Canonical Wnt signalling (Modified from Tada and 
Kai, 2009, Kühl et al., 2000 and Shitashige et al., 2008). 
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Under unstimulated conditions, the !-catenin destruction complex causes the 
phosphorylation of !-catenin by GSK3B (Dajani et al., 2003, Fearnhead et al., 2001). This 
results in ubiquitination of !-catenin and its subsequent degradation by the proteasome 
(see below for details).  
Axin has been identified as a scaffolding protein but there is nothing known about 
conformational changes when it is bound to its partners in the complex (Kimelman and 
Xu, 2006). 
APC is a very large protein, which is mutated in about 80% of sporadic colon cancers. It 
contains 3 repeat regions with the characteristic amino acid (aa) sequence serine-alanine-
methionine-proline (SAMP), which mediates the interaction of APC with Axin. 
Furthermore there are 7 20-aa repeats and another 3 15-aa repeats, which are used for 
binding !-catenin (Clevers, 2006). 
GSK3B binds to a central region of Axin where a single Axin helix interacts with a 
hydrophobic groove in the c-terminus of GSK3B. This binding does not interfere with the 
active site of GSK3B, which phosphorylates !-catenin (Dajani et al., 2003). 
A major mechanism to inhibit GSK3B and therefore prevent !-catenin degradation is the 
occurrence of conformational changes within Axin (Hedgepeth et al., 1999). 
Another member of the !-catenin destruction complex is Casein kinase 1 (CSNK1A1) 
which phosphorylates the APC 20-aa repeat and which therefore results in affinity 
changes for !-catenin (Ha et al., 2004, Tickenbrock et al., 2003, Xing et al., 2003). 
Even though its role in the destruction complex is unclear, Protein phosphatase 2a 
(PPP2R4) which consists of 3 subunits, the scaffolding A subunit, a catalytic C subunit 
and various regulatory B subunits, was shown to bind to Axin (Hsu et al., 1999, Ratcliffe 
et al., 2000). However, since there is conflicting evidence, PP2A might not be essential for 
the destruction complex (Clevers, 2006) or even inhibit Axin/APC/GSK3B (Seeling et al., 
1999). 
!-catenin, the central player in the canonical Wnt pathway, is encoded by the CTNNB1 
gene (Trent et al., 1995). It consists of a large central region with 12 3-helix repeats, the 
Armadillo repeats, and forms a superhelix (Huber et al., 1997) which provides a rigid 
binding scaffold for molecules such as TCF, E-cadherin, Axin and APC (Graham et al., 
2002, Graham et al., 2000, Ha et al., 2004, Huber and Weis, 2001, Xing et al., 2003, Xing 
et al., 2004). 
The N and C terminal regions of !-catenin are small and mostly flexible. When ! catenin 
is phosphorylated on its N terminus by GSK3B, the N terminus is recognised by a 
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ubiquitin ligase (Kikuchi et al., 2006). The exact recognition sites are amino terminal 
serines which are phosphorylated (Ser 33 and Ser 37) together with an invariant aspartate 
(Wu et al., 2003). Another ligase subsequently transfers multiple ubiquitins to Lysine 
residues Lys 19 and Lys 49. This polyubiqinated !-catenin then gets degraded by the 
proteasome (Kimelman and Xu, 2006). 
 
1.3 Why study !-catenin and the canonical Wnt pathway in prostate 
cancer? 
The Wnt signalling pathway can cause tumour formation when abnormally activated. 
Colorectal cancer (CRC) and gastrointestinal tumours have been associated with 
mutations in the tumour suppressor gene APC which can mimic Wnt stimulation (Giles et 
al., 2003b). Up to 80% of sporadic CRC and 76% of gastric adenomas can be linked to a 
mutation of APC which results in loss of the binding domain for !-catenin and therefore 
accumulation of !-catenin in the nucleus. !-catenin itself acts on transcription factors and 
activates transcription (van Es and Clevers, 2005). Activation of the Wnt pathway due to 
!-catenin mutations has also been found in hair matrix cell tumours, hepatocellular 
carcinoma in Hepatitis C patients, ovarian cancer and to a low but consistent level in 
prostate cancer. Among childhood cancers, !-catenin mutations were detected in over 
92% of hepatoblastomas (Giles et al., 2003b). In addition to that, the inhibition of Wnt 
using Dickkopf-1, a potent antagonist, resulted in blocking of proliferation and loss of 
proliferative crypts in adult mice (Kuhnert et al., 2004). 
Another reason for studying !-catenin in CaP is that many !-catenin – TCF/LEF target 
genes have been associated with cancer, e.g. c-Myc (He et al., 1998, Yochum et al., 2010, 
Yochum et al., 2007) and Cyclin D1 (Tetsu and McCormick, 1999, Yochum et al., 2007). 
c-Myc has recently been shown to be sufficient, on its own, to induce an embryonic stem 
cell like programme in normal human keratinocytes, increasing the tumour initiating cells 
by 150-fold (Wong et al., 2008). 
In colon cancer active !-catenin was associated with cancer cells at the invasive front of 
the tumour, at the site of potential cancer stem cells (Fodde and Brabletz, 2007). 
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1.3.1 A connection between !-catenin and the androgen receptor 
The majority of androgen-independent prostate tumours still express androgen receptor 
(AR). An aberrantly activated AR pathway, in the absence of normal levels of androgen, is 
believed to play a role in tumour progression (Zhu et al., 2004). 
One of the proteins which has been found to interact with the AR and potentiate its 
transcriptional activity is !-catenin, one of the major players of canonical Wnt signalling 
(Chesire and Isaacs, 2002, Heinlein and Chang, 2002, Pawlowski et al., 2002, Truica et 
al., 2000, Yang et al., 2002). 
Even though activating !-catenin mutations and APC mutations are rarely found in 
clinical prostate tumour samples (Chesire et al., 2000, Voeller et al., 1998, Watanabe et 
al., 1996), they have been reported in castration resistant CaP and a link between an 
aberrantly activated canonical Wnt pathway and androgen independence in prostate cancer 
is believed to occur (Zhu et al., 2004). 
High levels of both the AR protein and mRNA have been found to be associated with the 
transition of hormone sensitive to androgen-independent CaP (Chen et al., 2004, Koivisto 
et al., 1997, Linja et al., 2001, Schweizer et al., 2008). A recent study showed that while 
physiological levels of androgen inhibit tumour cell growth, the interaction between AR 
and Wnt signalling provides a growth advantage for prostate cancer cells at castration 
levels of androgen (Schweizer et al., 2008). 
 
1.3.2 !-catenin and E-cadherin 
Apart from its apparent role in Wnt signalling, !-catenin is also recognised as a key 
molecule in the E-cadherin adherens junctions and the link between Wnt signalling and 
adhesion through !-catenin has been investigated for some time (Moon et al., 1997). 
Under normal physiological condition, E-cadherin mediates cell adhesion of epithelial 
cells by connecting to the actin cytoskeleton via catenins in the cytoplasm (Giehl and 
Menke, 2008, Heasley and Petersen, 2004, Jamora and Fuchs, 2002, Morita et al., 1999, 
Götz, 2008) (Figure 14). Loss of this cell adhesion has been found to lead to tumour 
progression and formation of metastasis (Beavon, 2000).  
In prostate cancer it is thought that differences in E-cadherin expression are important for 
the development from a non-invasive into an invasive tumour (Isaacs et al., 1994, Isaacs et 
al., 1995, Verras and Sun, 2006). Loss of E-cadherin or reduced expression has been 
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associated with more poorly differentiated tumours and therefore later stages of prostate 
cancer (Bussemakers et al., 1992, Luo et al., 1999, Richmond et al., 1997, Umbas et al., 
1992). 
The significance of this was exemplified in a study by Ewing and colleagues. By 
expressing #-catenin in PC-3 prostate cells, which contained a dysfunctional adhesion 
complex due to loss of #-catenin, they were able to re-establish a normal cell-cell adhesion 
pathway. This also lead to decreased tumourgenicity when the PC-3 variant was injected 
into nude mice, therefore establishing that normal functioning of the E-cadherin complex 
is required to suppress tumour growth (Ewing et al., 1995). It was also previously 
investigated whether loss of E-cadherin in advanced prostate cancer was resulting in 
increased !-catenin in the cytoplasm and nucleus (Sasaki et al., 2000). 
In our study, we wanted to elucidate the importance of !-catenin in prostate cancer. 
Taking the relationship between !-catenin and E-cadherin into account our research was 
based on the following assumptions: Reduced E-cadherin due to the advanced stage of a 
tumour will lead to less !-catenin being required at cell junctions, which therefore will 
result in an increase of !-catenin availability in the cytoplasm. This in turn will increase 
the chances of !-catenin being transferred into the nucleus which mimics increased 
canonical Wnt signalling. The lentivirally delivered shRNAs against !-catenin would then 
target this aberrantly active signalling cascade. 
 
 
Figure 14: Basic model of an adherens junction 
E-cadherin forms a complex with !-catenin and "-catenin to connect to the actin cytoskeleton within 
the cell (Modified from Giehl and Menke, 2008, Heasley and Petersen, 2004 and Götz, 2008). 
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1.4 RNA interference 
In October 2006 it was announced that the Nobel Prize for Physiology and Medicine 
would be awarded to Andrew Z. Fire and Craig C. Mello for their discovery of RNA 
interference. The process of RNA interference (RNAi), also called post-transcriptional 
gene silencing, was first discovered in Caenorhabditis elegans in 1998 (Fire et al., 1998, 
Montgomery and Fire, 1998, Shi and Mello, 1998, Tabara et al., 1998, Timmons and Fire, 
1998). It was shown that the injection of double-stranded RNA (dsRNA) into adult worms 
resulted in silencing of the target genes and that the silencing was more efficient that the 
one achieved by either corresponding single-strand. RNAi was also observed in the 
progeny of the injected adults (Fire et al., 1998). Double-stranded RNA was also shown to 
induce RNAi in plants (Voinnet et al., 1998, Waterhouse et al., 1998), Trypanosoma 
brucei (Ngô et al., 1998) and Drosophila spec. (Kennerdell and Carthew, 1998). 
 
1.4.1 The RNAi mechanism 
The process of RNAi is based on the enzymatic activity of the Dicer enzyme. Dicer, a 
dimeric enzyme, is a member of the RNase III family and contains a helicase domain, 
which can cleave dsRNA. The enzyme has been shown to be evolutionary conserved in 
Caenorhabditis elegans, Drosophila melanogaster, Arabidopsis thaliana, 
Schizosaccharomyces pombe and mammals including human (Bernstein et al., 2001). 
Members of the RNase III family are dsRNA-specific endonucleases, which need specific 
structurally important components from their targets in order to function efficiently. First 
of all, the termini of the small interfering RNAs (siRNAs) have to have an intact 5’ 
phosphate group as well as a 3’ hydroxyl group. It was shown that, if the phosphate is 
missing, the endonuclease activity of the enzyme will be inefficient. Additionally, it is 
important for Dicer, that there are two single-stranded nucleotides on either 3’ end as 
blunt-ended siRNAs are also less efficient (Boutla et al., 2001, Caplen et al., 2000, 
Elbashir et al., 2001a, Elbashir et al., 2001b, Hutvagner and Zamore, 2002, Nykanen et al., 
2001, Parrish and Fire, 2001). 
If dsRNA enters the cell or is introduced into or produced within the cell, Dicer targets it 
and cleaves it into siRNAs of around 21bp, which are still double stranded. The siRNAs 
may differ in length according to the species used in experiments, as there may be 
structural differences in the RNase III domains of the Dicer homologues. This process is 
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ATP-dependent and therefore makes the Dicer enzyme unique among other RNase III 
family members, which do not need ATP. The dependence on ATP is supposed to be due 
to an ATP-dependent helicase domain or a RNA translocase at the amino terminus 
(Bernstein et al., 2001, Hutvagner and Zamore, 2002, Ketting et al., 2001, Nykanen et al., 
2001, Zamore et al., 2000). 
The siRNAs are then targeted by the RNA induced silencing complex (RISC). RISC, a ~ 
360kDa multi-component protein/RNA complex, which is assembled using ATP, unwinds 
the siRNAs in an ATP-dependent manner and keeps the strand whose 5’ end is less tightly 
attached while releasing the other strand.  The bound, active guide strand is then used to 
target the corresponding mRNA. As soon as the complementary mRNA is bound RISC 
cleaves it without requiring ATP and the enzyme complex can be recycled (Dykxhoorn 
and Lieberman, 2006, Nykanen et al., 2001). In Drosophila cells, the protein component of 
the RISC complex seems to be a member of the Argonaute family, which has been shown 
to be essential in gene silencing in Arabidopsis, Neurospora and C. elegans (Hammond et 
al., 2001). 
According to the processes described above, there is a 4 step model for the RNAi pathway 
(Hannon, 2002, Hutvagner and Zamore, 2002) (Figure 15). 
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Figure 15: Four step model of RNA interference 
(1) The initiation step is the cleavage of dsRNAs (green/red) into 21-25bp double stranded siRNAs by 
the dicer enzyme (dark blue). 
(2) The next step is the incorporation of siRNAs into the inactive RISC (light blue). 
(3) The third step uses ATP to unwind the RNA and activate RISC (star). 
(4) Finally, in the fourth step, the target mRNA (pink) is cleaved ATP-independently. 
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1.4.2 RNAi in the eukaryotic cell 
Even though RNAi was first thought to be a regulatory mechanism targeting mRNA in the 
cytoplasm, it is now clear that it also involves silencing at the genome level in the nucleus 
of a variety of species (Matzke et al., 2001). The effects include RNA-directed DNA 
methylation, DNA elimination and histone methylation. The main natural targets of RNAi 
are transposons and similar repeat regions, as they represent potential invasive sequences 
(Matzke and Birchler, 2005). 
Targeting and destruction of viral dsRNA, which is a common product during virus 
replication, might be one of the main biological roles of the RNAi pathways. However, 
viruses themselves have developed a number of suppressor molecules against RNAi to 
guard themselves from the host cell (Voinnet, 2005). 
 
1.4.3 Manipulating cells by RNAi 
Various groups have shown that synthetic siRNAs can be recognised and taken up into the 
cellular RNAi pathway in vitro and mediate RNAi not only in Drosophila cells but also in 
a variety of other species including human (Elbashir et al., 2001a, Elbashir et al., 2001c, 
Fire et al., 1998, Hammond et al., 2000, Nykanen et al., 2001). Elbashir et al. 
demonstrated that synthetic 21- and 22bp dsRNAs with 3’ overhangs mediate sequence-
specific mRNA degradation in a Drosophila in vitro model (Elbashir et al., 2001c). 
It has also been shown, that short hairpin RNAs (shRNAs) with a stem of 25 to 30 
nucleotides, which are also recognised by the Dicer enzyme, silence target mRNA more 
efficiently that 21mer siRNAs (Kim et al., 2005b, Siolas et al., 2005). There are eight 
characteristics, which have been identified with siRNA functionality. These are mostly 
empirical guidelines, e.g. it was suggested that two 21 nucleotide sense and antisense 
oligonucleotides, which both harbour a 2-nt overhang on the 3’ terminus, should be 
designed to target a gene of interest. In order to save the siRNA from degradation through 
endonucleases the overhanging bp should be dT (deoxythymidines). 
Furthermore, the siRNA sequence should not target any other mRNA sequence in the cells 
of interest (perform BLAST search on EST libraries) and should not be directed at introns, 
untranslated regions (UTRs), sequences less than 75bp away from the start codon and 
regions with a high G+C content (over 50%). Low internal stability at the 3’ end of the 
sense strand as well as a lack of inverted repeats are also important. In addition, sense 
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strand preferences at positions 3, 10, 13 and 19 should be observed, e.g. A at position 19 
(Mittal, 2004, Reynolds et al., 2004). There are several online tools available for the 
selection of siRNA sequences (Pei and Tuschl, 2006). 
RNAi is not only discussed as a powerful tool for functional genomics but also as a 
possibility for future therapeutic gene-silencing drugs (Shuey et al., 2002). One problem 
for the use of RNAi as a therapeutic method might be the activation of dsRNA-dependent 
protein kinase (PKR) by the introduction of short double-stranded RNA as this activation 
will lead to apoptosis in the target cells. 
Dimerisation of PKR due to dsRNA binding leads to autophosphorylation and activation 
of PKR. The activated PKR can then phosphorylate substrates such as the eukaryotic 
translation initiation factor eIF2". Once the small subunit of eIF2" is phosphorylated, a 
signalling cascade is altered which leads to apoptosis (Gil and Esteban, 2000). 
For in vivo therapy, safe delivery of siRNAs or shRNAs is a challenging obstacle. siRNAs 
could be transported into cells using cholesterol-conjugation, antibody-fusion, liposomes 
or viral expression vectors while microinjection is only relevant for in vitro assays 
(Dykxhoorn and Lieberman, 2006). The delivery of shRNA-expressing plasmids, 
targeting the liver, was successfully shown in mice by hydrodynamic tail-vein injection. If 
transient expression in non-dividing cells is favourable, nonintegrating vectors, like 
adenoviruses or herpesviruses, should be chosen. However, if dividing cells are targeted 
and stable, long-term expression is desired, retroviruses are the appropriate choice (Snove 
and Rossi, 2006). Paul et al. showed that RNAi can be induced in HeLa cells by 
introduction of synthetic duplex RNAs of around 20bp using liposome transfection. The 
RNAs were expressed using a human U6 small nuclear RNA promoter (Paul et al., 2002). 
Methods for promoter-based expression have already been successfully used for stable 
gene silencing in vitro. However in vivo application is more challenging as the silencing of 
specific genes might also induce unwanted side effects. Toxicity can be associated with 
delivery, shRNA expression or the sequence itself (Snove and Rossi, 2006). Paddison and 
colleagues described gene silencing in various mammalian cell lines after transfection 
with a plasmid containing an shRNA expression cassette under the control of a U6 
promoter (Paddison et al., 2002).  
The choice of promoters depends on the desired expression level. While pol II promoters 
are suitable for moderate expression levels, higher expression levels can be achieved by 
combining a pol III (U6) and a pol II (U1) promoter as the transcribed products have 
different export pathways. There is also the possibility of using an inducible or tissue-
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specific expression system, e.g. transcriptional elements which are responsive to 
tetracycline or the Cre-lox system for permanent genetic changes (Snove and Rossi, 
2006). 
Although it was originally suggested that in human cells silencing is associated with DNA 
methylation (Morris et al., 2004), Ting et al. showed that effective transcriptional gene 
silencing in breast and colon cancer cells was independent of DNA methylation. 
Furthermore, it was also achieved in a cell line that was genetically modified and lacked 
the capacity to methylate DNA (Ting et al., 2005). 
Furthermore, gene silencing by lentivirus-delivered shRNAs under a U6 promoter was 
successfully shown in HeLa as well as primary dendritic cells (Stewart et al., 2003). RNAi 
has also been used extensively in stem cell research over the last years. It was shown that 
the stem cell specific transcription factors Oct4 and Nanog play a significant role in stem 
cell self-renewal by using siRNAs or shRNAs, respectively, which were produced from 
lentiviral vectors to downregulate the gene expression. The promoters used were U6 and 
H1 respectively (Ivanova et al., 2006, Zaehres et al., 2005). Even though RNAi is a very 
attractive technique for functional genomics and human therapeutics, it was previously 
reported that oversaturation of endogenous small RNA pathways by high shRNA 
expression from a viral vector, lead to increased morbidity in mice (Barik, 2006, Grimm et 
al., 2006). 
To summarise, RNA interference can be used in a variety of scientific backgrounds and 
future research has to be focused on applying RNAi in gene or cancer therapy. 
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1.5 Lentiviruses 
1.5.1 Lentivirus structure and life cycle 
Lentiviruses belong to the family of retroviruses and different virus species have been 
isolated from a variety of mammals, including humans. A summary of the lifecycle is 
illustrated in Figure 16. The subfamily of retroviruses is strongly associated with chronic 
diseases involving the immune system or the central nervous system. In contrast to the 
minimal genetic structure of some retroviruses, which include the gag, pol and env genes, 
lentiviruses contain six additional genes (Figure 17). These genes (rev, tat, nef, vif, vpr 
and vpu) contribute to the highly efficient infection caused by the virus (Buchschacher and 
Wong-Staal, 2000, Tang et al., 1999, Ailles and Naldini, 2002). 
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Figure 16: Life cycle of lentiviruses 
After the virus has bound to the cell, the viral capsid is released into the cytoplasm. The genome is 
then reverse transcribed and integrated into the host cell genome. From there, viral RNA is 
transcribed and proteins are produced using the host cell enzymes. The viral RNA is then 
encapsidated and after assembly, the new viral particles are released (Buchschacher and Wong-Staal, 
2000). 
 
 
 
Figure 17: Genome structure of HIV-1 
Genome structure of HIV-1 (Buchschacher and Wong-Staal, 2000) 
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One of the most studied lentiviruses is the human immunodeficiency virus type 1 (HIV-1), 
the causative agent of AIDS (Barre-Sinoussi et al., 1983). After the virus has entered the 
target cell by interacting with a cellular receptor complex, containing CD4 for HIV-1 and 
HIV-2, and subsequent fusion of the virion membrane with the plasma membrane of the 
cell, the virion is uncoated (Tang et al., 1999). The nine open reading frames in the HIV-1 
genome can give rise to at least 15 different proteins. Apart from protein encoding genes, 
HIV-1 also possesses several cis-acting elements including the long terminal repeats 
(LTRs), a packaging and dimerisation signal (#) and a polyadenylation signal (polyA) 
(Ailles and Naldini, 2002). The long terminal repeats consist of either U3 (unique 3’ end) 
or U5 (unique 5’ end), R (repeat region) and either the Primer Binding Site (PBS) or the 
Polypurine Tract (PPT) respectively (Tang et al., 1999). The env gene is responsible for 
the production of envelope glycoproteins, which mediate the virus-host cell interaction. 
After translation the Env protein is cleaved by a cellular protease into the external 
envelope glycoprotein and the transmembrane protein (Buchschacher and Wong-Staal, 
2000). The gag gene, which encodes for the core proteins of the virion, is initially 
produced as a Gag-Pol fusion protein. Due to its own protease activity the polyprotein is 
then cleaved into Gag and Pol. Pol is then further processed to become a protease, an 
integrase and the reverse transcriptase (RT) (Buchschacher and Wong-Staal, 2000). 
The reverse transcriptase, discovered in 1970 by Temin, Mizutani and Baltimore (Temin 
and Mizutani, 1970) is the defining feature of all retroviruses as this enzyme enables them 
not only to produce a DNA copy of their (+)-RNA genome, it also has an RNase H 
activity (Ailles and Naldini, 2002). The enzyme is an asymmetric heterodimer where both 
subunits are important, either structurally or catalytically (Katz and Skalka, 1994). One of 
the HIV-1 proteins that is important for efficient reverse transcription is Tat (Apolloni et 
al., 2003, Harrich et al., 1997). However, Tat is also a major regulator of gene expression 
at the transcriptional and posttranscriptional level (Dull et al., 1998). 
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Figure 18: Reverse transcription11 
(1) A cellular tRNA (green) acts as a primer and binds to the Primer Binding Site (PBS) of the single-
stranded RNA genome (yellow). 
(2) RT transcribes in 5’$3’-direction and produces a DNA copy (orange) of U5 and its flanking R 
element bound to the viral RNA strand 
(3) RNase H activity degrades RNA, which is base-paired with DNA, resulting in a 5’ end of viral 
RNA starting with the PBS and a free single strand consisting of a DNA copy of R, U5 and the cellular 
tRNA. 
(4) The U5-R DNA strand can then base-pair with the R region on the 3’ end of the viral RNA, a 
process which is called strand switch. 
(5) RT can now continue synthesis producing a DNA strand with the PBS at its 3’ end. 
(6) Again, the RNA is degraded by RNase H activity, leaving only an RNA fragment that serves as a 
primer for the synthesis of the second DNA strand. 
(7) This fragment stays base-paired with the polypurine tract (PPT) and elongation from this primer 
results in DNA copies of U3, R, U5 and PBS. 
(8) After removal of the tRNA primer, the second strand switch occurs. The PBS on the 3’ end can 
bind to the homologous sequence on the other strand, forming a circular intermediate and elongation 
generates a double-stranded DNA, which can then be integrated into the host cell genome The double 
strand contains the LTR sequence (U3-R-U5) at both termini. 
                                                
11 modified from Molecular Biology of the Gene; 5th edition; page 322-323; by Watson et al. 2004 
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After reverse transcription nuclear import occurs when a nucleoprotein complex called the 
preintegration complex (PIC) is actively imported during interphase. PIC, which includes 
the lentiviral genome and a number of viral proteins, offers the virus the possibility to 
integrate into quiescent cells that are not dividing at the time of infection. The integration 
of the viral ds-DNA into the host cell genome is mediated by the integrase enzyme. The 
integrated virus is referred to as a provirus. Although, integration occurs at random the 
provirus is usually found at transcriptionally active regions of the genome (Tang et al., 
1999).  
 
1.5.2 Lentiviral vectors – 1st, 2nd and 3rd generation 
Lentiviruses have been at the focus of great research interest because of their infectious 
potential, especially since AIDS, associated with HIV-1 and HIV-2, poses a threat to 
human health worldwide. The development of early HIV-1 derived vectors was therefore 
initially intended for the study of HIV-1 biology. However, lentiviruses have proved to be 
a versatile tool for gene delivery in vivo due to the fact that they can integrate into the host 
cell genome and therefore they can provide stable and long-lasting gene expression. They 
also have a larger cloning capacity (8-9 kb) than other gene delivery systems (Ailles and 
Naldini, 2002). When comparing them to other possible gene therapy vectors like 
oncoretroviruses, which have been the primary choice for gene therapy application due to 
their simple genome organisation, lentiviruses have another advantage, as they are able to 
infect both dividing and non-dividing cells (Ailles and Naldini, 2002, Buchschacher and 
Wong-Staal, 2000, Lewis and Emerman, 1994). 
However, the first generation vectors were never considered safe for gene therapy or 
similar treatments as the risk of replication-competent retroviruses (RCR) could not be 
diminished and there were major biosafety concerns. First generation vectors contained a 
constitutive promoter instead of the 5’ LTR and an SV40 polyA signal, which replaced the 
3’ LTR. Apart from the env gene, which has been deleted, all other viral genes were still 
expressed. 
For the development of second generation lentiviruses, the viral genes vif, vpr, vpu and 
nef were deleted as they represent important virulence factors. Their deletion did not show 
any significant decrease in viral particle production. 
The major achievement in developing the third generation vectors was the deletion of tat, 
a powerful transcriptional activator, from the packaging construct. In order to compensate 
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for Tat, constitutive promoters like CMV or PGK, were introduced (Dull et al., 1998). It 
was also found that by deleting the Rev-responsive element from the vector, mobilisation 
rates of the vector from host cells was more than 104-fold lower (Lucke et al., 2005). 
Furthermore, rev is now supplied on a separate plasmid, thus limiting expression to the 
producer cell line. 
However, there is still a possibility of producing a replication competent virus, e.g. when 
the transduced cell is subsequently infected with a wild-type HIV-1. Moreover, abnormal 
expression of adjacent genes after integration due to 3’ LTR activity has to be addressed. 
For these reasons, new vectors with self-inactivating (SIN) LTRs were created, by 
deleting a part of the U3 sequence of the 3’ LTR. After reverse transcription, this deletion 
is also transferred to the 5’ LTR where the viral promoter is present, thus eliminating the 
expression of full-length viral RNA after transduction (Ailles and Naldini, 2002, Miyoshi 
et al., 1998, Zufferey et al., 1998). Moreover, as there is no full U3 sequence present, no 
recombination event would result in restoration of the wild-type U3 (Hanawa et al., 2005). 
SIN vectors, which were modified to harbour a cytomegalovirus (CMV) promoter in order 
to make them independent from Tat transcription, have also been shown to transduce 
target cells as efficiently as the wild type virus (Miyoshi et al., 1998). Increased biosafety 
was further assured when no mobilisation of SIN vectors was detected after the cells had 
been subsequently transduced with wild-type HIV-1 (Bukovsky et al., 1999). 
Additionally, recombination between transfer and packaging constructs might result in gag 
and pol being present in the transfer vector, however, after integration into host cells, there 
is no promoter present to drive expression and therefore the biosafety of this system is 
very high (Ailles and Naldini, 2002). 
In order to enhance virus production for gene therapy vectors, Hlavaty et al. found that the 
WPRE (woodchuck posttranscriptional regulatory element) greatly increased transgene 
expression while Hsp70 5’ UTR, which was also tested, did not result in a significant 
increase (Hlavaty et al., 2005). Another way to enhance successful gene transfer into 
resting or slowly dividing cells was achieved by pseudotyping lentiviruses with the 
envelope glycoproteins of MLV (murine leukaemia virus) and VSV-G (vesicular 
stomatitis virus, protein G). Pseudotyping also enables more specific targeting according 
to the tropism of the glycoproteins used (Stitz et al., 2000). 
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1.5.3 Using lentiviral vectors 
Lentiviral vectors have been used as gene delivery tools on a variety of cell types during 
the last years. Gerolami et al. showed in 2003 that lentiviral vectors could efficiently 
transduce a hepatocellular carcinoma cell line with the reporter gene LacZ and also with a 
Herpes simplex virus thymidine kinase GFP fusion gene in vitro and in vivo (Gerolami et 
al., 2004). It was also shown that murine neural stem cells could be transduced in vivo 
(Consiglio et al., 2004). Prostate cancer cell lines have also been targeted using 
lentiviruses. Bastide at al. targeted DU145 and PC3 cells with vectors containing the 
marker gene EGFP. In vitro, the cell lines continued to express the transduced gene for 4 
months while in vivo, the majority of the tumours kept expressing the transgene at in vitro 
levels as well (Bastide et al., 2003). When a prostate tumour specific lentivirus was 
administered systemically into SCID mice, the transduction levels were significantly 
higher at the site of the tumour than in other organs (Iyer et al., 2006). Furthermore, stable 
transduction of primary epithelial tissue from human prostate tumours using a 
recombinant retrovirus has also been shown (Maitland et al., 2001). 
A major concern is of course non-specific targeting when considering gene therapy 
against cancers. However, Yu et al. developed an in vitro gene therapy system, which 
selectively targeted prostate cancer cell lines while non-cancer cells were not affected. The 
group introduced a short DNA sequence within the lentiviral vector, which is recognised 
by the translation initiation factor eIF4E. This initiation factor is often overexpressed in 
cancer cells. When transducing the cancer cell lines with a lentiviral construct harbouring 
the initiation factor recognition sequence in front of the suicide gene HSV thymidine 
kinase, cancer cells had a high sensitivity to the prodrug ganciclovir. On the other hand, 
non-cancer cells required 100-fold more ganciclovir in order to be killed than cancer cells. 
This showed an example of selective drug targeting of cancer cells (Yu et al., 2006). 
Another way to manipulate cancer cells is to target overexpressed genes by RNAi. There 
have been reports where either artificially introduced reporter genes or malignancy related 
genes were silenced using RNAi mediated through lentiviral vectors. Abbas-Terki et al. 
showed successful silencing of EGFP using a lentiviral vector, which encoded EGFP 
specific siRNAs under the RNA-polymerase III dependent H1 promoter (Abbas-Terki et 
al., 2002). In 2006 Liu et al. used lentiviral shRNA expression cassettes in a colorectal 
cancer cell line and a nude mice xenograft model for the knockdown of Tiam1, a 
metastasis related gene, which promotes tumour progression in a variety of cancers (Liu et 
Sarah Jakoby  PhD thesis 2010 
 55 
al., 2006). There have been a number of recent studies using lentiviruses to deliver 
shRNAs into cancer cells. Klier et al. succesfully downregulated cyclin D1 using a 
lentiviral expressed shRNA in mantle cell lymphoma (Klier et al., 2008) and Wang and 
colleagues used lentiviral vectors to deliver a MAT2B shRNA into hepatocellular 
carcinoma cells. They were able to show growth inhibition and increased apoptosis 
following the treatment (Wang et al., 2008b). STAT3 is also a popular target bearing in 
mind its role in cytokine signalling and overexpression in a number of cancers. It was 
shown recently that donwregulation of STAT3 by lentiviral expressed shRNAs in a 
glioblastoma cell line induced apoptosis (Li et al., 2009) and a similar result was shown on 
growth and invasive potential of pancreatic tumour cells following STAT3 knockdown 
(Yang et al., 2009). Studies have also used lentiviruses to deliver shRNAs into in vivo 
models of breast cancer (Krishnamachary et al., 2009) and to reverse multi-drug-resistance 
in a leukaemia cell culture model (Ye et al., 2009). 
All these results illustrate the advantages of successful lentiviral shRNA treatments and 
open new ways of cancer research and, ultimately, therapy. 
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2. Materials and Methods 
2.1 DNA preparation, manipulation and analysis 
2.1.1 Primer design and polymerase chain reaction (PCR) 
Primers (Table 2) were obtained from Invitrogen. GC content, melting temperature, dimer 
and possible hairpin formation were analysed using the OligoAnalyzer 3.0 tool (Integrated 
DNA Technologies, http://www.idtdna.com). 
 
Primer name Sequence 
CMV-SJ1 5’ 5’ tagttattaatagtaatcaatt 3’ 
CMV-SJ2 5’ 5’ ccgccatgcattagttattaat 3’ 
Fluor 3’ 5’ ttacttgtacagctcgtccatg 3’ 
EGFP Luc-rev 5’ gatacattgatgagtttggac 3’ 
CMV sense 5’ gcgttgacattgattattgac 3’ 
 
Table 2: Primer sequences 
Both CMV-SJ1 5’ and CMV-SJ2 5’ can be combined with either Fluor 3’ or EGFP Luc-rev. 
Amplification with EGFP Luc-rev results in a sequence containing a polyA signal after the fluorescent 
gene, whereas Fluor 3’ binds at the end of the fluorescent genes mOrange, Citrine and tdTomato, 
without amplifying the polyA tail. 
 
The Expand High Fidelity PCR system (Roche Applied Science) was used for routine 
PCR amplifications in the Gene Amp PCR 9700 machine (Applied Biosystems). For a 
total reaction volume of 50 µl, 5 µl of concentrated Expand High Fidelity Buffer 
containing 15 mM MgCl2, were combined with 1.5 $l of each primer (10 µM), 5 $l of 
dNTPs (2 mM) and 1 U of Expand High Fidelity Enzyme Mix. Template DNA was used 
at 5 ng/µl. The DNA was initially denatured for 5 min at 94° C. 30 cycles were carried out 
using a 1 min denaturing step at 94° C, a 1 min primer annealing step at 50° C and a 2 min 
elongation step at 72° C. Final extension was carried out for 7 min at 72° C, followed by 
storage at 4° C, if necessary. 
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2.1.2 Agarose gel electrophoresis and gel purification 
PCR products and plasmids were analysed on 1 % (w/v) TAE agarose gels using 0.1 µl/ml 
SYBR Safe DNA Gel Stain (Invitrogen). Gel purification was routinely carried out at 60-
80 V for a minimum of 1 h. 
Bands were cut under UV light exposure and purified using the QIAquick Gel Extraction 
Kit (Qiagen) as instructed by the manufacturer. The DNA was eluted using 50 µl ddH2O. 
 
2.1.3 Insertion of fluorescent reporter gene constructs into pENTR 5’ TOPO 
pENTR 5’ entry vectors were cloned using the pENTR 5%-TOPO TA Cloning Kit 
(Invitrogen) according to the manufacturer’s instructions. 2 $l of PCR product (gene and 
promoter construct) were combined with 1 $l of linearised pENTR 5’ TOPO plasmid and 
1 µl salt solution. Sterile ddH2O was added to make up the reaction mix with a total 
volume of 6 µl. 2 µl of this reaction mix was used for transformation into One Shot 
TOP10 chemically competent E. coli (Invitrogen) by heat shock transformation at 42° C. 
After 1 h incubation in SOC medium, bacteria were plated onto Luria Bertani (LB) agar 
plates containing 50 µg/ml kanamycin for selection. Colony growth was analysed after 
24 h incubation at 37° C and DNA from transformants was analysed by restriction digest. 
Plasmid products were sequenced to confirm correct recombination prior to being stored 
as bacterial glycerol stocks. 
 
2.1.4 Construction and selection of shRNAs 
Double stranded shRNA constructs against PSCA (Table 3) were designed using the 
Origene RNAi collection (OriGene Technologies Inc., HuSH 29mer shRNA constucts) as 
a reference. The Origene sequences were modified using the Invitrogen BLOCK-iT% 
RNAi Designer to combine them with the BLOCK-iT% U6 RNAi Entry Vector Kit 
(pENTR/U6 plasmid, Invitrogen). All sequences were blasted against the NCBI human 
EST database to ensure that the constructs exclusively targeted PSCA mRNA. Each 
construct contained a different 29 nucleotide long stem loop. The top strands included 
direct cloning overhangs at the 5’ end with the nucleotide sequence ‘caccg’. The 
corresponding bottom strands contained a 3’ overhang ‘aaaa’, to enable successful ligation 
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with the plasmid. The hairpin sequence in all constructs was ‘cgaa’ (default loop 
sequence). 
 
2.1.5 Insertion of shRNA into pENTR/U6 
pENTR/U6 entry vectors were cloned using the BLOCK-iT U6 RNAi Entry Vector Kit 
(Invitrogen) according to the manufacturer’s instructions. An annealing reaction was set 
up and incubated at 95° C for 4 min to generate double stranded (ds) oligos from single 
stranded shRNAs. The resulting ds oligos were then diluted to a final concentration of 
5 nM in 1x Oligo Annealing Buffer for the ligation reaction. Ds oligos were cloned into 
pENTR/U6, which was transformed into One Shot TOP10 chemically competent E. coli. 
Heat shock transformation was carried out as described under 2.1.3. DNA from 
transformants was analysed by restriction digest. Plasmid products were sequenced to 
confirm correct recombination prior to being stored as bacterial glycerol stocks. 
 
2.1.6 Isolation of plasmid DNA 
Plasmid DNA was isolated from 5 ml of E. coli One Shot TOP10 bacterial overnight 
culture using the Qiagen QIAprep Spin Miniprep according to the manufacturer’s 
instructions. The DNA was eluted from the column using 50 µl of ddH2O. Plasmid DNA 
was stored at -20°C. 
 
2.1.7 Generation of pLenti6 expression constructs by site-specific recombination 
Lentiviral expression constructs were generated using the ViraPower Promoterless 
Lentiviral Gateway Kit (Invitrogen). 10 fmol pENTR 5’ TOPO containing a fluorescent 
marker gene under the constitutive CMV promoter and 10 fmol pENTR/U6 containing an 
shRNA construct were combined with 20 fmol destination plasmid pLenti6/R4R2/V5-
DEST. After the recombination reaction was performed according to the manufacturer’s 
instructions, pLenti6 expression vectors were obtained. 
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2.1.8 Restriction analysis of pENTR and pLenti6 plasmids 
pENTR 5’ and pENTR/U6 entry clones and pLenti6 expression clones were digested 
using NcoI (NEB) and NcoI/EcoRI (Promega) to confirm correct insertion of PCR 
products and shRNA oligos or correct recombination, respectively. 5 U (0.5 µl) of 
restriction enzyme was combined with 3 µl of the respective buffer, 10 µl plasmid DNA 
(from miniprep) and 16.5 µl water and incubated at 37° C for 2 h. Digests were examined 
on 1 % (w/v) TAE agarose gels using 0.1 µl/ml SYBR Safe DNA Gel Stain (Invitrogen). 
 
2.1.9 Sequencing and sequence analysis 
Sequencing was performed either by the Technology Facility at the University of York 
(TF) or by Cogenics (now Beckman Coulter Genomics). Plasmid DNA at the 
recommended concentrations (115-150 ng/$l for TF; 100 ng/$l for Cogenics) was sent for 
sequencing. Universal primers (M13-20; M13 rev-26; M13R), which were provided with 
the sequencing service, were used. pENTR/U6 plasmids, containing shRNA sequences, 
were sequenced using Cogenics Silver sequencing service and special conditions for 
hairpin DNA. 
 
2.1.10 siRNA and shRNA constructs 
Sequences of siRNA and shRNA constructs are listed in Tables 3 and 4. 
 
 
  
 
 
Table 3: Sequences of shRNA top strands 
Top strands to be annealed to the corresponding bottom strand and then cloned into pENTR/U6. 
shRNA name DNA sequence 
beta-actin 5’ caccgctgtccaccttccagcagatgtggatcagcgaactgatccacatctgctggaaggtggacag 3’ 
Luciferase 5’ caccgagttgcgcccgcgaatgatatttataatgcgaacattataaatatcattcgcgggcgcaac 3’ 
PSCA_S1 5’ caccgtgctgtgacaccgacttgtgcaacgccagcgaactggcgttgcacaagtcggtgtcacagca 3’ 
PSCA_S2 5’ caccgttcctgaggcacatcctaacgcaagtctcgaaagacttgcgttaggatgtgcctcaggaac 3’ 
PSCA_S3 5’ caccgtcggctctattgacacagatccgcctgcacgaatgcaggcggatctgtgtcaatagagccga 3’ 
PSCA_S4 5’ caccgtctatgacttgagccaggtctggtccgtgcgaacacggaccagacctggctcaagtcataga 3’ 
MSMB_S1 5’ caccggagattcaaccaggaaatgcatggatctcgaaagatccatgcatttcctggttgaatctcc 3’ 
MSMB_S2 5’ caccgccaataaactcggagtggcagactgacaacgaattgtcagtctgccactccgagtttattgg 3’ 
MSMB_S3 5’ caccgaagaaggaggactgcaagtatatcgtggtcgaaaccacgattaacttgcagtcctccttc 3’ 
MSMB_S4 5’ caccgagacctgttctgtcagtgaatggataatccgaagattatccattcactgacagaacaggtc 3’ 
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siRNA name RNA sequence 
PSCA_S1 (rna) 5’ (Cy3) ugcugugacaccgacuugugcaacgccagTT 3’ 
PSCA_S2 (rna) 5’ (Cy3) guuccugaggcacauccuaacgcaagucuTT 3’ 
Luciferase (rna) 5’ (Cy3) aguugcgcccgcgaaugauauuuauaaugTT 3’ 
siGENOME D-003697-01 PSCA (Dharmacon) 5’ gaacugcguggaugacucauu 3’ 
siGENOME D-003697-02 PSCA (Dharmacon) 5’ gcugugacaccgacuuguguu 3’ 
siGENOME D-003697-03 PSCA (Dharmacon) 5’ gcaaaggcugcagcuugaauu 3’ 
siGENOME D-003697-04 PSCA (Dharmacon) 5’ gcugugcuacuccugcaaauu 3’ 
siCONTROL D-001140-01-05 GAPDH (Dharmacon) proprietary 
siCONTROL D-001210-01 Non-targeting #1 (Dharmacon) proprietary 
AllStars Neg. siRNA Cy3 (Qiagen) proprietary 
Silencer !-actin siRNA Control (Ambion) proprietary 
 
Table 4: Sequences of siRNA sense strands 
siRNAs were supspended in siRNA suspension buffer (Qiagen) for a final concentration of 2 !g/!l. 
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2.2 Transfections 
2.2.1 Plasmid transfections 
Cells were plated at 4x104 cells/well into 24-well plates 24 h prior to transfection. Medium 
was removed and fresh growth medium was added before transfection. Transfection 
reagent (Fugene6 transfection reagent, Roche) was diluted in serum-free medium or PBS 
at a ratio of 1:50, according to the manufacturer’s instructions. 1 !g plasmid DNA was 
added to the diluted reagent. The complex was incubated for 20 min at RT before it was 
added to the cells. Transfected cells were incubated for 48-96 h. 
 
2.2.1 siRNA transfections using X-tremeGENE siRNA transfection reagent 
Cells were plated at 2x104 cells/well into 24-well plates 24 h prior to transfection 
according to the manufacturer’s instructions (Roche). Medium was removed and fresh 
growth medium was added before transfection. 0.5 !l X-tremeGENE reagent per well was 
diluted in serum-free Opti-MEM medium. 0.5 !g siRNA (Table 4) was diluted in serum-
free Opti-MEM medium before the diluted reagent was added to the siRNA solution. The 
complex was incubated for 20 min at room temperature (RT) before it was added to the 
cells. Transfected cells were incubated for 48-96 h prior to analysis. 
 
Sarah Jakoby  PhD thesis 2010 
 64 
2.3 Lentiviral infections 
2.3.1 Generation of lentivirus using the Invitrogen Gateway system 
After the MultiSite Gateway recombination reaction was performed, the resulting 
expression vector and the Packaging Mix plasmids (Invitrogen) were used to cotransfect 
293FT producer cells according to the manufacturer’s instruction outlined in the 
ViraPower Promoterless Lentiviral Gateway Kits manual (Invitrogen). For each 
transfection, 9 µg ViraPower Packaging Mix plasmids and 3 µg pLenti6 expression vector 
plasmid DNA were added to 1.5 ml serum-free OptiMEM medium and mixed. In a 
separate vial, 36 !l Lipofectamine 2000 was diluted in 1.5 ml serum-free OptiMEM 
medium. The diluted plasmid DNA was combined with the transfection reagent solution 
and incubated for 20 min at RT. After complexes had formed, the solution was transferred 
into a 10 cm cell culture dish containing 5 ml OptiMEM, before 6x106 293FT producer 
cells were added. Cells were incubated over night at standard culture conditions and 
medium was changed after 24 h. Virus containing supernatant was harvested after 48-96 h. 
The supernatant was centrifuged at 1350 x g (3000 rpm) for 15 min at 4° C to remove 
debris. Virus was then stored in aliquots at -80° C. 
 
2.3.2 Titering of Gateway lentiviruses 
One day prior to titering, HT1080 cells were plated at 2x105 cells per well into a 6-well 
plate. A ten-fold serial dilution of lentiviral stock (from 10-2 to 10-5) was prepared and a 
final volume of 1 ml (lentiviral stock in complete culture medium) was added to the cells 
in each well. Polybrene was also added to the cells at 6 µg/ml prior to over night 
incubation. Medium was replaced after a further 24 h with selection medium containing 
10µg/ml Blasticidin. Selection medium was replenished every 2-3 days. After 10-12 days 
post selection, wells were washed with 2 ml PBS and colonies were stained with 
0.5 ml/well 1 % (w/v) crystal violet (Sigma) in 10 % ethanol for 5 min. After two further 
washing steps, colonies were counted to determine titre. Titre was calculated by 
multiplying the number of colonies with the dilution factor, e.g. 12 colonies and dilution 
factor 10-2 will give titre of 12 x102, or 1.2 x103 TU/ml. 
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Viruses were diluted according to the following scheme: 
 
 
Figure 19: Titration dilution layout 
 
2.3.3 Lentiviral infection using Sigma shRNA lentiviruses 
Cell lines were plated at 2x103 cells per 24-well. After 24 h, medium was replaced with 
new culture medium containing 8 !g/ml polybrene, prior to infection. Lentiviruses were 
added to the cells at a multiplicity of infection (MOI) of 10. Cells were incubated at 37° C, 
and medium was changed after 24 h. If long term, stable transduction was desired, the 
selection medium, containing 2 µg/ml puromycin, was added 48-72 h post infection. 
Medium was changed every 2-3 days for a minimum of 14 days.  
Primary cells were cultured to approximately 70-80% confluency prior to infection in 
order to reduce the relative amount of mouse feeder cells present in the culture. 
Lentiviruses were added to 2x104 cells in suspension (1 ml stem cell medium, SCM, 
without polybrene) at an MOI of 10. The cell suspension was then incubated at RT or 
37° C on a rotating spinner for 45 min. Cells were plated onto collagen-coated 35 mm cell 
culture dishes with irradiated mouse feeder cells and incubated at 37° C. SCM was 
changed after 24 h and more feeder cells were added, if necessary. If stably transfected 
cells were desired, selection medium, containing 0.5 µg/ml puromycin, was added 72 h 
post infection. Medium was changed every 2-3 days for 10 days and feeder cells were 
added as required. Afterwards, cells were placed into normal culture medium (SCM). 
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2.3.4 Puromycin Kill Curve 
A puromycin kill curve was performed to determine the minimum concentration for 
100 % cell death. Cells were plated at 1.6x104 cells per well of a 96-well plate. Medium 
was exchanged with 120 µl puromycin-containing medium per well one day post plating. 
Puromycin was added at the following concentrations, in triplicate: 0.5 µg/ml, 2 µg/ml, 
4 µg/ml, 6 µg/ml, 8 µg/ml and 10 µg/ml. Cell lines were selected for a minimum of 14 
days. For primary cells, which were plated at 5x104 cells per well, the concentrations were 
1 µg/ml, 0.5 µg/ml, 0.3 µg/ml and 0.2 µg/ml, respectively. Primary cells were selected for 
a maximum of 10 days. Medium was changed every 3 days and surviving cells were 
visually examined every 2 days. 
Sarah Jakoby  PhD thesis 2010 
 67 
2.4 Cell culture 
2.4.1 Bacterial cell culture 
E. coli One Shot TOP10 cells were cultured on LB agar plates or in LB medium 
supplemented with antibiotics at 37° C if applicable. Liquid cultures were incubated under 
agitation at 180 rpm in an orbital shaker incubator. For cryopreservation E. coli were 
frozen at -80° C in LB medium containing 35 % glycerol. 
 
2.4.2 Primary cell culture 
For culturing primary prostate epithelial cells, collagen coated plasticware (BioCoat, BD 
Bioscience) was used. Cells were cultured in stem cell medium (SCM) with the addition 
of irradiated or mitomycin C treated mouse feeder cells (STOs). Feeders were replaced if 
necessary, and the medium was changed every two days. Cells were subcultured at a ratio 
of 1:2-1:4 once they reached 80-100 % confluence. 
Prostate fibroblasts (stroma) were cultured in R10 containing 1 x Antibiotic-Antimycotic 
(Gibco by Invitrogen). Medium was exchanged initially after 5-7 days and then every 3-4 
days until confluency. 
SCM consists of KSFM medium supplemented with 2 ng/ml Leukaemia Inhibitory Factor 
(LIF), 2 ng/ml Stem Cell Factor (SCF), 100 ng/ml cholera toxin (CT) and 1 ng/ml 
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). 
 
 
 
  
 
2.4.3 Mammalian cell lines and culture conditions 
Cell line Medium Subculture ratio Medium components 
293FT D10 plus 1:6 
every 2-3 days 
D10 plus 0.1 mM MEM non-essential amino acids; 1 mM 
MEM sodium pyruvate; supplemented with 500 ng/!l G418  
in culture 
BPH-1 R5 1:6 
every 3-4 days 
RPMI (GIBCO, Invitrogen); 5 % FBS; 
6 mM L-Glutamine 
Caco-2 DR10 1:10 
every 2-3 days 
1:1 mix of R10 and D10 
HeLa D10 1:8 
every 2-3 days 
DMEM (GIBCO, Invitrogen); 10 % FBS; 
6 mM L-Glutamine 
HT1080 ATCC MEM (E10) 1:10 
every 3-4 days 
Minimum essential medium, Eagle’s (ATCC); 
10 % FBS; 6 mM L-Glutamine 
LNCap R10 1:4 
every 2-3 days 
RPMI (GIBCO, Invitrogen); 10 % FBS; 
6 mM L-Glutamine 
MCF-7 D10 1:4 
every 2-3 days 
DMEM (GIBCO, Invitrogen); 10 % FBS; 
6 mM L-Glutamine 
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Cell line Medium Subculture ratio Medium components 
P4E6 K2 1:3 
every 2-3 days 
Defined Keratinocyte-SFM (GIBCO, Invitrogen); 2 % FBS; 
6 mM L-Glutamine; K2 supplements EGF and bovine pituitary 
extract (supplied with medium) 
PC-3 H7 1:4 
every 2-3 days 
Ham’s F12 (GIBCO, Invitrogen), 7 % FBS; 
6 mM L-Glutamine 
PNT2-C2 R10 1:5 
every 2-3 days 
RPMI (GIBCO, Invitrogen); 10 % FBS; 
6 mM L-Glutamine 
SaOS-2 !DMEM 1:4 
every 3-4 days 
Invitrogen #A10490-01 
STO D10 1:10 to 1:20 every 
3-4 days 
DMEM (GIBCO, Invitrogen); 10 % FBS; 
6 mM L-Glutamine 
SW480 DR5 1:2 to 1:8 every 
3-4 days 
1:1 mix of R5 and D5 (DMEM; 5 % FBS; 6 mM L-Glutamine) 
Table 5: Medium and subculture requirements for cell lines 
All cells were cultured in humidified atmosphere with 5 % CO2 at 37°  C. 
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2.5 Invasion assay 
Cell culture inserts (BD Biosciences) were coated with matrigel (dilution in KSFM, 
approximately 750 µg/ml) and left to polymerise for 1 h at 37° C. Cells were seeded into 
matrigel-coated cell culture inserts and non-matrigel control inserts at a density of 2 x 104 
cells per insert. The inserts were transferred onto a plate containing conditioned medium 
from stromal cultures or R10 as the attractant and incubated for 48 h at 37° C. Cells were 
washed twice in cold PBS and fixed in ice-cold methanol at -20° C for 20 min. The 
bottom membrane of the inserts was cut out, mounted bottom-side up, using Vectashield 
mounting medium with Dapi (Vector Laboratories) and examined under a fluorescent 
microsope. 4 random images per membrane were taken at 20 x magnification, avoiding 
the edges of the membrane. Nuclei were counted either by eye or using the cell count 
analysis function of ImageJ or Nikon NIS Elements software. The number of invasive 
cells in each cell line was compared. Invasion-motility-ratios were calculated to determine 
the number of invasive cells relative to migratory cells. 
 
2.6 Immunomagnetic isolation of CD133 cell population 
Cultured primary cells were subjected to immunomagnetic separation once they reached 
approximately 80 % confluency. To isolate CD133-expressing cells from the culture, the 
direct CD133 Cell Isolation Kit (Miltenyi Biotec) was used. 
Cells were washed in PBS, trypsinised and pelleted. The cell pellet was washed again 
twice before the cell suspension was passed through a 40 µm cell strainer (BD Bioscience) 
in order to remove cell clumps. Cells were pelleted again and suspended in 300 µl MACS 
buffer. Magnetic cell labelling and separation over MACS MS columns was performed 
according to the manufacturer’s instructions. To increase purity of the CD133 population, 
this procedure was repeated over a second column. Separated cell populations were the 
used for IF. 
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2.7 Injection of PC-3 cells into mice 
Stably transfected PC-3 cells (PC-3v45, PC-3_2V) and untransfected PC-3 cells were 
injected subcutaneously into the left flank of GC-1-RAG2 !c -/- mice to measure tumour 
induction and growth. Cells were counted and 5 x 105 cells per mouse were suspended in 
matrigel (BD Bioscience). Cells were kept on ice prior to injection. For each animal, an 
aliquot of 50 "l cells-in-matrigel suspension was used, with 3 replicates in each group. 
The procedure was carried out by Dr Anne Collins, Paul Berry and Katy Hyde. Tumour 
growth was measured every 2-4 days from the time point of first, visible tumour detection. 
Mice were sacrificed once tumours reached 15 mm in length or earlier, if tumour size was 
inhibiting movement or when tumours started to break up. Tumours were then subjected 
to depletion to remove hematopoietic cells and infiltrated mouse cells, followed by 
Western Blot for !-catenin. 
 
2.8 Depletion of hematopoietic cells and mouse cells from PC-3 tumours 
Due to possible infiltration of murine cells into subcutaneous PC-3 tumours, depletion by 
magnetic separation was performed. During this procedure, mature hematopoietic cells (T 
cells, B cells, NK cells, dendritic cells, monocytes, granulocytes, erythroid cells) are 
removed using a lineage depletion kit (Miltenyi Biotech). Afterwards, the remaining cells 
are depleted from any infiltrated murine cells, using a mouse-specific CD31 antibody. 
Firstly, fresh collagenase was weighed out for a final concentration of 200 IU/ml, 
dissolved in 2.5 ml KSFM per tumour (up to 1 g of tissue). 5 ml serum containing medium 
(R10 with ABM) was added. Tissue was placed into a 10 cm petri dish and washed in 
PBS. A small piece (2 mm x 2 mm x 1 mm, approximately) was cut off for fixation in 
10% formalin and stored at 4 °C. The collagenase solution was added to the remaining 
tumour, which was then diced into small pieces using tweezers and a scalpel. The tissue-
collagenase mixture was then transferred into a 125 ml sterile Erlenmeyer flask and 
incubated at 37 °C overnight in a small orbital shaker for digestion (80 rpm). 
Following the digestion, repeated pipetting was used to break up any remaining pieces of 
tumour, before the mixture was centrifuged at 670 x g (2000 rpm) for 10 min to sediment 
the cells. The pellet was resuspended in 10 ml of PBS to wash out any remaining 
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collagenase, followed by further centrifugation at 670 x g for 10mins. Washing and 
centrifugation were then repeated once more. 
For further digestion, the pellet was resuspended in 10 ml of 1 x trypsin and incubated at 
37 °C for 30 min in a small orbital shaker (80 rpm). The digestion was stopped by adding 
10 ml of R10. After short centrifugation (300 x g for 4 min) and another washing step in 
PBS, the pellet was resuspended in 500 !l pre-cooled (4 °C) MACS buffer and kept on ice 
for the whole procedure. Cells were passed through a 40 !m cell sieve before lineage 
depletion was carried using the MACS Lineage Cell Depletion Kit human (Miltenyi 
Biotech) as outlined in the manufacturer’s instructions. 
80 !l of MACS buffer were used to resuspend the pellet before 20 !l of Biotin-Antibody 
Cocktail were added, mixed and the mixture then incubated for 10 min at 4 °C on a 
rotating spinner. 60 !l of MACS buffer, followed by 40 !l of Anti-Biotin MicroBeads 
were added, for incubation for 15 min at 4 °C on a rotating spinner. Cells were washed by 
adding 4 ml of buffer and pelleted by centrifugation (300 x g for 4 min).  
For magnetic separation, cells were resuspended in 500 !l of MACS buffer. An LS 
column was placed in the magnetic field of a MACS Separator and washed using 3 ml of 
MACS buffer. Cells were applied to the column to collect the unlabelled, enriched, 
lineage negative fraction (Lin- cells). Further collection of Lin- cells was carried out after 
washing the column 3 times with 3 ml of buffer. The retained cells (Lin+) were collected 
outside the magnetic field. Cells were then subjected to magnetic separation of stromal 
and endothelial cells using a mouse-specific biotin-CD31 antibody (AbD Serotec). 
Pelleted Lin- cells were resuspended in 90 !l of buffer. 10 !l of CD31 antibody were 
added and the mixture incubated for 10 min at 4 °C on a rotating spinner. Following 
incubation, 60 !l of buffer and 40!l of Anti-Biotin MicroBeads were added, for 
incubation for 15 min at 4 °C on a rotating spinner. Cells were washed by adding 4 ml of 
buffer and pelleted by centrifugation (300 x g for 4 min). The pellet was resuspended in 
500 !l of buffer and cells were subjected to magentic separation as outlined above. The 
unlabelled, collected fraction represented (human) CD31- cells, while the retained cells 
were mouse CD31+. CD31- cells were pelleted and either stored frozen at -20 °C or used 
immediately lysed for Western Blot using CytoBuster (see 2.14.1). 
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2.9 Wnt pathway activation 
Cells were activated using 20 mM final concentration of LiCl 24 h post plating, for 24 h. 
NaCl served as the negative control, according to the protocol used by Spencer and 
colleagues (Spencer et al., 2006). Alternatively, Wnt1 protein (Abcam) was added to cells 
at 100 ng/ml to induce Wnt signalling. 
 
2.10 Fixation techniques 
Adherent cells were cultured in chamber slides (BD Falcon™ 8-well CultureSlides; Nunc 
Lab-Tek™ 8-well Chamber Slide; BD BioCoat™ Collagen I 8-well CultureSlides). Cells 
were washed twice with PBS prior to fixation. 200 µl 4 % paraformaldehyde (PFA) or 
4 % formaldehyde solution (Formalin, FA) was added per well and cells were incubated 
for 20 min at RT. Fixed cells were washed 3 x with PBS before chamber slides were dried 
for approximately 30 min at RT. Unless fixing was directly followed by 
immunofluorescence staining, slides were wrapped in parafilm and stored at -20 °C. 
 
2.11 Immunofluorescence for !-catenin 
Fixed cells were washed 3 x with PBS before they were permeabilised using 0.5 % Triton 
X-100 in PBS for 10-20 min at RT. Blocking was performed in 10 % normal goat serum 
(Sigma) in PBS for 30 min at 37° C. The primary antibody was diluted in blocking 
solution at appropriate concentrations (Table 6) and incubated for 1 h at RT or 37° C. 
Cells were washed 3 x with PBS before the secondary antibody (Alexa Fluor 488 goat 
anti-rabbit IgG, A11034; Alexa Fluor 568 goat anti-rabbit IgG, A11036; Alexa Fluor 568 
goat anti-mouse IgG, A11031; all Invitrogen) was added at a dilution of 1:1000 in 
blocking solution. Cells were washed 3 x with PBS, then mounted using Vectashield 
mounting medium with Dapi (Vector Laboratories). Slides were examined under a Nikon 
TE300fluorescent microsope or a multiphoton Zeiss LSM 510 NLO meta confocal 
microscope. Slides were kept at 4° C if necessary. 
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Table 6: Antibodies used for immunofluorescence 
 
2.12 Colocalisation 
IF images of !-catenin (red) and DAPI (blue) staining were opened in ImageJ software. If 
necessary, a stack of images was separated into 2 images (2 channels). From the ‘Plugins’ 
menu, ‘Colocalization’ was selected and ‘Channel 1 (red)’ was assigned the !-catenin 
image, ‘Channel 2 (green)’ the DAPI image. The resulting red/green colocalisation image 
type was changed into a 32-bit image (black and white). Colocalisation of !-catenin and 
DAPI was seen as white dots within the nucleus. 
 
2.13 TOPFlash reporter assay 
Prostate cell lines PC-3, P4E6 and PNT2-C2 (as well as SW480 and Hela control lines) 
were plated at 200 and 500 cells per 96-well. 24 h post plating, cells were transfected with 
0.1 !g reporter plasmid MO50 (Super8XTOPFlash), MO51 (Super8XFOPFlash) or MO72 
Antibody name Company & Cat. No. Dilution 
Anti-!-catenin antibody Sigma; C2206 1:1000 
!-Catenin (6B3) Rabbit monoclonal 
antibody 
Cell Signaling; 9582 1:1000 
Phospho-!-Catenin (Ser552) Antibody Cell Signaling; 9566 1:1000 
Phospho-!-Catenin (Ser675) Antibody Cell Signaling; 9567 1:1000 
Phospho-!-Catenin (Ser33/37/Thr41) 
Antibody 
Cell Signaling; 9561 1:1000 
Phospho-!-Catenin (Thr41/Ser45) 
Antibody 
Cell Signaling; 9565 1:1000 
Anti-Active-!-Catenin (anti-ABC), clone 
8E7 
Millipore; 05-665 
lot no. DAM1487766 & 
TR1510175 
1:50, 1:100 
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(Super16XTOPFlash), respectively, using 0.28 !l/well TransIT-LT1 (Mirus) transfection 
reagent, according to the manufacturers instructions. If desired, cells were activated with 
20 mM LiCl 24 h post transfection. The luciferase assay was performed 48 h post 
transfection. 
 
2.14 Luciferase Assay 
Luciferase assays were performed using the Bright-Glo Luciferase Assay System 
(Promega). The Glo Lysis Buffer was equilibrated to RT before use. Cells were washed 
with PBS prior to the addition of 50 µl of Glo Lysis Buffer to each well of a 96-well plate. 
To ensure complete and equal coverage of the cells, the plate was slowly rocked several 
times. After 5 min incubation at RT to allow for cell lysis, the lysate was transferred to 
black-out luminometer plates and 50 µl Bright-Glo Assay Reagent was added. 
Luminescence was measured using a microplate reader (BMG Labtech POLARstar 
OPTIMA). 
 
2.15 Cell cycle analysis 
Cells from one 6-well or the equivalent amount from a larger culture container, were 
trypsinised and suspended in 5 ml R10. Cells were centrifuged at 280 x g (1300 rpm) for 
5 min. The cell pellet was then resuspended in 1 ml PBS. 2.5 ml absolute ethanol was 
added to fix the cells and the suspension was immediately mixed to prevent clustering of 
cells. Cells were incubated on ice for 15 min or at -20 °C for up to one month. On the day 
of the FACS analysis, cells were centrifuged at 280 x g for 5 min. The pellet was 
resuspended in 500 !l propidium iodide (PI) solution and incubated at 37 °C for 40 min. 
3 ml PBS were added and the suspension was again centrifuged at 280 x g for 5 min. Most 
of the supernatant was removed, leaving approximately 500 !l for resuspension prior to 
FACS analysis. 
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2.16 Protein analysis 
2.16.1 Cell lysis 
Cells were washed with PBS and the appropriate amount of CytoBuster Protein Extraction 
Reagent (Millipore), depending on cell culture surface area or number of cells, was added, 
according to the manufacturer’s instructions. When producing lysate from adherent cells 
in culture, cells were scraped off to maximise recovery, after the initial incubation of 
5 min at RT. The solution was transferred to a 1.5 ml tube and centrifuged for 4 min at 
670 x g (2000 rpm). Supernatant was transferred to a fresh tube. 1x complete Protease 
Inhibitor Cocktail, PIC, (Roche Applied Science) was added to the supernatant which was 
then stored at -80 °C. 
 
2.16.2 Bradford assay 
Bradford assays were performed using the ‘Protein Bradford’ application on the Nanodrop 
1000 software (Thermo Scientific). A serial dilution of protein standards of 0, 2000, 1000, 
500, 250, 125, 62.5, 31.25, 15.625, 7.8125 and 3.9063 !g/ml BSA was prepared and 
mixed in a 1:50 dilution with Coomassie Protein Assay Reagent (Thermo Scientific 
Pierce). After production of a standard curve, 1:50 sample dilutions in Coomassie reagent 
were prepared and measured. 
 
2.16.3 SDS-PAGE -Gel-electrophoresis 
10 % acrylamide gels were prepared and left for polymerisation for a minimum of 2.5 h or 
overnight before loading. SDS running buffer was used with these gels. Alternatively, 
10 % pre-cast Precise Protein Gels (Thermo Scientific) were pre-run at 60 V in Tris-
HEPES-SDS buffer prior to sample loading. 
Samples were mixed with SDS loading dye (final concentration of approximately 1x) and 
incubated at 100 °C for 15 min. Per lane of marker, 5 !l Kaleidoscope Prestained 
Standards (Bio-Rad) and 2 !l Biotinylated Protein Ladder (Cell Signaling) were mixed 
with 8 !l SDS loading dye and incubated at 100 °C for 5 min. 20 !l sample or 15 !l 
marker mix were added per lane. Gels were run at 60-100 V for up to 1 h or up to 2.5 h 
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(non-pre-cast gels). Gels were then used for wet or semi-dry transfer of proteins onto 
PVDF membranes. 
 
2.16.4 Wet transfer 
Wet transfer was performed using the Mini Trans-Blot Electrophoretic Transfer Cell 
system (BioRad). Membranes were wet in Methanol and washed with ddH2O before being 
soaked in pre-cooled transfer buffer for approximately 5 min. The gel holder cassette was 
loaded while submerged in transfer buffer to minimise bubbles starting from the black side 
of the cassette. One ScotchBrite foam pad and two pieces of pre-soaked 3 mm Western 
Blotting paper were laid onto the black side of the cassette before the gel, followed by the 
membrane were carefully laid onto the card. On top of the membrane another two pieces 
of blotting paper and one ScotchBrite foam pad were added. The cassette was firmly 
closed and placed in the transfer cell tank. Transfer was performed at 4 °C at 100 V for 
1 h. If necessary, dried membranes were stored in between Western Blotting paper at 4 °C. 
 
2.16.5 Semi-dry transfer 
Using a Trans-Blot SD cell (Bio-Rad), proteins were transferred from gels onto PVDF 
membrane by semi-dry blotting. Membranes were pre-soaked in Methanol, washed in 
ddH2O and then incubated in transfer buffer B. Gels were equilibrated for 10-15 min in 
transfer buffer B. Onto the bottom plate of the Trans-Blot cells 2 sheets of Extra Thick 
Blot Paper (Bio-Rad), pre-soaked in transfer buffer A and 2 sheets, pre-soaked in buffer B, 
were added. Air bubbles were removed between each step by rolling a pipette across the 
stack. The membrane, followed by the gel and 4 sheets of pre-soaked blot paper (buffer B) 
were added on top, before semi-dry transfer was performed at 200 mA using a Power Pac 
200 (Bio-Rad), for 45 min. After disassembly, membranes were stored dry in between 
Western Blotting paper, or re-wet in methanol prior to protein detection. 
 
2.16.6 Western Blot 
All washes and incubations were performed while rocking. Membranes were wet in 
Methanol, rinsed in dH2O and washed in TBST for 10 min prior to blocking. Membranes 
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were blocked in 3 % Marvel or 3 % BSA for a minimum of 1 h at RT or over night at 
4 °C. Primary antibodies were added and incubated according to Table 7. 
After washing 3 times in TBST for 10 min each, the respective secondary antibody 
(Table 8) was added. The anti-biotin antibody to detect biotinylated marker bands on the 
membrane was added together with the secondary antibody. Incubation of secondary 
antibody was performed at room temperature. After another washing step (3x 10 min) in 
TBST, a chemiluminescent substrate mix (Roche) was added. Blots were developed using 
the Kodak® BioMax™ system (GBX developer, GBX fixer) and Amersham Hyperfilm 
ECL (GE Healthcare). 
If necessary, western blot membranes were stripped by incubating them in stripping buffer 
at 56 °C for 45-60 min. Membranes were washed in TBST 3 times. In general, stripping of 
blots was only performed to re-probe for !-actin as a control. 
 
 
Table 7: Primary antibodies for Western Blots 
Antibody name Company & 
Cat. No. 
Dilution Incubation 
Time 
PSCA polyclonal antibody (A01) Abnova; 
H00008000-A01 
1:750; 
1:1250 
2 h 
PSCA antibody Abcam; ab53159 1:500, 
1:1000 
2 h 
Anti-!-catenin antibody Sigma; C2206 1:2000 1 h or o. n. 
!-Catenin (6B3) Rabbit monoclonal 
antibody 
Cell Signaling; 
9582 
1:1000 2 h or o. n. 
Phospho-!-Catenin (Ser33/37/Thr41) 
Antibody 
Cell Signaling; 
9561 
1:1000 2 h 
Monoclonal Anti-Actin clone AC-40 
produced in mouse 
Sigma; A3853 1:10000 1 h 
Monoclonal Anti-!-Actin antibody 
produced in mouse 
clone AC-74 
Sigma; A5316 1:5000 1 h 
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Table 8: Secondary antibodies for Western Blots 
 
2.16.7 Western Blot using the Snap i.d. system 
Western Blots for !-actin (with antibody A5316, Sigma), were routinely performed using 
the Snap i.d. system (Millipore) according to the manufacturer’s instructions. 0.3 % 
Marvel was used for blocking and the antibody was added in a 1:1000 dilution in blocking 
solution, instead of 1:5000 for standard Western Blots. The total volume of antibody mix 
was 3 ml per blot in single blot holders. The secondary antibody (P0260, Dako) was also 
used at a 1:1000 dilution in blocking solution. 
The Snap i.d. system was initially also used with !-catenin antibodies C2206 (Sigma) at 
1:500, and 6B3 (9582, Cell Signaling) at 1:250, together with secondary antibodies A6667 
or A0545 for C2206, at 1:1000, or 7074 (Cell Signaling) at 1:250, respectively. 
 
Antibody name Company & 
Cat. No. 
Dilution Incubation 
Time 
Anti-Rabbit IgG (whole molecule) - 
Peroxidase antibody 
Sigma; A0545 1:5000 1 h 
Polyclonal Rabbit 
Anti-Mouse Immunoglobulins/HRP 
Dako; P0260 1:5000 1 h 
Anti-Rabbit IgG (whole molecule), 
F(ab!)2 fragment"Peroxidase 
Sigma; A6667 1:5000 1 h 
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling; 
7074 
1:1000 1 h 
Anti-biotin, HRP-linked Antibody Cell Signaling; 
7075 
1:5000 1 h 
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Chapter 3 
 
Aims and Hypothesis 
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3. Aims and hypothesis 
Currently, there is no effective treatment for the late stages of prostate cancer due to 
tumours becoming resistant to standard therapeutic approaches. The aim of this project 
was to evaluate the use of lentiviral delivery of shRNAs into prostate cancer cells, to 
target overexpressed genes. In principle, there are two potential cell populations within a 
prostate tumour which could be targeted: the committed basal (CB) population, which 
forms the mass of the tumour, or the far rarer proposed cancer stem cell (CSC) population, 
which expresses the surface marker CD133 (Collins et al., 2005, Richardson et al., 2004). 
The aim of this study was to establish a method for lentiviral transfer of shRNAs into 
primary prostate epithelial cells, and if possible, the cancer stem cell population to 
elucidate the role of the overexpressed shRNA target within prostate tumours. To test the 
feasibility of the method, we initially developed a cell line model (based on PC-3 cells) 
and targeted PSCA, an established marker for prostate basal differentiation (Tran et al., 
2002). PSCA has also been shown to be overexpressed in a large number of prostate 
tumours (Reiter et al., 1998, Zhigang and Wenlv, 2004) and its expression is associated 
with higher Gleason score and more advanced tumours (Gu et al., 2000). Furthermore, 
xenografted animals treated with anti-PSCA antibody displayed decreased tumour growth 
and increased survival (Saffran et al., 2001). In addition, PSCA has been shown to be 
higher expressed in CB cells during a microarray study on primary tissue, with a mean 
fold expression change of 20.11 in committed versus stem cells (Birnie et al., 2008). 
PSCA has also been under discussion as a potential target for T-cell-based immunotherapy 
(Dannull et al., 2000). It therefore provided an interesting shRNA target for 
downregulation within a selected tumour population. 
The hypothesis was that successful stable downregulation of such a highly expressed gene 
by shRNAs will alter the biological tumour properties, such as growth, invasion and 
metastasis formation. 
The cell line model was approached from two different angles. Firstly, ‘home-made’ 
lentiviruses targeting PSCA were constructed but use of these was abandoned due to 
insufficient titres. Secondly, commercial viruses were used to infect PC-3 cells and 
generate stable shRNA-cell lines. 
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As the cell line model was only a proof of principle and the ultimate aim was to use 
shRNA-lentiviruses on primary prostate epithelial cells from patient samples, and more 
specifically, the prostate cancer stem cell population within them, PSCA was abandoned 
as a target in favour of !-catenin. This decision was based on microarray expression data 
obtained in our laboratory, where patient tissue was analysed (Birnie et al., 2008). Of a 
total of 54618 probes in the array, about 17000 showed high enough expression levels for 
statistical analysis. The first !-catenin probe was at place 2409 and there were two further 
probes above the expression threshold (at position 2087 and 11762). Furthermore, TCF-4, 
a direct interaction partner of !-catenin was also found to be differentially expressed 
(positions 4828, 6485, 8939 and 10575). In the Affimetrix array, TCF-4 showed an 
average 1.37 or 1.30 fold change between stem versus committed and malignant versus 
benign, respectively. This data was confirmed by RT-PCR (Birnie et al., 2008). 
Our interest in the role of !-catenin in prostate cancer, and prostate CSCs, was based on its 
widely known importance in stem cell self renewal pathways (O'Brien et al., 2010), as 
well as its role in other types of cancers, with colon cancer being the most prominent 
example (Kanwar et al., 2010, Kolligs et al., 2002, Morin et al., 1997). In the majority of 
colon and gastrointestinal cancers, canonical Wnt signalling is abnormally activated due to 
mutations in the tumour suppressor gene APC (Giles et al., 2003b, van Es and Clevers, 
2005). Although mutations of !-catenin in prostate cancer are relatively rare, they have 
been found to contribute to aberrant activation of Wnt signalling in hepatocellular, ovarian 
and hair matrix cell tumours (Giles et al., 2003b). 
For prostate cancer, it is still under discussion whether !-catenin is an important 
contributor to cancer formation and if so to what degree and in which type of prostate 
tumours. There are varying reports about !-catenin mutation, expression and its cellular 
location in prostate (cancer) tissue (Chesire et al., 2000, Shah et al., 2009, Voeller et al., 
1998), and interaction between !-catenin and the androgen receptor has been documented 
(Chesire and Isaacs, 2002, Schweizer et al., 2008, Wang et al., 2008a). 
Being the essential mediator between extracellular Wnt signals and the TCF family of 
transcription factors, !-catenin has been shown to alter gene expression of a large number 
of genes. Some of these, like c-myc, Cyclin D1 and Cyclin D2 have been implicated in 
cancer development or progression (Cole et al., 2010, Jung et al., 2001, Tetsu and 
McCormick, 1999, Yochum et al., 2010, He et al., 1998). 
The aim of infecting prostate cancer primary cells with sh-!-catenin lentiviruses was 
based on the hypothesis that high expression of !-catenin might provide the cancer cells 
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with certain advantages regarding growth, invasion and metastasis formation. 
Downregulation of such an important gene would therefore interfere with these important 
tumour properties and provide a new anchor point for future therapeutical approaches. 
Considering the encouraging results in the cell line model, where sh-!-catenin lentiviruses 
did interfere with growth and invasion, as well as tumour onset in vivo, !-catenin remains 
an interesting target in the study of prostate cancer. 
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4. Results 
4.1 Generation of reporter-shRNA-lentiviruses 
4.1.1 Amplification of fluorescent genes and CMV promoter for cloning into pENTR 
5’ TOPO 
The Invitrogen Gateway system has been designed to quickly produce vectors with 
different combinations of promoters and genes without traditional, restriction enzyme 
based cloning steps. We wanted to adapt this system for the production of lentiviral 
vectors carrying an shRNA and a fluorescent marker plus their respective promoters 
(Figure 20). The fluorescent marker would allow for easy monitoring of the infection and 
its effects on prostate cancer cells. 
Plasmids, which contained one of three fluorescent reporter genes, mOrange, mCitrine or 
tdTomato (Table 9) (Shaner et al., 2005) were used to amplify each gene and its promoter 
(CMV). 
Reporter genes were cloned into the Gateway pENTR 5’ TOPO plasmid under the control 
of a CMV promoter. Constructs were amplified by PCR from pCMVmOrange, 
pCMVcitrine or pCMVtdTomato, respectively (Hager et al., 2008), with or without the 
polyA sequence following the fluorescent gene (Figure 19, Table 10). Gelelecrophoresis 
was performed to confirm the PCR products (Figure 21, see Table 10 for product sizes). 
Since tdTomato is a dimer, two bands were visible on the gel. CMVmOrangeA and 
CMVcitrineA were used for cloning into pENTR 5’ TOPO. 
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Protein Origin Structure Relative brightness compared 
to EGFP [%] 
mOrange DsRed Monomer 146 
mCitrine YFP Monomer 174 
tdTomato mRFP1 Dimer 142 
 
Table 9: Fluorescent proteins 
Listing of fluorescent proteins used in this study, which proteins they were derived from, their 
structure (monomer or dimer), their relative brightness compared to EGFP (Campbell et al., 2002, 
Griesbeck et al., 2001, Shaner et al., 2004, Shaner et al., 2005, Zacharias et al., 2002). 
 
 
 
 
 
Figure 20: Schematic drawing of the MutiSite Gateway recombination reaction 
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Figure 21: Position of PCR primers 
 
 
Primer 1 Amplified product using CMV-SJ1 5’ or 
CMV-SJ2 5’ as Primer 2 
Size in bp 
(approximate) 
CMV antisense CMV promoter 589 
Fluor 3’ CMV promoter + mOrange 1325 
Fluor 3’ CMV promoter + citrine 1332 
Fluor 3’ CMV promoter + tdTomato 2043 
EGFP-Luc rev CMV promoter + mOrange + polyA 1525 
EGFP-Luc rev CMV promoter + citrine + polyA 1532 
EGFP-Luc rev CMV promoter + tdTomato + polyA 2243 
 
Table 10: Products amplified by PCR using different primer combinations 
 
 
  
 
 
 
Figure 22: Gelelectrophoresis of PCR products after amplification 
Gelelectrophoresis of PCR products after amplification of CMV, CMVtdTomato, CMVtdTomatoA, CMVmOrange, CMVmOrangeA, CMVcitrine and 
CMVcitrineA using primers CMV-SJ1 5’ and CMV-SJ2 5’ with either CMV antisense, Fluor 3’ or EGFP-Luc rev, respectively.  
            Sarah Jakoby 
 
 
 
 
 
 
 
        PhD
 thesis 2010 
  
 
 
 
 
 
 
 
          88 
Sarah Jakoby  PhD thesis 2010 
 89 
4.1.2 Cloning of reporter expression cassettes into pENTR 5’ TOPO 
CMVmOrangeA and CMVcitrineA were cloned into pENTR 5’ TOPO. NcoI restriction 
digests were performed to confirm the successful generation of the entry clones pENTR-
CMVmOrangeA and pENTR-CMVcitrineA (Figure 23). Successful cloning followed by 
NcoI digest of pENTR-CMVmOrangeA should have resulted in 3 bands: 2833 bp, 663 bp 
and 484 bp, or 2916 bp, 663 bp and 401 bp, depending on orientation of the fragment post 
integration. There should be 2 bands for pENTR-CMVcitrineA (3496 bp and 484 bp, or 
2779 bp and 1201 bp, respectively). 
For pENTR-CMVmOrangeA, DNA gel electrophoresis resulted in 6 correct clones (1, 2, 
4, 5, 9, 10) (Figure 23), which showed bands around the 3000 bp marker, as well as 
around 650 bp and 450 bp. As the digest made it difficult to distinguish between a 
possible band at 484 bp or 401 bp, further confirmation was necessary. Sequencing as well 
as a functionality test of the construct via mOrange expression post transfection was 
performed. The digest also resulted in an additional band around 250 bp, which also 
appeared in one of the incorrect clones (clone 3), and might therefore have been a 
contamination. However, it was not visible in the three clones without an insert (clones 6, 
7 and 8). 
The NcoI digest of pENTR-CMVcitrineA resulted in 7 correct clones (2, 3, 4, 7, 8, 9,10) 
(Figure 23). They all showed 2 bands after DNA gel electrophoresis, one around the 
3000 bp marker, the other at 1200 bp. This confirmed that the construct had integrated in 
reverse orientation, compared to the reading frames of pUC origin and the kanamycin 
resistance gene. 
As the tdTomato construct (Figure 22) resulted in double bands after PCR amplification, 
due to tdTomato being a tandem-dimer, only pENTR-CMVmOrangeA and pENTR-
CMVcitrineA were chosen for further cloning. 
To confirm functionality of the fluorescent marker, 293 cells were transfected with 
pENTR-CMVmOrangeA and pENTR-CMVcitrineA plasmids. All transfections resulted 
in strong fluorescence after 48 h and visually estimated transfection efficiencies were 
between 40 and 50% (Figures 24 and 25). 
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Figure 23: NcoI digest of pENTR-CMVmOrangeA and pENTR-CMVcitrineA 
NcoI digest of pENTR-CMVmOrangeA (top) and pENTR-CMVcitrineA (bottom). Clones indicated 
by asterisk (*) were sequenced. 
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Figure 24: Transfection of 293 cells with pENTR-CMVmOrangeA 
Transfection of 293 cells with pENTR-CMVmOrangeA clone 5 (A), clone 9 (B) and clone 10 (C) at 
48 h post transfection. 
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Figure 25: Transfection of 293 cells with pENTR-CMVcitrineA 
Transfection of 293 cells with pENTR-CMVcitrineA clone 4 (A), clone 8 (B) and clone 10 (C) at 48 h 
post transfection. 
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4.1.3 Sequencing analysis of promoter and fluorescent reporter construct 
Sequences were analysed and aligned using Vector NTI software (Invitrogen). As 
differentiation between the fragments after NcoI digest was not possible, sequencing 
confirmed that pENTR-CMVmOrangeA clones 5, 9 and 10 contained the insert in reverse 
orientation (Figures 26 and 27). The sequence of the CMV promoter was also confirmed 
as correct (Figure 26). Sequencing also confirmed the result of the NcoI digest of pENTR-
CMVcitrineA clones 4, 8 and 10. These clones contained the insert in reverse orientation 
(Figure 28). 
 
  
 
 
 
 
Figure 26: Sequence alignment of pENTR-CMVmOrangeA clones 
Sequence alignment of pENTR-CMVmOrangeA clones 5, 9 and 10 using primer M13rev-26. Partial CMV promoter sequence shown in yellow and 
plasmid backbone in blue. 
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Figure 27: Confirmed layout of pENTR5-CMVmOrangeA after sequencing analysis 
 
 
 
Figure 28: Confirmed layout of pENTR5-CMVcitrineA after sequencing analysis 
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4.1.4 Cloning of shRNAs for PSCA, !-actin and luciferase into pENTR U6 
The U6 promoter is an RNA polymerase III type 3 promoter, which is responsible for the 
transcription of small nuclear RNAs. It is one of the promoters commonly used to express 
shRNAs (Bannister et al., 2007) and it is present in a number of commercially available 
vectors. 
The aim of this part of the project was to develop a model system for lentiviral shRNA 
transfer into prostate cancer cells before later modifying the system to use in cultured 
prostate primary cells and cancer stem cells. The chosen gene for downregulation was 
PSCA (Reiter et al., 1998), which has been found to be upregulated in a large proportion 
of prostate cancers (Zhigang and Wenlv, 2004). According to a recent microarray study, 
PSCA is over-expressed in the malignant transit-amplifying population of prostate 
samples (Birnie et al., 2008), and therefore provided a suitable model target for 
downregulation in a prostate cancer cell line. 
 
Single stranded shRNA oligos for PSCA, !-actin (as a positive control) and luciferase (as 
a negative control), were annealed and the double stranded shRNAs were then cloned into 
pENTR/U6 (Figure 29). 
Even though plasmids were initially digested using MluI, the short sequence of the 
shRNA insert (66 bp or 67 bp), made it impossible to distinguish between clones with 
successfully integrated shRNA (fragment size 1988/1989 bp and 932 bp) and empty 
backbones (fragment size 1922 bp and 932 bp) (Figure 30). Using BanII for restriction 
analysis (fragment size of backbone 2100 bp, with insert 830 bp, without 760 bp) did also 
not improve resolution to a high enough level to sort negative from positive clones (Figure 
31). BanII digests were also examined on VisiGel (Stratagene) in an attempt to enhance 
visibility (Figure 31). There was no suitable restriction site common to all shRNA 
sequences, which could have been used. This made it necessary to have a reliable method 
for sequencing shRNA clones to confirm correctness of inserts. 
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Figure 29: Construction of pENTR/U6 
Construction of pENTR/U6 plasmids using the Invitrogen BLOCK-iT!  U6 RNAi Entry Vector Kit 
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Figure 30: MluI restriction digest of pENTR/U6 
MluI restriction digest of pENTR/U6 shRNA clones (1-10; negative control X) with MluI.  
 
 
Figure 31: BanII restriction digest of pENTR/U6 
Restriction digest of pENTR/U6 shRNA clones with BanII on agarose gel (top) and Visigel (bottom). 
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Sequencing was optimised to confirm correctly inserted shRNA cassettes, as the hairpins 
within the constructs caused problems during standard sequencing procedures. This is a 
common phenomenon when sequencing hairpin structures and has been reported 
previously (Devroe and Silver, 2002, Guo et al., 2005, McIntyre and Fanning, 2006, 
Miyagishi et al., 2004, Yu et al., 2003). Different strategies have been discussed to 
overcome this shortfall (Taxman et al., 2006). 
Initial sequencing of the pENTR/U6 clones with primer M13R resulted in short read outs 
around 150 bp with a break off after a few bases into the shRNA sequence. The only 
exception was clone 24_9 (with shRNA PSCA_S2) with a read out of around 700 bp. 
However, in this clone there was a 3 bp deletion within the shRNA. The primer M13F also 
gave a low read out of about 400 bp. The promoter was confirmed in all clones without 
detectable mutations but the read out stopped a few base pairs into the shRNA sequence, 
similar to the results from M13R (Figure 32) 
After the initial problems, successful sequencing across the hairpin using Silver 
sequencing service with special conditions (SAM plus, Cogenics), confirmed correct 
sequences for pENTR/U6_PSCA_S2, pENTR/U6_PSCA_S3, pENTR/U6_PSCA_S4, as 
well as the positive control pENTR/U6_PSCA_sh-!-actin and the negative control 
pENTR/U6_PSCA_sh-luciferase. Sequences were analysed and aligned using Vector NTI 
software (Invitrogen). Even though the read out still dropped slightly at the beginning of 
the hairpin structure in all constructs, sequencing was of good enough quality for analysis 
(Figure 33). 
Analysis of the sequences confirmed positive clones for all pENTR/U6 constructs (Figure 
34 A, B, D-F) except the clones containing PSCA_S1 shRNA. None of the 10 sequenced 
pENTR/U6_PSCA_S1 clones was positive and they all showed the same pattern of 
sequence disruption (Figure 34 C). 
It was decided that, for lentivirus production, pENTR/U6_PSCA_S3 clone 2 and 
pENTR/U6_PSCA_S4 clone 10 would be used initially. 
 
  
 
 
 
Figure 32: Sequence alignment of pENTR/U6 clones 
A. Alignment result of pENTR/U6_PSCA_S2 clone 9 (bottom line) with its hypothetical correct sequence (complete plasmid: top line, actual clone 
sequence with 3 bp deletion (red arrow): 2nd line from top, shRNA insert only: 3rd line from top). 
B. pENTR/U6_PSCA_S1 clone 5 with break off of the read out a few bases into the shRNA sequence, illustrated by red rectangle (complete plasmid: 
top line, shRNA insert only: 2nd line from top, M13F forward read out: 3rd line from bottom; M13R reverse complement read out: 2nd line from 
bottom). 
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Figure 33: Example of sequencing spectrum 
Example of read-out with drop after the start of the shRNA (red arrow). The read-out improves later 
(green arrow). The sequence shown is from pENTR/U6_PSCA_S3 clone 7. 
 
 
  
 
 
(A) pENTR/U6_sh-!-actin 
 
 
(B) pENTR/U6_sh-luciferase 
 
 
(C) pENTR/U6_PSCA_S1 
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(D) pENTR/U6_PSCA_S2 
 
 
(E) s pENTR/U6_PSCA_S3 
 
 
(F) pENTR/U6_PSCA_S4 
 
Figure 34: Sequence alignments of pENTR/U6 clones containing shRNAs 
The location of the shRNA sequences is indicated in yellow, the hypothetical correct sequence is listed first, with the shRNA sequence alone underneath, 
followed by the different clones and the consensus sequence on the bottom line. 
  
 
 
 
 
 
 
 
         103 
            Sarah Jakoby 
 
 
 
 
 
 
 
        PhD
 thesis 2010 
Sarah Jakoby  PhD thesis 2010 
 104 
4.1.5 Generation of pLenti6 expression plasmids 
The MultiSite Gateway LR recombination reaction using the LR Clonase II Plus Enzyme 
Mix occurs between the att-sites of the different entry vectors and the destination vector. It 
results in an expression vector carrying both fluorescent gene and shRNA with their 
respective promoters (Figure 35). Expression plasmids were constructed using site specific 
recombination (Hartley et al., 2000) between pENTR-CMVmOrangeA, pENTR/U6 entry 
clones containing an shRNA and the destination  vector pLenti6/R4R2/V5-DEST (referred 
to as pLenti6 below) (Figure 35). 
The resulting pLenti6 expression constructs were confirmed by restriction digest with 
EcoRI and NcoI (Figures 36, 38 and 39). 
To confirm the functionality of the fluorescent reporter gene in the context of the lentiviral 
construct, pLenti6 expression clones were transfected into PC-3 and P4E6 cells. High 
levels of mOrange expression were detected after 72h for pLenti6mOrangePSCA_S3 and 
pLenti6mOrangePSCA_S4 as well as the positive and negative controls, 
pLenti6mOrange!-actin and pLenti6mOrangeLuc, respectively (Figure 37). 
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Figure 35: Recombination reaction to generate pLenti6 plasmids 
pENTR 5’ TOPO containing the fluorescent gene mOrange under the control of the constitutive 
promoter CMV and pENTR/U6 containing an shRNA under the control of the U6 promoter were 
combined with the pLenti6 destination vector. 
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Plasmid clones    Virus names 
pLenti6mOrangePSCA_S3 clone 2  Lenti6mOrangePSCA_S3 
pLenti6mOrangePSCA_S4 clone 10  Lenti6mOrangePSCA_S4 
pLenti6mOrangeLuc clone 1   Lenti6mOrangeLuc 
pLenti6mOrange!-actin clone 1  Lenti6mOrange!-actin 
 
Table 11: Plasmid clones chosen for virus production with corresponding virus names 
 
 
Figure 36: EcoRI and NcoI digests of pLenti6mOrangePSCA 
Digest of pLenti6mOrangePSCA_S3 clones with EcoRI (E) and NcoI (N). Undigested (0). 
CMVmOrangePSCA_S3 was cut out using EcoRI (approx. 1580bp). 
 
 
Figure 37: Transfection of PC-3 with pLenti6mOrangePSCA 
Representative example of PC-3 cells transfected with pLenti6mOrangePSCA_S4 at 72 h post 
transfection. 
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Figure 38: EcoRI and NcoI digests of pLenti6mOrange!-actin 
Digest of pLenti6mOrange!-actin clones 1-5 with EcoRI (E) and NcoI (N). CMVmOrange!-actinA 
was cut out using EcoRI (approx. 1580bp). 
 
 
Figure 39: EcoRI and NcoI digests of pLenti6mOrangeLuc 
Digest of pLenti6mOrangeLuc clones 1-3 with EcoRI (E) and NcoI (N). CMVmOrangeLucA was cut 
out using EcoRI (approx. 1580bp). 
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4.1.6 Production and titering of recombinant lentiviruses 
A cotransfection of the pLenti6 expression constructs and the ViraPower Packaging Mix 
into 293FT producer cells was performed to generate functional, VSV-G pseudotyped 
lentiviruses, which has been described previously (Hager et al., 2008). 
In general, viral particle numbers, obtained from titration in HT1080 cells, were very low, 
ranging from 0.9 x 102 to 5.4 x 102. For the initial titration of Lenti6mOrangePSCA_S3, 
Lenti6mOrangePSCA_S4, Lenti6mOrangeLuc and Lenti6mOrange!-actin, virus-
containing supernatant was harvested at 72 h, according to manufacturer’s 
recommendations. In order to improve viral yield, virus production was repeated with 
Lenti6mOrangePSCA_S3 harvested at 48 h, 72 h and 96 h, respectively (Figure 40). 
Titres obtained at 48 h, were higher than at 72 h and 96 h. However, the maximum titre 
achieved after optimisation was still only 5.4 x 102. According to the manufacturer, titers 
between 5 x 105 to 2 x 107 should be obtained12. Repeated communication with Invitrogen 
did not result in additional information to improve results. 
Since work by Stefanie Hager and Fiona Frame had also shown the limitations of the 
Invitrogen lentivirus production system, especially for primary prostate cancer cells 
(Hager et al., 2008), this work was not continued. 
Instead, it was decided to use custom made shRNA-lentiviral particles, which had become 
commercially available (Sigma) and focus on over-expressed genes from the prostate 
cancer stem cell population according to microarray data provided by Birnie and 
colleagues (Birnie et al., 2008). 
 
 
                                                
12 Invitrogen ViraPower™ Promoterless Lentiviral Gateway® Kits manual, Version C, 23 
August 2007, for catalog nos. K591-10 and K5910-00 
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(B) 
 
(C) 
 
(D) 
 
Figure 40: Titer of Lenti6mOrangePSCA viruses 
Titer of Lenti6mOrangePSCA_S3 virus, harvested at different time points. Virus was harvested from 
293FT producer cells at 48 h (B), 72 h (C) and 96 h (D). (A) Titres obtained: 5.4 x 102 (48 h), 2.7 x 102 
(72 h) and 1.2 x 102 (96 h). 
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4.2 !-catenin studies in prostate cancer cell lines 
One of the signalling pathways, that has long been associated with cancer formation due to 
its important role in various stages of embryonic development, is the Wnt signalling 
pathway. It was named after its upstream ligands (Wnts). The key molecule of this 
pathway, !-catenin, has been associated with a variety of different cancers, most 
prominently, colon cancer (Giles et al., 2003b). Results from a recent microarray analysis, 
which compared gene expression in the committed basal and stem cell populations of 
prostate patient samples, found an overrepresentation of genes involved in Wnt signalling 
(Birnie et al., 2008). Therefore, we wished to investigate the role of !-catenin in prostate 
tumour initiation, growth and dissemination. 
We used lentiviral delivered shRNAs to knock down !-catenin expression in a prostate 
cancer cell line (PC-3). Following the generation of stable cell lines, the effects of reduced 
!-catenin expression on the biological properties of tumour cells were studied. 
 
4.2.1 Generation of PC-3 cell lines with stable knockdown of !-catenin (PC-3v) 
To determine the long-term effects of a constitutively expressed shRNA targeting 
!-catenin, PC-3 cells were infected with shRNA-containing lentiviruses. As lentiviruses 
integrate into their host cell genome, the transported shRNA is stably expressed in the cell 
line. After having technical difficulties with producing suitable high titre shRNA-
lentiviruses ourselves, we purchased commercially available lentiviral particles (Sigma), 
as these offered a time- and cost-effective tool for our study. 
 
4.2.1.1 Puromycin selection of prostate cell lines 
Before stable cell lines were generated, a kill curve experiment was performed to 
determine the minimum concentration of puromycin that caused complete cell death after 
3-5 days. This concentration was then used to select lentivirus-infected cells. Prostate 
cancer cell lines PC-3 and LNCaP as well as the normal prostate cell line PNT2-C2 were 
used for puromycin titration. 
PC-3 cells were sensitive to puromycin at 2 µg/ml and showed extensive cell death at day 
5. By day 8 there were no viable cells left (Figure 41). Both LNCaP and PNT2-C2 cell 
lines were more sensitive to puromycin than PC-3 cells, and extensive cell death was 
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observed with 0.5 µg/ml at day 5 (Figure 42). Cells were cultured in selection medium for 
14 days. Even though some PC-3 cells remained at the optimal concentration of 2 µg/ml, 
these cells did not start growing when selection medium treatment was terminated and 
cells were placed in normal growth medium. 
Since PC-3 cells presented as the most robust cell line, whilst still being susceptible to 
puromycin, they were chosen for lentivirus infection. 
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Figure 41: Puromycin susceptibility in PC-3 cells 
PC-3 cells at day 5 (a, b) and day 8 (c, d) of puromycin selection. The medium contained 0.5 µg/ml 
(a, c) or 2 µg/ml (b, d) puromycin, respectively. 
 
Figure 42: Puromycin susceptibility in PNT2-C2 and LNCaP cells 
PNT2-C2 (a, b) and LNCaP (c, d) at day 5 with 0.5 µg/ml (a, c) or 2 µg/ml (b, d) puromycin. 
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4.2.2 Infection of PC-3 prostate cancer cells and selection of stable clones 
PC-3 cells were infected with four lentiviruses (Sigma, Clone IDs TRCN0000003843, 
TRCN0000003844, TRCN0000003845 and TRCN0000003846; subsequently referred to 
as virus 43, 44, 45 and 46, respectively). All four lentiviruses contained a different shRNA 
targeting !-catenin. PC-3 cells were infected at MOI = 10 in the presence of media alone 
or media supplemented with polybrene at 8 µg/ml. Following an initial medium change at 
approximately 15 h post infection, the selection was started 24 h post infection. 2 µg/ml 
puromycin was used for selection, as this was the lowest concentration, which effectively 
killed untransfected PC-3 cells (Figure 41). The selection medium was changed every 2-3 
days and the first colonies were usually observed 6 days post infection. At 15 days post 
infection, cells were split from one 24-well into two 6-wells to culture with and without 
puromycin, in order to determine if puromycin itself had any adverse effect on the growth 
of positively selected cells. Puromycin did not have any obvious negative effects on cell 
morphology or cell growth (Figure 43) and selection was concluded to not interfere with 
the later experiments on !-catenin knockdown. 
Stable PC-3 cell lines resulting from virus infection were named PC-3v or PC-3v43, 
PC-3v44, PC-3v45 and PC-3v46 respectively. Cells cultured in selection at the time of 
experiment, are indicated with a “+”, e.g. PC-3v43+. 
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Figure 43: Puromycin has no effect on cell morphology 
Positively selected PC-3v43 (a, b) and PC-3v45 (c, d) cells were cultured with (b, d) and without (a, c) 
puromycin. 
b 
c  
 
 
 
d  
a 
300 µm 
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4.2.3 Determination of !-catenin protein expression 
Prostate cell lines PC-3, LNCaP, P4E6, PNT2-C2 and BPH-1 as well as the colon cancer 
cell line Caco-2 were used to determine endogenous !-catenin protein levels before 
knockdown experiments were initiated (Figure 44). In addition to the predominant 
!-catenin band at 94 kDa, some nonspecific binding at lower molecular weight was 
observed, probably due to overloading of the gel. 
This was done to ensure that protein levels in the negative control (untreated cells) were at 
a detectable level for Western Blot. We postulated that !-catenin signalling may be 
responsible for giving prostate cancer cells stem cell like abilities, like enhanced 
proliferation and long-term self-renewal, which would enable them to be more successful 
during tumour establishment, invasion and metastasis formation. 
There has already been some evidence that this is an important feature in other cancers, 
including colon (Le et al., 2008). Therefore, PC-3 cells, which were originally derived 
from a prostate cancer bone metastasis, represented a suitable model for our experiments.  
!-catenin protein levels were compared in cell lines infected with 4 lentiviruses, all 
carrying a different shRNA targeting !-catenin (virus 43, 44, 45 and 46). 
48 h after lentiviral infection of PC-3 cells, lysates were made to determine any changes in 
!-catenin protein. In PC-3 cells viruses 43, 44 and 45 showed a reduction of !-catenin 
protein level. Apart from the main band for full-size !-catenin at 94 kDa, there was also a 
fainter, smaller second band observed in all samples (Figure 45). 
A puromycin selection was performed to generate a stable cell line, in order to analyse the 
long-term effects of !-catenin shRNAs in PC-3 cells. Infected cells were selected with 
puromycin for 8 - 9 passages post infection before cell lysates were produced. PC-3v45 
cells consistently showed a reduction in !-catenin protein level (at 94 kDa) while the 
levels in all other infected cells were variable. Statistical analysis was performed to 
determine the level of !-catenin knockdown in PC-3v cells (Figures 46 and 47). Band 
intensity was measured using ImageJ software and averages as well as standard deviation 
were calculated. The reduction of !-catenin protein in PC-3v45+ was highly significant 
compared to the uninfected PC-3 control with P < 0.01 and a downregulation of > 50 %. 
PC-3v43 and PC-3v44 cells exhibited reduced levels of the protein, however, this was not 
statistically significant. 
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These experiments suggest that lentivirus 45 was most effective at reducing !-catenin 
protein levels in PC-3 prostate cancer cells. This virus was therefore the choice when 
infecting cultured primary cells from patient samples at a later stage. 
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Figure 44: !-catenin expression in different cell lines 
Identification of !-catenin protein (94 kDa) in whole protein lysates with antibody C2206 (Sigma). 
!-actin loading control at 42 kDa. 
 
 
 
Figure 45: !-catenin knockdown in PC-3 cells 48 h post infection 
Western Blot in PC-3 using antibody C2206 (Sigma) for the detection of total !-catenin (94 kDa). 
!-actin loading control at 42 kDa. 
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Figure 46: !-catenin expression in stable transfected PC-3v cells 
Representative immunoblot with !-catenin (94 kDa) targeting antibody C2206 (Sigma) and !-actin 
loading control (42 kDa). Whole protein lysates of PC-3 cells infected with lentiviruses 43, 44, 45 and 
46 and under selection at time of experiment (+). Cell line controls: (uninfected) PC-3, LNCaP and 
BPH-1, plus primary epithelial (PE) culture 07/021. For statistical analysis see figure 47. 
 
 
Figure 47: PC-3v45+ showed a significant reduction of !-catenin 
Statistical analysis of a triplicate of Western Blot experiments (see Figure 46) to determine !-catenin 
protein levels in stable transfected cell lines. p-value of PC-3v45+ was p = 0.0079. 
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4.2.4 Lentiviral infections of P4E6 and LNCaP prostate cancer cells 
In order to have a wider variety of stably transfected prostate cancer cell lines, two more 
cell lines were subjected to infection experiments. P4E6 cells, derived from primary 
prostate cancer cells after transfection of the HPV E6 gene (Maitland et al., 2001) and the 
androgen-sensitive LNCaP, originally derived from a lymph node metastasis, were both 
chosen for these experiments. These two cell lines represent different stages of tumour 
differentiation and would therefore give valuable insight into the importance of !-catenin 
at different times in tumour development. Furthermore, P4E6 cells contain a CD133+ 
subpopulation which has previously been established as a model for prostate cancer stem 
cell studies using lentiviruses (Hager et al., 2008). 
In parallel, PC-3, P4E6 and LNCaP were infected at MOI=10 with shRNA-containing and 
control viruses. These control viruses included the TurboGFP® expression lentivirus 
(Sigma, MISSION Control Transduction Particle SHC003V; referred to as 3V below), a 
scrambled shRNA control (2V) and an empty vector without shRNA (1V). 
 
First, whole cell lysates were taken 3 days post infection. Cells were also selected using 
2 !g/ml puromycin. No stable cell lines were obtained from LNCaP cells.  
Lysates of selected PC-3 and P4E6 were made at P. 3 or 4, between 19 and 23 days post 
infection, depending on growth. Protein knockdown was observed in PC-3 and P4E6 cells 
(Figure 48). 
Cells infected with the shRNA - !-catenin virus 45 exhibited a downregulation of 
!-catenin, confirming the results of earlier experiments. Control viruses 1V (empty 
vector), 2V (scrambled shRNA) and 3V (GFP) showed minor reductions at P. 1 post 
infection, which was no longer detectable in the stable PC-3v cells at P. 16/17 post 
infection (Figure 48). Similarly, P4E6 cells infected with control viruses showed minor 
reductions. We observed a strong decrease of !-catenin protein in cells infected with 
shRNA - !-catenin virus 45 (Figure 48). 
Using GFP expression from the 3V virus as a measure of successful infection, it could be 
shown that 100% of puromycin-selected P4E6 cells had taken up the viral genome (Figure 
49) and had a strong expression of GFP. 
To conclude, the approach used for infecting prostate cancer cell lines PC-3 and P4E6 was 
successful. We were able to obtain stable cell lines, incorporating lentivirally delivered 
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shRNAs, which were selected using puromycin. We could also show that downregulation 
of !-catenin at the protein level was stable over a long period of time and several 
passaging events. 
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Figure 48: !-catenin protein detected by C2206 antibody 
Western blot from PC-3v and P4E6v P.1 p.i. (left and middle, respectively) and stable PC-3v post 
selection (right). 
 
 
 
Figure 49: GFP expressing P4E6_3V cells 
Cells at passage 3 post infection were under selection medium containing 2 !g/ml puromycin. 
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4.2.5 Analysis of !-catenin knockdown in stable transfected cells  
4.2.5.1 Cell growth in PC-3v cell lines 
In normal development and growth, the canonical Wnt signalling pathway plays an 
important role (Peifer and Polakis, 2000). It has been shown previously, that siRNA-
mediated knockdown of !-catenin reduced the viability of hepatocellular carcinoma cells 
and compromised proliferation (Zeng et al., 2007). It has also been reported that 
hematopoietic stem cells from conditional !-catenin knockout mice showed reduced long-
term growth (Zhao et al., 2007). 
 
To determine if the reduction in !-catenin protein level had an effect on cell growth, PC-3, 
PC-3v43 and PC-3v45 were plated at 1000 cells per well into a 6-well plate. Cells of one 
well were counted every 24 h over a period of 6 days to establish a growth curve. Cells 
were not confluent up to and including day 6. 
The experiment was repeated, using two plates per cell line and analysing the average of 
these replicates (Experiment 1 and 2, Figure 50). 
Both transfected cell lines showed reduced growth. PC-3v45 showed the largest reduction 
in growth compared to PC-3v43 and non-infected PC-3. At day 6 both PC-3v45 and PC-
3v43 reached a similar growth level which was about 30% lower than that of the PC-3 
control, however, the reduction in PC-3v43 was not statistically significant (Experiment 1, 
Figure 50). PC-3 cells grew about 50% more than the lentivirus infected cells. The 
difference between PC-3 and PC-3v45 was significant with a p-value of p ! 0.05 
(Experiment 2, Figure 50). 
Therefore, we can conclude, that reduced levels of !-catenin reduces growth of PC-3 cells. 
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Figure 50: Growth analysis of PC-3v43 and PC-3v45 
Experiment 1 (top) showed that lentiviral transfected PC-3v43 and PC-3v45 cell lines exhibited 
reduced growth. Experiment 2 (bottom) showed that growth reduction in PC-3v45 is reproducible and 
statistically significant compared to uninfected PC-3 cells. 
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4.2.5.2 Effect of !-catenin knockdown on the cell cycle of PC-3v cells 
As a transcriptional regulator, !-catenin has long been shown to be responsible for the 
expression of cyclin D1. A mutated or abnormally regulated !-catenin could therefore lead 
to accumulation of cyclin D1 and a disruption of the normal cell cycle (Tetsu and 
McCormick, 1999). 
 
Initial FACS analysis of PC-3v cells at passage 16 p. i., using propidium iodide staining, 
did not show any changes in the cell cycle. The experiment was repeated with cells at P. 1, 
5 and 11 p. i. to confirm results. Cells were selected with puromycin for a minimum of 14 
days but placed under non-selective medium conditions for a minimum of 1 day prior to 
analysis. Cells in each experiment were at similar levels of confluency of around 60%. 
The analysis revealed no significant changes in the cell cycle (Figure 51). At passage 
1 p. i. there was no difference detectable (Figure 51). At passages 5 and 11 p. i. slight 
changes were observed with more PC-3v45 cells in the S-phase and less in G0/G1, 
however these changes were consistently very small (around 5%) and not significant 
enough to explain the previously observed reduction in growth (Figure 51). 
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Figure 51: Cell cycle analysis of PC-3v cells 
Percentages of PC-3v cells at passage 1, 5 and 11 post infection, in different phases of the cell cycle 
(top). Representative example of cell cycle analysis FACS trace from PC-3v cells at P. 5 p. i. Gate (R1) 
was used to remove dead cells from analysis (bottom left). Cells in G0/G1 phase (blue), S phase (green) 
and G2/M phase (pink) (bottom right). 
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4.2.6 Wnt activation and immunofluorescence !-catenin staining 
Wnt ligands cause the inhibition of the !-catenin destruction complex, which results in 
!-catenin being able to accumulate in the cytoplasm from where it translocates to the 
nucleus (Kobayashi et al., 2000). The predominant interaction partners of !-catenin in the 
nucleus are transcription factors of the TCF/LEF family (Gordon and Nusse, 2006). 
Staining for !-catenin therefore gives an indication on the status of the Wnt signalling 
pathway in the examined cells. 
 
In all experiments, !-catenin staining was detected in the plasma membrane. This was 
expected as !-catenin localises with E-cadherin (McCrea and Gumbiner, 1991, McCrea et 
al., 1991, Nagafuchi and Takeichi, 1989). The !-catenin-E-cadherin-complex is an 
essential part of cell adhesion and plays an important role in the correct formation of 
adherens junctions. It is also linked to the cytoskeleton via !-catenin (Aberle et al., 1994, 
Gooding et al., 2004, Hülsken et al., 1994, Jou et al., 1995). 
 
To optimise immunofluorescent staining of !-catenin localisation within the cell, a 
reliable positive control was required. To increase reliability and homogeneity during 
immunofluorescence, artificial activation of the canonical Wnt signalling pathway using 
20 mM LiCl or recombinant Wnt1 protein was used, as described previously (Spencer et 
al., 2006). LiCl inhibits the kinase GSK3!, which forms part of the !-catenin destruction 
complex. This inhibition allows !-catenin to accumulate and translocate to the nucleus 
(Klein and Melton, 1996). 
The osteosarcoma cell line SaOS-2, which was recommended as a positive control for 
Wnt activation (personal communication Paul Genever), was activated for 24 h with 
20 mM LiCl. SaOS-2 cells showed nuclear !-catenin staining following activation (Figure 
52). Using the imaging software ImageJ, the amount of colocalisation of !-catenin with 
the nuclear DAPI stain was visualised (Figure 52). Activated SaOS-2 cells, treated for 
24 h with LiCl, showed a considerable increase in colocalisation, compared to the negative 
control, which was treated with NaCl. It was noted that some SaOS-2 cells exhibited a 
weaker response to activating conditions (Figure 52). These results confirmed that 
immunofluorescence can be used to detect active Wnt signalling. 
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Wnt activation experiments were also performed in prostate cell lines PC-3, LNCaP and 
PNT2-C2 cells. No nuclear !-catenin staining was observed in PC-3 cells under activating 
conditions (Figure 53). LNCaP cells did not attach firmly to slides and most cells were 
either lost or destroyed during the staining procedure (Figure 54). In PNT2-C2 cells, some 
nuclear staining was observed but results remained inconclusive (Figure 54). 
Caco-2 cells were also stained for !-catenin in order to determine whether they can be 
used as a positive control for nuclear staining. However, the cells grew in very tightly 
packed colonies, and did not show any nuclear staining. Membrane staining was observed 
(Figure 55). 
 
The results obtained from prostate cell lines might give an indication of the importance of 
!-catenin with regard to Wnt signalling, as no nuclear staining (active canonical Wnt 
pathway) was observed in most samples. They also suggest that another function of the 
protein might be a prominent factor in prostate cancer, such as the E-cadherin-!-catenin 
complex, which is not directly influenced by LiCl activation. 
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Figure 52: !-catenin staining in activated SaOS-2 cells 
SaOS-2 were activated for 24 h with 20 mM LiCl (top), 20 mM NaCl served as a negative control 
(bottom). Colocalisation of !-catenin (red, Alexa568) staining in the area of the nucleus (blue, DAPI) 
indicated as white dots on corresponding colocalisation images (far right) by arrows. 
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Figure 53: !-catenin staining in activated PC-3 cells 
PC-3 were activated for 24 h with 100 ng/ml Wnt1 protein or 20 mM LiCl for 24 h, according to the 
method used by Spencer and colleagues (Spencer et al., 2006). Negative controls included 24 h 
incubation with medium containing 20 mM NaCl, medium only and staining with secondary antibody 
only. 
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Figure 54: !-catenin staining in activated LNCaP and PNT2-C2 
Prostate cancer cell line LNCaP and normal prostate cell line PNT2-C2 were activated with 100 ng/ml 
recombinant Wnt1 protein for 24 h.  
 
 
Figure 55: !-catenin staining of Caco-2 colony 
Z-series of a Caco-2 colony stained for !-catenin (green) and nuclei visualized with DAPI (blue). The 
cells grow very close together and !-catenin is observed in the middle (A, arrows) and on the edges of 
the colony (B, arrows) as a membranous staining. 
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4.2.7 TOPFlash reporter assay to monitor Wnt activity 
TOP-flash reporter assays (Molenaar et al., 1996) and the later developed SuperTOPFlash 
reporter plasmids have been widely used. These plasmids are luciferase reporters of 
!-catenin-mediated transcriptional activation, and therefore able to detect active Wnt 
signalling. We used three reporter plasmids, each based on the pTA-Luc vector 
(Clontech), harbouring a TA viral promoter to drive the expression of the firefly luciferase 
gene. Each plasmid also contains multiple TCF/LEF recognition sites (sequence: 
AGATCAAAGG, followed by a spacer gggta), where !-catenin can bind to. The plasmid 
MO50 (Super8XTOPFlash) contains 8 recognition sites, while its partner MO51 
(Super8XFOPFlash), containes 8 mutated sites (Veeman et al., 2003), in order to be used 
as a negative control. MO72 (Super16XTOPFlash) contains 16 recognition sites 
(DasGupta et al., 2005). 
 
Prostate cell lines PC-3, P4E6 and PNT2-C2 (as well as SW480 and Hela control lines) 
were transfected with reporter plasmids MO50, MO51 and MO72. The cells were 
activated with 20 mM LiCl 24 h post transfection, or 20 mM NaCl (negative control) and 
a luciferase assay was performed 24 h post activation (Figure 56, 57 and 58). 
 
Activated PC-3 cells exhibited a 12-22 fold change in luciferase with MO50 and MO72 
respectively, compared to the luciferase expression in cells transfected with the negative 
control plasmid MO51, which was normalised to 1. Without activation, however, PC-3 
cells did not show !-catenin activity above the background level (Figure 56 and 58). This 
is probably due to the expression of the endogenous Wnt inhibitor Dkk-1 in PC-3 cells 
(Emami and Corey, 2007, Hall et al., 2005). The fold-change in Hela cells was in a similar 
range (Figure 56). 
LiCl-treated SW480 showed a much higher luciferase activity than PC-3 cells with a fold 
change of over 900 (Figure 57). In contrast to PC-3 cells, SW480 showed a high 
background activity of !-catenin even in non-activated conditions (data not shown). 
It was concluded therefore that there were no or very low levels of residual active 
!-catenin in PC-3 cells. 
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Figure 56: TOPFlash assay in PC-3 and Hela cells 
Cells were activated with 20 mM LiCl. Fold change in luciferase activity normalised to negative 
control plasmid Super8XFOPFlash (MO51), set to 1. 
 
 
Figure 57: TOPFlash assay in SW480 cells 
Cells were activated with 20 mM LiCl. Fold change in luciferase activity normalised to negative 
control plasmid Super8XFOPFlash (MO51), set to 1. 
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Figure 58: Luciferase activity measured in TOPFlash assay in PC-3 cells 
PC-3 cells transfected with TOPFlash plasmids 8XTOP (MO50), 8XFOP (MO51) or 16XTOP (MO72) 
were activated with 20 mM LiCl or 20 mM NaCl, and compared to transfected but not activated cells 
(neg.), PC-3 cells only treated with TransIT trasnfection reagent and PC-3 cells only. Values shown 
are units of luciferase activity. 
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To summarise, we have seen that active !-catenin levels in PC-3 cells are very low, but 
we were able to successfully activate these cells using LiCl. Upon activation, the 
TOPFlash reporter assay was used to detect the level of Wnt signalling activity. These 
results confirm observations made using IF, where we were not able to detect nuclear 
!-catenin staining in PC-3 cells. 
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4.2.8 Reduction of invasive potential in PC-3v cells 
Currently, there is no cure for metastatic prostate cancer, which shortens patient survival 
and negatively impacts on quality of life. As such, metastatic prostate cancer is a priority 
for novel therapeutic strategies (Moro et al., 2008). 
Therefore, studying the invasive potential of cancer cells is important to determine how 
successful they are at escaping the confines of the original tumour and metastasising to 
other parts of the body. During the process of epithelial-mesenchymal transition (EMT), 
among other changes, gene mutations and variation in expression in cadherins and 
catenins, occur in epithelial tumour cells. This facilitates their ability to invade 
surrounding tissue (Friedl and Wolf, 2003). 
In order to determine the invasive potential of sh-!-catenin (PC-3v45) cells, which 
exhibited reduced !-catenin protein levels, invasion assays were performed. In brief, cells 
were plated into matrigel coated inserts and placed into wells containing conditioned 
medium for an incubation period of 48 h. Inserts without the addition of matrigel served as 
a control for measuring motility (see Figure 59 for a schematic of the experimental 
layout). 
Cells that had migrated through the matrigel to the bottom side of the insert’s PET 
membrane (Figure 60) were counted by eye using a cell count analysis tool (ImageJ) 
(Figure 61). Images were taken of 4 random fields per membrane and cell counts were 
averaged. After optimisation of positive and negative control cell lines, it was decided to 
use normal, non-invasive prostate epithelial cells (PNT1A) as a negative control and the 
highly invasive, metastatic breast cancer cell line MDA-MB-231 as a positive control. 
One of the important technical aspects of the invasion assay experiments was the 
reliability of cell counting, to determine the number of cells, which had invaded through 
the matrigel and/or the membrane. Automated counting using the NIS Elements software 
(Nikon) was abandoned in favour of manual counting. After comparing both methods, it 
was found that the latter gave more consistent results. In our experience, the NIS software 
is a good way of counting a whole membrane with small to medium amounts of invasive 
cells. However, if the cell density is too high, the software did not distinguish between 
clumps of cells and debris. Modifications to the set-up are possible, for example, to 
exclude large conglomerates of nuclei or oddly shaped (not round) nuclei, however, this 
then reduced the number of actually counted cells. This reduced the number of counted 
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cells to a falsely lower number. Depending on the individual membrane, results were 
therefore often biased in favour of highly invasive cell lines. 
After analysing the number of invasive cells, PC-3v45 cells showed a significant reduction 
compared to the scrambled control (Figures 62, 63, 64, 65 and 67). Numbers of cells that 
invaded varied between experiments though they always showed the same trend. 
It is advisable to take motility of cells into account when looking at their invasiveness. 
Highly motile cells can still be non-invasive if they do not express the necessary proteases 
to digest matrigel. In addition, invasive cells which are less motile than another invasive 
cell line, will take longer to invade and consequently, might show lower numbers in the 
invasion assay. Therefore it is reasonable to analyse invasiveness with respect to motility 
of each cell line and look at these ratios in addition to invasion-only numbers (Figures 66 
and 68). However, in contrast to the reduction of invasive capacity by !-catenin shRNA, 
there was no significant difference observed in motility. 
 
 
 
 
Figure 59: Invasion assay experimental layout 
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Figure 60: Invasion assay cell counts 
Representative examples of images from invasion assay membranes with Matrigel of PNT1A, 
MDB-MB 231 PC-3-sh-scrambled (PC-3_2V) and PC-3-sh-!-catenin (PC-3v45) with counted cell 
numbers in brackets, e.g. (6). Cell nuclei shown in blue (DAPI). 
 
  
 
 
 
 
Figure 61: Invasion assay cell counting with ImageJ 
Representative examples of counting highly invasive cells using ImageJ cell counter tool. Each cell was marked manually (coloured dots) and was then 
automatically added to the cell count by the software. 
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Figure 62: Invasion sh-!-catenin vs. sh-scrambled control cells (I) 
Invasion capacity of sh-!-catenin (PC-3v45) cells compared to sh-scrambled control cells (PC-3_2V), 
measured as cell number per membrane, not normalised to motility. 
 
Figure 63: Invasion sh-!-catenin vs. sh-scrambled control cells (II) 
Invasion capacity of sh-!-catenin (PC-3v45) cells compared to sh-scrambled control cells (PC-3_2V) 
and the negative, non-invasive PNT2-C2 cells, measured as cell number per membrane, not 
normalised to motility. 
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Figure 64: Invasion sh-!-catenin vs. sh-scrambled control cells (III) 
Invasion capacity of sh-!-catenin (PC-3v45) cells compared to sh-scrambled control cells (PC-3_2V) 
and the negative, non-invasive PNT2-C2 cells, measured as cell number per membrane, not 
normalised to motility. 
 
Figure 65: Invasion sh-!-catenin vs. sh-scrambled control cells (IV) 
Invasion capacity of sh-!-catenin (PC-3v45) cells compared to sh-scrambled control cells (PC-3_2V), 
negative, non-invasive PNT1A cells and positive, highly invasive MDA-MB-231 cells, measured as cell 
number per membrane, not normalised to motility. 
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Figure 66: Invasion vs. motility in sh-!-catenin cells (I) 
Invasion capacity normalised to motility (in %) of sh-!-catenin (PC-3v45) cells compared to 
sh-scrambled control cells (PC-3_2V), negative, non-invasive PNT1A cells and positive, highly 
invasive MDA-MB-231 cells. 
 
 
Figure 67: Invasion sh-!-catenin vs. sh-scrambled control cells (V) 
Invasion capacity of sh-!-catenin (PC-3v45) cells compared to sh-scrambled control cells (PC-3_2V) 
and negative, non-invasive PNT1A cells, measured as cell number per membrane, not normalised to 
motility. 
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Figure 68: Invasion vs. motility in sh-!-catenin cells (II) 
Invasion capacity normalised to motility (in %) of sh-!-catenin (PC-3v45) cells compared to 
sh-scrambled control cells (PC-3_2V), negative, non-invasive PNT1A cells and positive, highly 
invasive MDA-MB-231 cells. 
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To summarise, we have shown here that !-catenin knockdown also reduced invasion in 
PC-3 cells. It did not however have an effect on the motility of cells. It is therefore 
possible to hypothesise that !-catenin plays an important part in (metastatic) prostate 
cancer, where a high invasion capacity is a major growth advantage for tumour cells. Even 
if !-catenin expression is at a relatively low level, e.g. PC-3 cells compared to MDA-MB 
231 cells, knockdown of !-catenin has a dramatic and significant effect on invasion. 
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4.2.9 Effects of !-catenin knockdown in xenografts 
4.2.9.1 PC-3v tumour growth in mice 
In order to examine tumour induction and growth in vivo, the stably transfected PC-3 cell 
lines PC-3v45 (sh-!-catenin) and PC-3_2V (sh-scrambled) as well as untransfected PC-3 
cells were injected subcutaneously into GC-1-RAG2 !c -/- mice. Each group consisted of 
3 animals and tumour growth was measured at regular intervals from the time point of 
first, visible tumour detection. The procedure was carried out by Dr Anne Collins, Paul 
Berry and Katy Hyde. 
In the PC-3 control, the first tumour was detected on day 16 post injection with a lengths 
of 5.8 mm. By day 21 all three mice had measurable tumours of 5.0-5.8 mm. The average 
size of PC-3 tumours at day 65 post injection was 14.95 mm (Figure 69). The scrambled 
shRNA control cells produced a tumour in one mouse by day 16 (5.8 mm) and the second 
tumour developed by day 23 (6.0 mm). The final mouse showed a detectable tumour on 
day 28 (5.0 mm). The third tumour was considerably smaller than those in the other two 
mice and its growth rate varied more than in any of the other xenografts. There was also 
some regression of growth observed. Tumours from the scrambled control grew to an 
average size of 12.67 mm at day 65 post injection, with two tumours at 15 mm and the 
third tumour at 8 mm (Figure 70). 
In contrast to both controls, the sh-!-catenin cell line PC-3v45 did not produce measurable 
tumours until day 18, and the first tumour was 4 mm in length, and therefore smaller than 
the initial tumours in both controls. The second and third mice exhibited measurable 
tumour growth on day 23, when all tumours were 5 mm in length (Figure 71). However, 
the growth of sh-!-catenin xenografts had caught up with the controls by day 25 (Figure 
72). The average size of PC-3v45 tumours was 16.48 mm on day 65 post injection. This 
indicated a delay in tumour induction with reduction of !-catenin (Figure 72, insert). 
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Figure 69: Tumour growth in mice injected with PC-3 control cells 
 
 
Figure 70: Tumour growth in mice injected with sh-scrambled (PC-3_2V) control cells. 
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Figure 71: Tumour growth in mice injected with sh-!-catenin (PC-3v45) cells. 
 
 
  
 
 
 
 
Figure 72: Tumour growth in mice compared 
Tumour size was averaged per time point. Tumour growth after injection of sh-!-catenin (PC-3v45) cells was delayed and did not catch up with 
controls until day 25 (see arrows in insert). 
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To conclude, although sh-!-catenin (PC-3v45) xenografts produced tumours of the same 
size as scrambled and negative control cells, these tumours occured at a later time point. 
This is a promising result, as it indicated that the knockdown of !-catenin in sh-!-catenin 
(PC-3v45) tumours caused changes in the tumours cells, which were significant enough to 
result in delayed tumour induction. To study this phenomenon in more detail, xenografting 
a larger cohort of mice would be advantageous. 
 
4.2.9.2 Relation between !-catenin knockdown and !-actin protein expression 
Xenografted mice were sacrificed once tumours reached 15 mm in length or were 
restricting movement of the animals. Tumours were then processed to deplete them from 
any infiltrated mouse cells. Non-epithelial cells, e.g. blood cells, were also extracted to 
gain a pure human epithelial cell population. Lysates were made of the depleted xenograft 
cells, which were then subjected to Western Blot, to detect !-catenin. As in previous 
Western Blot experiments, !-actin was used as a loading control. We were not able to 
detect !-actin in sh-!-catenin lysates from mouse A and F (Figure 73). Therefore 
!-catenin knockdown could not be measured in relation to the loading control !-actin. 
At this point, no further conclusions could be drawn as the results above were preliminary 
and only covered a small number of xenografted tumours. For future experiments, 
alternative loading controls which are not related to the !-catenin/E-cadherin/!-actin 
cytoskeletal complex, such as GAPDH, should be used. 
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Figure 73: Western Blots from xenograft tumours 
Western Blot of cell lysates made from xenograft tumours. No !-actin bands were detected in sh-
!-catenin lysates (mouse A and F, red arrows). 
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4.3 !-catenin studies in primary prostate cells 
4.3.1 Reanalysis of microarray data 
For most cancers, it is widely accepted now, that there is a small population of tumour 
initiating stem cells, the cancer stem cells, which are responsible for tumour maintenance, 
formation of metastasis and recurrence post therapy. Genetic profiles of tissue stem cells 
and various tumours, including prostate, have been obtained over the last years, to 
elucidate the genetic events, which lead to tumour initiation (Birnie et al., 2008, Forsberg 
et al., 2006, Hwang-Verslues et al., 2008, Lukacs et al., 2008, Marquardt and 
Thorgeirsson, 2010, Menicanin et al., 2009, Nelson, 2004). 
For this project, microarray data obtained in our laboratory and published by Birnie et al. 
was reanalysed to examine the expression of genes involved in Wnt signalling. We were 
particularly interested in any expression differences between the stem cell population and 
the committed basal population of malignant prostate tumours. We focussed on samples 
with a Gleason score of 7 and above, because gene expression differences were very clear. 
When Gleason 6 was included the differences were not clear. 
Even though there was considerable variation in the data obtained from primary tumour 
samples, there was a clear trend for higher !-catenin expression in the proposed prostate 
cancer stem cell population (CSC; CD133+ phenotype), than in the malignant committed 
basal population (CB; !2"1low phenotype) (Figure 74, Table 12). The average expression 
level in CSC was more than 60% higher than in the CB population. 
The same trend was also observed in the expression of two different microarray probes for 
TCF4, the direct downstream target of activated !-catenin. TCF4 was expressed to a lesser 
extent in the CB cells than in the CSC population. Expression differed between 30 % and 
50 % (Figure 74, Table 12). 
Since mutations in the tumour suppressor gene APC are rarely found in prostate cancer 
(Brewster et al., 1994, Watanabe et al., 1996), it was not surprising to note that APC 
expression results from the microarray did not differ between the two populations (Table 
12). Similarly to the analysis of !-catenin expression, the variation of expression levels 
between the same populations of different tumour samples was high. Expression was also 
analysed for GSK3B, the kinase, which phosphorylates !-catenin prior to degradation. 
GSK3B expression varied among the different probes and no clear trend was seen. It also 
showed 10 % to 15 % variation between the different populations (Table 12). Expression 
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levels of Axin, one of the major proteins of the !-catenin destruction complex, remained 
the same between the two populations with only a minor difference of about 6 % (Table 
12). 
Target genes of !-catenin mediated Wnt signalling include MYC (c-myc) and CCND1 
(Cyclin D1) (Chien et al., 2009). Cyclin D1 showed a very high expression level. It was 
expressed to a slightly higher extent in the CB population although the variation between 
samples was again very high (Table 12). MYC expression remained the same in CSC and 
CB cells with a minor difference of about 0.7 % (Table 12). 
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Figure 74: Gene expression of !-catenin (CTNNB1) and TCF4 in CSC and CB cells 
Differences in gene expression of !-catenin (top) and TCF4 (bottom) between CSC and CB cells from 
from 9 prostate tumour samples (Gleason 7 and above). Reanalysed Affimetrix gene expression 
microarray data (Birnie et al., 2008). 
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Gene Name CSC CB 
Change in 
expression 
APC Adenomatous polyposis coli 246.0 238.0 3.4% 
AXIN1 Axin 1 85.1 80.3 6.0% 
940.3 1063.3 -11.6% 
GSK3B 
  
Glycogen synthase kinase 
3 ! 
  592.6 514.0 15.3% 
CTNNB1 !-catenin 153.7 95.3 61.3% 
387.7 304.2 27.4% 
238.3 157.5 51.3% 
465.0 515.9 -9.9% TCF4 
  
T cell factor 4 
  365.3 435.7 -16.2% 
2087.6 2363.1 -11.7% CCND1 
  
Cyclin D1 
  683.0 780.3 -12.5% 
MYC c-Myc 894.8 888.8 0.7% 
 
Table 12: Gene expression of genes involved in canonical Wnt signalling 
Average gene expression levels according to microarray data from 9 prostate tumour samples 
(Gleason 7 and above). Levels are given for the CD133+ CSC population as well as the !2!1low CB 
population. The percentage (change of expression) indicates to what extent the gene is higher or lower 
(-) expressed in CSCs compared to CB cells, where expression was set to 100%. Rows indicate 
expression levels of separate microarray probes of the same gene (Birnie et al., 2008). 
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4.3.2 Immunofluorescence for !-catenin in primary prostate cultures 
As microarray results indicated that !-catenin was differentially expressed in the 
committed basal (CB) and stem cell (CSC) populations of prostate tumours 
("2!1low / CD133- vs. "2!1hi / CD133+), one of the aims of this project was to determine 
the effect of downregulation of !-catenin in the prostate CSC population, using shRNA-
lentiviruses. The scientific question we wanted to answer was if downregulation of 
!-catenin changed CSCs with regard to growth, invasive properties and metastases 
formation. 
Downregulation at the protein level had to be visualised in order to evaluate experimental 
results. However, since the CSC population consists of a very small number of cells 
(about 0.1% of the whole tumour), standard Western Blot, was not feasible, as this method 
requires large amounts of cells.  
Cultured primary tumour cells were therefore examined with immunofluorescence for 
!-catenin. Cells were stained with antibodies for total !-catenin (C2206; 6B3), 
dephosphorylated, active !-catenin (anti-ABC clone 8e7) and phosphorylated !-catenin 
(Phospho-!-Catenin (Ser33/37/Thr41); Phospho-!-Catenin (Ser552)). 
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4.3.2.1 Immunofluorescence for total !-catenin 
Primary prostate tumour samples and benign prostate hyperplasia (BPH) samples were 
stained to identify !-catenin location within the cells. Depending on its function within the 
cell, either the regulation of cell adhesion, or signal transduction through the Wnt 
pathway, there are two different pools for !-catenin in the cytoplasm. 
When bound to PSEN1 and cadherin, !-catenin is associated with the actin cytoskeleton 
and therefore serves as part of the cell adhesion complex. If, however, !-catenin is 
associated with AXIN, APC and GSK3B, it is phosphorylated and subsequently degraded 
in the proteasome, as part of an inactive Wnt signalling pathway. This signalling cascade 
becomes active through Wnt ligands, which results in a stabilised, dephosphorylated 
!-catenin, which translocates to the nucleus, where it binds to members of the TCF/LEF-1 
family of transcriptional regulators (Shitashige et al., 2008) (Figure 75). Therefore, 
determining the location of !-catenin, already gives an indication of its activity and 
function within a cell. 
 
Cultured, primary cells were plated onto collagen-coated chamberslides without the 
addition of STO feeder cells. Cells were fixed after 2 h-4 h to ensure adherence and 
minimise any effects of the non-feeder culture conditions. Two secondary antibodies 
(Alexa 488, green and Alexa 568, red) were tested in combination with primary antibody 
C2206 for immunofluorescence. !-catenin was detected in the cell membrane with both 
secondary antibodies, however, Alexa 568 gave a slightly stronger signal and was 
therefore used in subsequent experiments (Figure 76). !-catenin was clearly detectable on 
the cell membrane in all samples, indicating that it was serving its function in the cell 
adhesion complex (Figures 77 and 78). 
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Figure 75: !-catenin localisation within the cell 
Aberrantly active Wnt signalling can cause !-catenin to accumulate in the cytoplasm and nucleus, 
where it can be detected by immunofluorescent staining (Modified from Shitashige et al. 2008). 
 
 
  
 
 
 
Figure 76: !-catenin staining in sample 007/08 (I) 
Images taken of BPH sample 007/08 fixed in 4% FA solution and stained for !-catenin using antibody C2206 and secondary antibody Alexa 488 (A, 
green) or Alexa 568 (B, red). Cell nuclei were stained with DAPI (blue). 
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Figure 77: !-catenin staining in sample 010/08 
Confocal micrograph of sample 010/08 stained for !-catenin (C2206, red). Extended focus image (left) and image of middle section (right) of z-series, 
nuclei stained with DAPI (blue). 
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Figure 78: !-catenin staining in sample 007/08 (II) 
Confocal micrograph of BPH sample 007/08 stained for !-catenin (C2206, red), localised at the 
membrane, nuclei stained with DAPI (blue). 
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As we wanted to examine the location of !-catenin in the proposed prostate cancer stem 
cell subpopulation (CD133+), immunofluorescence experiments were extended to cultured 
primary cells, which had been fractionated by immunomagnetic selection. Cells were 
selected, then plated onto collagen-coated chamberslides without the addition of STO 
feeder cells and fixed within 2-4h, prior to staining. 
 
We observed mainly cytoplasmic staining for !-catenin, but also membranous staining in 
both the CSC and CB population (Figures 79 and 81). Using ImageJ software for 
colocalisation, !-catenin was found to localise with the nuclear DAPI stain in most cells of 
the CSC subpopulation (Figure 80). There was also a considerable size difference between 
most of the CSC and the CB cells. Many CSC appeared ‘flattened’ out and bigger than the 
other populations, which indicated differentiation (Figure 80). This is a common 
phenomenon when cells are plated without feeder cells. Colocalisation images revealed 
that there was nuclear staining in both populations (Figures 80 and 81), but that there was 
a higher percentage of cells with nuclear !-catenin in the CSC population than in the CB 
population, when counted by eye. CB cells generally were more variable in the extent of 
their nuclear !-catenin staining (Figure 81). 
 
Results imply that !-catenin is still fulfilling its different functions within the cells, being 
found both in the cytoplasm and on the cell membrane. The variable but still slightly 
higher appearance of nuclear !-catenin in the CSC population compared to the CB 
population suggests that !-catenin’s function as a transcriptional activator might be more 
important there, than its role as an adhesion molecule. 
However, variable results were observed for both populations and !-catenin might 
therefore also be a feature of different stages of differentiation of cells within the same 
subpopulation. 
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Figure 79: !-catenin staining in CSC subpopulation 
Representative confocal micrographs of CSC from primary sample 525 stained for total !-catenin 
(red), using antibody C2206. Nuclei stained with DAPI (blue). 
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Figure 80: Colocalisation of !-catenin within the nucleus in CSC subpopulation 
Colocalised image of cells from primary sample 525 stained for total !-catenin, using antibody C2206 
(see previous figure). Colocalised image points are indicated as white spots within nucleus (arrows). 
 
  
 
 
 
Figure 81: !-catenin staining in CB subpopulation 
CB population of primary sample 525 stained with C2206 !-catenin antibody (red). Colocalisation of !-catenin with nuclear DAPI stain (blue) (image 
on far right, arrows). 
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Figure 82: !-catenin staining in CB subpopulation (secondary antibody control) 
CB population of primary sample 525, secondary antibody control, including colocalisation (image on far right). 
 
  
 
 
 
 
 
 
 
          164 
            Sarah Jakoby 
 
 
 
 
 
 
 
        PhD
 thesis 2010 
Sarah Jakoby  PhD thesis 2010 
 165 
4.3.2.2 Immunofluorescence for dephosphorylated and phosphorylated !-catenin 
The phosphorylation status of !-catenin is controlled via the canonical Wnt signalling 
cascade (van Noort et al., 2002). Therefore, Staal and colleagues developed an antibody to 
specifically detect !-catenin, when it is dephosphorylated at Serine 37 and Threonine 41 
(Staal et al., 2002). The antibody anti-active !-catenin (anti-ABC) has since been made 
commercially available through Millipore (hybridoma clone 8E7). 
As previous dilutions of anti-ABC antibody (1:50 and 1:100) were not successful, a 
dilution of 1:25 was used on selected CB cells of samples 042/08 and 045/08 (Figures 83 
and 84). We observed nuclear !-catenin in cells treated with anti-ABC antibody but as 
with previous results, the cells exhibited some heterogeneity even within the same 
subpopulation and sample (Figures 83 and 84). 
Apart from anti-ABC, three other antibodies were used for staining, 6B3 (total !-catenin), 
Phospho-!-Catenin (Ser33/37/Thr41) and Phospho-!-Catenin (Ser552) (see Table 13 for 
overview). 
Phospho-!-Catenin (Ser33/37/Thr41) specifically detects endogenous levels of !-catenin 
when it is phosphorylated at serines 33, 37 or threonine 41. Phosphorylation is catalysed 
by GSK-3! and happens after the phosphorylation of !-catenin by CK1 on Ser45 (Amit et 
al., 2002, Liu et al., 2002, Morin et al., 1997, Yanagawa et al., 2002, Yost et al., 1996). 
Phospho-!-Catenin (Ser552) antibody specifically detects !-catenin, which is 
phosphorylated at Ser552. This phosphorylation occurs through either Akt or PKA and 
leads to !-catenin accumulation in the nucleus, which increases its transcriptional activity 
(Fang et al., 2007, He et al., 2007, Taurin et al., 2006). 
In the primary patient samples examined, antibody 6B3 resulted in cytoplasmic staining in 
the majority of cells, however, extensive nuclear staining was also observed. There was 
some distinct peri-nuclear staining but no membranous staining observed (Figure 85). 
Phospho-!-Catenin (Ser552) antibody staining was observed in the area of the nucleus, 
which indicated its potential for increasing !-catenin transcpriptional activation. 
Furthermore, there was also clear cytoplasmic staining detected in almost all cells (Figure 
86). 
The staining observed with antibody Phospho-!-Catenin (Ser33/37/Thr41) was 
predominately cytoplasmic and nuclear (Figure 87). These phosphorylation sites (Serine 
33, Serine 37 and Threonin 41) are used by GSK-3! to destabilise !-catenin prior to its 
degradation in the cytoplasm (Yost et al., 1996). Even though the nuclear distribution was 
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contradictory to the current literature, which suggests that phosphorylated !-catenin is 
rapidly degraded, it has been reported previously, in invasive breast cancer cell lines 
(Nakopoulou et al., 2006). In one of our samples, staining was particularly weak and few 
conclusions could be drawn from these results (Figure 87). 
 
  
 
 
Name Detection Function Results References 
anti-active !-
catenin (anti-ABC) 
clone 8E7 
!-catenin dephosphorylated 
at Ser37 or Thr41 
Active form (Wnt 
signalling pathway) 
Weak nuclear, some 
cytoplasmic 
Staal et al. 2002 
6B3 Total !-catenin Various Cytoplasmic, nuclear, 
peri-nuclear, 
membranous 
http://www.cellsignal.com/ 
products/9582.html 
Phospho-!-catenin 
(Ser33/37/Thr41) 
!-catenin phosphorylated at 
serines 33, 37 or threonine 
41 
GSK-3! destabilises 
!-catenin for 
degradation 
Some nuclear, 
inconclusive 
Amit et al. 2002; Liu et al. 
2002; Yanagawa et al. 
2002; Yost et al. 1996; 
Morin et al. 1997 
Phospho-!-catenin 
(Ser552) 
!-catenin phosphorylated at 
Ser552. 
Induction of !-catenin 
accumulation in the 
nucleus and increase in 
transcriptional activity 
Nuclear, cytoplasmic Taurin et al. 2006; Fang et 
al. 2007; He et al. 2007 
Table 13: Phospho-!-catenin antibodies, their function and IF results 
            Sarah Jakoby 
 
 
 
 
 
 
 
        PhD
 thesis 2010 
  
 
 
 
 
 
 
 
          167 
  
 
 
 
 
Figure 83: CB cells stained with anti-ABC antibody 
Confocal images of sample 045/08, stained for active !-catenin (red), including colocalisation of !-catenin with nuclear DAPI stain (blue) (image on far 
right, white arrows). 
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Figure 84: CSC and CB cells stained with anti-ABC antibody 
Nuclei stained with DAPI (blue). Nuclear staining of !-catenin (red) indicated by white arrows. CSC 
(bottom row) and CB (top and middle row), secondary antibody control (middle left). 
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Figure 85: !-catenin (6B3) staining in CB subpopulation of primary sample 042/08 and 045/08 
Confocal micrograph of cells stained for total !-catenin (red), using monoclonal antibody 6B3. Nuclei 
stained with DAPI (blue). Sample 042/08 (top, 2 rows) and 045/08 (bottom, 2 rows). Arrows indicating 
nuclear and peri-nuclear staining. 
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Figure 86: Phospho-!-catenin (Ser552) staining in CB subpopulation of primary sample 042/08 and 
045/08 
Confocal micrograph of cells stained for Ser552-phosphorylated !-catenin (red). Nuclei stained with 
DAPI (blue). Sample 042/08 (bottom, 2 rows) and 045/08 (top, 2 rows). Arrows indicating nuclear 
staining. 
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Figure 87: Phospho-!-catenin (Ser33, 37, Thr41) staining in CB subpopulation of primary sample 
042/08 and 045/08 
Confocal micrograph of cells stained for phosphorylated !-catenin, at Ser33, Ser37 or Thr41 (red). 
Nuclei stained with DAPI (blue). Sample 042/08 (bottom, 1 row) and 045/08 (top, 2 rows). Arrows 
indicating nuclear staining. 
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4.3.3 Infection of primary prostate epithelial cells with shRNA-lentiviruses 
4.3.3.1 Targeting lentiviruses to primary cells 
Our experiments on PC-3 cells had shown successful application of commercially 
available lentiviruses for knocking down !-catenin, resulting in slower growth in culture 
and reduced tumour take in mice. Just like gene-expression profiles which should ideally 
be produced from primary tumour cells, and not cell lines (Pardal et al. 2003), we wanted 
to repeat the infection experiments on cultured primary cells to obtain data which would 
be more closely related to actual conditions in the patient. 
 
Using a gfp expressing lentivirus (3V), the transfection efficiency of commercially 
available shRNA-lentiviruses in primary prostate epithelium was examined. Cells were 
selected in puromycin-containing medium from day 3 post infection (p. i.) and they were 
monitored during selection (Figure 88, day 2 and figure 89, day 7). Most were flattening 
out to some extent from early in the selection (Figure 88) and the selection was continued 
for a total of 22 days. 
FACS was performed at day 18 p. i. (Figures 90 and 91). The rate of successful infection 
as measured by gfp expression was low, between 1.6 and 1.7 % (Figure 91). Selection did 
not influence the number of cells expressing gfp and no extensive cell death was observed 
in gfp-expressing cells, as measured by DAPI staining (Figure 90). 
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Figure 88: Primary sample 030/09 infected with gfp-expressing control lentivirus (3V), day 2 of 
puromycin selection. 
 
  
 
 
 
Figure 89: Primary sample 030/09 infected with gfp-expressing control lentivirus (3V), day 7 of puromycin selection 
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Figure 90: FACS analysis of primary sample 030/09 (I) 
Sample 030/09 infected with gfp-expressing control lentivirus (3V, green arrows) at day 18 of puromycin selection, with DAPI (B, blue arrows) and 
without DAPI (A). 
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Figure 91: FACS analysis of primary sample 030/09 (II) 
Micrographs of sample 030/09 (pre FACS analysis) and FACS analysis (right) to determine infection efficiency of gfp-expressing control lentivirus (3V) 
at day 18 of puromycin selection (right). 
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4.3.3.2 Phenotypic changes in shRNA-lentiviruses infected primary cells 
During consistent visual monitoring of primary cells infected with shRNA-lentiviruses, 
we observed, that undifferentiated colonies of epithelial cells did not express gfp. These 
colonies consisted of small, tightly-packed cells with a distinct light edge and could be 
clearly distinguished form the more differentiated, flattened epithelial cells (indicated by 
white arrows in figures), which did express gfp (Figures 92 and 93). 
Non-infected cells, which were always monitored as an additional control during 
infections, showed mostly tightly-packed colonies (Figure 94), while cells infected with 
sh-!-catenin-lentivirus and the scrambled control virus (Figures 95 and 96) usually 
exhibited more flattened cells as well as some distinct colonies (indicated by red circles in 
figures). 
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Figure 92: Phenotypic changes in lentiviruses infected primary prostate epithelium under puromycin 
selection (I) 
Sample PE Y 061/09 infected with 3V lentivirus (GFP) at day 3 of puromycin selection, showing 
undifferentiated colonies (red circles) and more differentiated, gfp expressing cells (arrows). 
 
 
 
 
Figure 93: Phenotypic changes in lentiviruses infected primary prostate epithelium in SCM (I) 
Sample PE Y 061/09 infected with 3V lentivirus (GFP) post puromycin selection showing flattening of 
cells (arrows). 
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Figure 94: Phenotypic changes in lentiviruses infected primary prostate epithelium in SCM (II) 
Sample PE Y 061/09 non-infected cells, showing undifferentiated colonies (red circles). 
 
 
 
Figure 95: Phenotypic changes in lentiviruses infected primary prostate epithelium in SCM (III) 
Sample PE Y 061/09 cells infected with scrambled control sh-lentivirus (top) and sh-!-catenin-
lentivirus (bottom), showing undifferentiated colonies (red circles) and some flattened out, more 
differentiated cells (white arrows). 
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Figure 96: Phenotypic changes in lentiviruses infected primary prostate epithelium under puromycin 
selection (II) 
Sample PE Y 061/09 cells infected with scrambled control sh-lentivirus (top) and sh-!-catenin-
lentivirus (bottom), showing mostly flattened out, more differentiated cells (white arrows) and some 
undifferentiated colonies (red circles). 
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Cultured primary prostate cells were repeatedly, successfully infected with sh-lentiviruses. 
They were also successfully drug-selected, however, their growth eventually ceased and 
no further experiments (examining invasion or cell death, for example) could be 
performed due to lack of cell numbers. Most infected primary cells also grew larger and 
flattened out during the selection process, which indicated terminal differentiation. 
Nevertheless, the potential for valuable data obtained from primary cancer cells is very 
important and future attempts should focus on improved infection conditions or modified 
viruses to overcome these obstacles. 
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5. Discussion 
The overall aim of this study was to develop a tool to target prostate cancer cells using 
shRNA-containing lentiviruses, with a view to study the outcome of targeted gene 
knockdown in the prostate cancer stem cell (CSC) subpopulation. CSCs represent 
promising targets for new therapies, as they are the population within a tumour that shows 
a high potential for tumour initiation (Maitland and Collins, 2008a). Similar properties to 
those of normal stem cells, such as self-renewal and longevity, have also been attributed to 
CSCs. Recently, Bae and colleagues found that factors which are normally expressed in 
pluripotent stem cells, including OCT3/4, Nanog and SOX2, could be found in potential 
prostate tumour initiating cells (Bae et al., 2010). Semiquantitative RT-PCR was used on 
DU145 and PC-3 prostate cancer cell lines and patient tissue to evaluate the expression of 
several reprogramming factors. The cells, which were enriched by FACS for E-cadherin 
were confirmed to have cancer stem cell-like characteristics in soft agar, spheroid and 
tumorigenicity assays. The potential prostate tumour initiating cells from DU145 and 
PC-3 also showed a high tumourigenicity in mice. In vivo growth was inhibited by the 
application of shRNA knockdown of OCT3/4 or SOX2 (Bae et al., 2010). 
 
As a proof of principle, we developed fluorescent reporter gene-containing 
shRNA-lentiviruses to target PSCA, a highly expressed gene in the abundant committed 
basal (CB) subpopulation of prostate cancers. 
However, thanks to the commercial availability of custom-made shRNA-lentiviral 
particles, we were able to study the biological effects of !-catenin knockdown in the 
prostate cancer cell line PC-3. To achieve this, we successfully infected PC-3 cells and 
generated stable knockdown cell lines, which showed reduced growth, decreased 
invasiveness and slower tumour growth kinetics in mice. Furthermore, we achieved 
infection of cultured primary prostate cells with commercial shRNA-lentiviruses. 
 
In the following chapter, the outcomes of this study will be discussed, highlighting 
potential future uses with respect to studying !-catenin knockdown in primary prostate 
cells and the potential to develop future therapeutic tools. 
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5.1 Development of lentiviral vectors with reporter-shRNA-constructs 
The aim of this study was to develop functional lentiviral particles that contained a 
fluorescent reporter gene as well as an shRNA against a chosen target. At the beginning of 
our study commercial vectors combining shRNAs and fluorescent reporters were not 
available, which made it necessary for us to develop our own constructs. 
Due to the small number of cancer stem cells within the bulk population of a tumour (0.3 
– 1.6 %), (Collins et al., 2005), the need to develop methods to monitor this population 
during development of new therapeutic tools becomes necessary. 
Fluorescent reporters have been used extensively to track not only cancer cells both in 
vitro and in vivo, but they have also been applied for cell tracking of embryonic and adult 
stem cells (Consiglio et al., 2004, Stuelten et al., 2007, Sun et al., 2009, Wu et al., 2006). 
Previous studies from our laboratory have shown that prostate CSCs could be tracked 
using lentiviral constructs containing the fluorescent reporter genes mOrange and citrine 
(Frame et al., 2010, Hager et al., 2008). 
Delivery of genetic material in vivo is often problematic, however, dual-targeted 
lentiviruses have been shown to successfully infect prostate cancer bone metastases in 
SCID mice. Transgene expression in the liver was 190 times lower, emphasising the site-
specific transgene expression possible with these vectors (Pariente et al., 2007). When 
C4-2 prostate tumour xenografts were treated intratumorally or intravenously with 
trastuzumab-bound lentivirus harbouring a prostate specific promoter, targeting was 
highly specific as shown via viral gene expression in xenografted tumours (Zhang et al., 
2009b). 
Furthermore, the application of RNA interference tools gives hope for the development of 
cancer treatments, which are highly specific and could one day potentially become patient-
specific as well (Mullenders and Bernards, 2009, Rolle et al., 2010, Stege et al., 2010). 
For this study, the more abundant CB population was used initially to establish a working 
methodology, before moving on to CSCs. Microarray data was available, which 
highlighted strong expression of the glycosylphosphatidylinositol-anchored cell membrane 
glycoprotein PSCA in the large population of CB cells in patient tumours (Birnie et al., 
2008). Due to PSCA expression being upregulated in a large proportion of both androgen-
dependent and –independent prostate tumours (Reiter et al., 1998), PSCA was chosen as 
our initial target for shRNA-mediated downregulation. 
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We therefore developed shRNA-containing lentiviruses harbouring three different 
sequences to target PSCA. The Gateway technology (Hartley et al., 2000) was employed 
to generate VSV-G pseudotyped self-inactivating lentiviruses containing a fluorescent 
reporter construct (mOrange or citrine) and a PSCA- or control-shRNA under the control 
of the U6 promoter. 
The fluorescent reporter constructs (CMV promoter, fluorescent gene, polyA) were cloned 
into the pENTR 5’ TOPO vector. The downstream polyadenylation signal (polyA) from 
simian virus 40 (SV40), used as part of the reporter expression cassettes, has been shown 
to aid stability of transgene expression (Maxwell et al., 1991, Narita et al., 2000, 
Shimotohno and Temin, 1981). In our laboratory, it increased fluorescent reporter 
expression in producer cells as well as target cells infected with CMV-mOrange 
lentiviruses (Hager et al., 2008). Dual gene expression from lentiviral vectors, using 
transcriptional units which included a polyA signal, have been succesfully used in 
epidermal keratinocytes, bone marrow mesenchymal stem cells and hair follicle stem cells 
(Tian and Andreadis, 2009). 
However, it has also been shown that the polyA signal, which can cause truncation of the 
full-length viral genome (Shimotohno and Temin, 1981), reduces lentiviral titer in CMV 
and inducible promoter containing constructs (Hager et al., 2008, Liu et al., 2010b). 
Ultimately, increase in fluorescent protein expression was deemed to be the most 
important feature for tracking purposes. 
 
After confirmation of the correct inserts for pENTR-CMVmOrangeA and pENTR-
CMVcitrineA, sequencing confirmed that the expression cassette was located in opposite 
orientation to the remaining reading frames on the plasmid backbone (3.1.1). This meant 
that following recombination with the shRNA-construct-containing plasmid, the resulting 
expression vector contained both expression cassettes in opposite orientations. 
It has long been understood that transcriptional interference can cause a decrease in 
expression levels in tandem promoter constructs (Greger et al., 1998, Proudfoot, 1986). 
Having the two promoters in opposite orientation could therefore be beneficial as it was 
previously shown that, to yield satisfactory expression levels, expression constructs could 
be arranged in opposite reading frame orientation (Maetzig et al., 2010). 
However, Eszterhas and colleagues found that there was a difference between convergent 
and divergent arrangement of promoters which were facing in opposite directions. In 
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addition, the integration site as well as the gene’s orientation within the integration site 
played a role in suppressing expression in double constructs (Eszterhas et al., 2002). 
To optimise constructs for future studies, vectors could be modified to harbour so-called 
insulator sequences (Bell et al., 2001). Under natural circumstances, promoter interference 
is avoided by separating genes using these DNA sequences. Insulators have been shown to 
reduce the effect of transcriptional interference between two promoters within the same 
construct, including in lentiviral vectors (Hasegawa and Nakatsuji, 2002, Tian and 
Andreadis, 2009). Examples of insulators include MAR (beta-interferon matrix attachment 
region) (Girod et al., 2007), H19ICR (H19 imprinting control region) (Yoon et al., 2007) 
and cHS4 (chicken hypersensitive site 4) (Arumugam et al., 2007, Arumugam et al., 2009, 
Urbinati et al., 2009). 
 
Our aim was to use shRNAs with a stem loop of 29 nucleotides, which had the advantage 
of increased specificity over 21mer constructs (Kim et al., 2005b, Siolas et al., 2005). This 
could potentially reduce the number of side effects due to off-target effects, if constructs 
were to be used in patients in the future. Established design protocols (Invitrogen 
BLOCK-iT! RNAi Designer) were applied to generate shRNA constructs using 
published sequences (Origene HuSH 29mer RNAi collection).  
Confirmation of hairpin constructs by sequencing can prove challenging and these 
challenges have been reported widely in the literature (Devroe and Silver, 2002, Guo et 
al., 2005, McIntyre and Fanning, 2006, Miyagishi et al., 2004, Yu et al., 2003). Taxman 
and colleagues developed strategies for optimal sequencing of such constructs (Taxman et 
al., 2006). Some problems during sequencing were also observed in this study in the first 
instance. 
Initial sequencing attempts resulted in break off after a few base pairs into the hairpin 
structure. After consulting the sequencing company about alternative methods, sequencing 
conditions were successfully optimised, and sequencing confirmed the correctness of our 
constructs. We achieved the generation of multiple clones for most plasmids. 
Plasmids were then tested for functionality of the fluorescent reporter, which was 
confirmed by transfection into prostate cells, pre and post recombination. Following this 
we produced infectious lentiviral particles. The titres obtained were considerably lower 
than suggested by the manufacturer. We successfully improved lentiviral titres by time 
course titration, using the Invitrogen Lentiviral Gateway Kit. However, titres obtained 
were still too low to conduct successful infection experiments. With the present titres, a 
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larger volume of crude virus supernatant than was available at the time would have to be 
used in order to gain a suitable MOI. Poluri and Sutton also described the low titre 
phenomenon in shRNA-lentiviruses. They found that HIV-based vectors encoding for 
shRNAs produced a 30-fold lower titre than the comparable empty vector controls (Poluri 
and Sutton, 2008). Even after much trouble-shooting and discussion with Invitrogen by 
colleagues and myself regarding optimal virus production, no reassurance was given that 
titers could be improved. 
Suggestions for improving lentiviral titres are readily available in the literature and span a 
variety of methods. First of all, inhibitors of the dicer-dependent RNAi pathway could be 
employed. One example for increasing titres was to include the adenovirus VA.1 RNA 
(Andersson et al., 2005) or the nodamura virus B2 protein (Sullivan and Ganem, 2005). 
Including these components increased titres to levels similar to the empty vector control 
(Poluri and Sutton, 2008). Co-expression of RNA-silencing suppressors of viral and plant 
origin (VP35, E3L, NS1 or P19, respectively) have been used to increase HIV-1 virus 
yield in HEK293 cells (de Vries et al., 2008, Haasnoot et al., 2007). 
A similar line of thought uses (over-) saturation of the RNAi pathway in the cell. In 
accordance with the above findings, Liu and colleagues reported recently, that saturation 
of the RNAi pathway could be used to rescue vector production (Liu et al., 2010b). 
Furthermore, the amount of shRNAs within one plasmid could be increased to 5, or 
plasmids harbouring an shRNA target decoy, with the corresponding shRNA sequence, 
could be co-transfected into virus producing cells (Liu et al., 2010b). To inhibit the RNAi 
pathway in producer cells directly, siRNAs targeting Dicer (Paddison et al., 2002), or 
shRNAs against Drosha (Liu et al., 2010b) have been investigated. It is still controversial 
whether self-targeting in shRNA vectors, is a major cause for titer reduction (Poluri and 
Sutton, 2008, Zhou et al., 2009), due to the fact that different lentiviral vector systems 
have been studied, thus preventing direct comparison of the results. 
Lastly, promoters used for expression of genes contained on lentiviral vectors have been 
under discussion in the literature for some time now, including their role in titre reduction 
of RNA vectors. In one study it was found that the lentiviral production system used for 
miRNA vectors seemed to be incompatible with the CMV promoter. Replacement of this 
promoter with a tetracycline inducible promoter increased titres up to 400-fold (Liu et al., 
2010b). Improvements could therefore be achievable by exchanging the CMV promoter 
for another universal, e.g. eF1! or "-actin, or prostate tissue specific promoter (PSA/Pb), 
as has been shown in a recent study (Hager et al., 2008). 
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Even though improvement of viral titres was achieved through protocol optimisation, no 
high titre stocks could be produced. However, commercial shRNA-lentiviruses (Sigma 
Mission® shRNA lentiviral particles) became available at that time and we chose to use 
these particles, in order to move on to studies of biologically relevant functions in prostate 
cells treated with shRNA lentiviruses. This enabled us to focus on the main aim of this 
study – the investigation of pathways relevant in prostate CSCs. !-catenin was chosen for 
developing this study further, because of its relevance in signalling and cell-adhesion in 
cancers and its role in cell differentiation in embryonic stem cells (Birnie et al., 2008, 
Cleton-Jansen et al., 2009, Jiang et al., 2007, Kanwar et al., 2010, Lu et al., 2009, Mishra 
et al., 2009, Takahashi-Yanaga and Kahn, 2010, Wang et al., 2010). 
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5.2 Generating prostate cancer cell lines with stable !-catenin 
knockdown 
We were interested in how !-catenin and Wnt signalling affect prostate tumours and 
especially their relevance to the prostate CSC population. Our primary aim was to produce 
a suitable cell line model for the knockdown of !-catenin to study its biological effects 
and to investigate possibilities to carry these experiments forward into cultured primary 
cells, for the first time. 
It has been shown in colon cancer that invasiveness might be the principal trait most 
commonly associated with potential CSCs. Fodde and Brabletz showed that the cells at the 
invasive front of a tumour contained more nuclear !-catenin than the rest of the tumour 
cells, thus providing evidence that !-catenin/Wnt-signalling might have an important role 
in the invasive property of CSCs (Fodde and Brabletz, 2007). 
The PC-3 prostate cancer cell line was chosen, as these cells were derived from a bone 
metastasis (Kaighn et al., 1979) and therefore represented an aggressive form of prostate 
cancer, providing us with a good model in which to study biological features such as 
invasiveness. Additionally, tumour growth from PC-3 cells can also be studied in 
immunocompromised mice, where they can give rise to metastases (Waters et al., 1995). 
In addition, the prostate cancer cell lines LNCaP and P4E6, representing different stages 
of prostate cancer differentiation (Horoszewicz et al., 1980, Horoszewicz et al., 1983, 
Maitland et al., 2001) were also used in this study. As PC-3 cells were the most robust and 
gave highly reproducibly results, these cells were taken further into biological studies. 
Another reason for choosing PC-3 cells was that they represent an androgen-independent 
prostate cancer model (Kaighn et al., 1979). This was important as we wanted to continue 
our studies in primary prostate cancer cells, particularly the CSC population, which do not 
express androgen receptor (Maitland and Collins, 2008b). PC-3 cells were therefore closer 
to our long-term study model than other cell lines, such as the androgen responsive 
LNCaP cells (Horoszewicz et al., 1980, Horoszewicz et al., 1983).  
We successfully generated stable cell lines harbouring an shRNA against !-catenin or a 
scrambled control, respectively, the former showing stable knockdown at the protein level 
over the course of antibiotic selection and long-term culture. 
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The stability of knockdown achieved (3.2.4), due to the integration of lentivirally 
transferred expression cassettes into the DNA of infected cells, permitted experiments on 
long-term cultures. 
 
5.2.1 Lentiviruses as the vector of choice 
Lentiviruses integrate into their host cell genome upon infection, therefore providing a 
tool for long-term studies. They are also able to infect both dividing and non-dividing 
cells, which gives them an advantage over other viral vectors (Buchschacher and Wong-
Staal, 2000). As (cancer) stem cells are either dormant or only very slowly dividing, and 
we decided to target the CSC population in prostate cancer as the ultimate aim of this 
study, lentiviruses seemed an obvious choice. Furthermore, lentiviruses containing 
shRNAs have recently been used to study the Wnt signalling pathway in different cell 
lines, including prostate cancer cells (Fiorentino et al., 2008, Yochum et al., 2010, Zeng et 
al., 2008). 
The commercial viruses we used for this study (Sigma Mission® shRNA lentiviruses) have 
now been used extensively in cancer research. They have been shown to infect CSCs in 
human glioma (Bao et al., 2008), leading to growth arrest during a kinase screening study 
(Yang and Stockwell, 2008) and were able to suppress growth and metastasis formation in 
pancreatic cancer (Wei et al., 2008). Sigma lentiviruses have been used in prostate cancer 
cell lines, including PC-3 and LNCaP, to study growth arrest (Gray et al., 2007), apoptosis 
(Elis et al., 2008) and hormone refractory prostate cancer. The latter showed that shRNAs 
targeting the ErbB3-binding protein and AR corepressor EBP1 in stable transfected 
LNCaP cells promoted a hormone refractory phenotype. Knockdown also cancelled out 
growth arrest caused by ErbB3 ligand heregulin (HRG), in cells which would normally 
undergo apoptosis upon HRG treatment (Zhang et al., 2008b). 
When PC-3 cells were infected with shRNA-lentiviruses for !-catenin a consistant 
knockdown of !-catenin was observed at the protein level in puromycin selected stable 
cells. Stable knockdown of !-catenin resulted in decreased cell growth in prostate cells but 
no changes to the cell cycle. 
The double bands, which we observed at ~ 75 kDa and ~ 92 kDa during Western Blot 
experiments using total !-catenin antibody C2206 (Sigma), were reported previously by 
Rios-Doria and colleagues as a characteristic of metastatic prostate tumours, as well as 
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several prostate cancer cell lines, including PC-3 (see 4.2.3, figure 45). The smaller 
(75 kDa) fragment represents a proteolytic !-catenin fragment, which was closely 
associated with expression of calpain, a calcium-dependent protease. Calpain caused 
proteolytic cleavage of the N-terminal regulatory domain of !-catenin. This takes place in 
metatstatic prostate cancer and might be a mechanism by which !-catenin is activated 
during tumour expansion. This would also be one explanation why in most prostate, and 
also breast cancers, !-catenin mutations are rare but !-catenin activity has been widely 
reported (Rios-Doria et al., 2004). Initial observations during the transient infection phase 
before the establishment of stable clones, indicated an shRNA induced slower growth in 
treated cells, so we examined this more closely in several experiments. Growth of cancer 
cells can give some indication of their aggressiveness and any growth reduction in treated 
cells would therefore be a positive result of the treatment. 
After the generation of stable shRNA expressing cell lines, growth curve experiments to 
compare PC-3-sh-!-catenin cells (PC-3v45) and the scrambled control were carried out. 
For these experiments, cells were no longer under puromycin-containing selection 
medium, but they had been selected prior to the experiment, to ensure that only cells 
which express the lentivirally transfected constructs, would be examined. 
!-catenin knockdown did indeed affect proliferation of stable PC-3-sh-!-catenin cells, and 
a statistically significant growth reduction compared to the scrambled control was 
observed (p ! 0.05). This is in line with recently published reports (Jiang et al., 2009, Liu 
et al., 2010a). Jiang and colleagues used shRNA expression plasmids, with the shRNAs 
under a U6 promoter, which were transfected into cells with Lipofectamine. They 
examined the knockdown of !-catenin in human gastric carcinoma cell lines, e.g. AGS, 
and observed suppression of cell proliferation (Jiang et al., 2009). They were also able to 
use the treatment to induce apoptosis, which is in line with further reports by Liu et al. It 
was shown that !-catenin knockdown not only inhibited proliferation in malignant glioma 
cells, but it also caused the induction of apoptosis and a cell cycle arrest in the G0/G1 
phase (Liu et al., 2010a). 
Based on the observed reduced growth in the stable knockdown cell line PC-3v45, 
changes in the cell cycle in these cells were measured next. However, no major effect, 
such as a cell cycle arrest, which could have explained the growth reduction seen in the 
stable cell line, was found. 
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To summarise, the experiments showed that lentivirus targeted !-catenin expression 
knockdown, caused a reduction in cell growth in PC-3 cells. As lentiviral infection and 
expression of small dsRNA can by itself perturb cell metabolism, e.g. by induction of an 
interferon response (Bridge et al., 2003, Stark et al., 1998), experiments always included a 
non-targeting, scrambled shRNA lentivirus control. 
In the future, an apoptosis assay could determine whether the reduced cell counts, which 
were observed here, were due to increased apoptosis. This is unlikely however, as no 
obvious increase in cell death was observed in PC-3v cells compared to the scrambled 
control when cells were visually examined every 1-2 days during the experiment. This 
suggests that induction of apoptosis may not have been the predominant factor of growth 
reduction as reported elsewhere (Jiang et al., 2009, Liu et al., 2010a). 
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5.2.2 Monitoring Wnt pathway activity in PC-3 cells 
PC-3 cells were stained for total !-catenin in native and activated state. Compared to the 
positive control (SaOS-2 cells), PC-3 cells did not show nuclear !-catenin staining.  
This absent Wnt activity in PC-3 cells is in line with reports on how canonical Wnt 
signalling contributes to bone metastases in prostate cancer. Active Wnt signalling causes 
new bone formation and osteoblastic metastases. However, PC-3 cells generally form 
osteolytic bone lesions. The cells have been shown to express not only a number of 
different Wnts but also high amounts of Wnt antagonist Dkk1 (Hall et al., 2005, Li et al., 
2008b), resulting not in osteoblastic, but osteolytic phenotypes. In addition, experiments 
to modify Wnt signalling by various methods (natural and synthetic inhibitors or Wnt 
antagonists, receptor modifications, adenoviral gene therapy approach) showed a 
suppression of growth and invasiveness in these cells (Davies et al., 2000, Fishman et al., 
2003, Giladi et al., 2007, Grandy et al., 2009, Lu et al., 2010, Zi et al., 2005). This 
highlights the importance of the Wnt signalling pathway and its antagonists in androgen-
independent prostate cancer cells like PC-3. 
In order to confirm the immunofluorescence results, the Topflash assay, which is 
commonly used for examining !-catenin activity (Korinek et al., 1997), was successfully 
employed to measure Wnt activity in PC-3 cells. We found that, through external 
activation using LiCl, PC-3 cells transfected with either 8XTOPFlash or 16XTOPFlash 
plasmids, responded with a luciferase read-out of 12-22 fold higher than the negative 
control (NaCl) (3.2.7). However, if PC-3 cells were not artificially activated, !-catenin 
activity was too low to be detected by this assay. As reviewed above, due to the 
abundance of Wnt inhibitor Dkk1 (Hall et al., 2005, Li et al., 2008b), this was an expected 
result and confirmed previous immunofluorescence experiments. 
 
5.2.3 Decreased invasion in stable sh-!-catenin cells 
To determine the cause of growth reduction we saw in sh-!-catenin (PC-3v45) cells, the 
role of !-catenin, which did not directly relate to the Wnt pathway, was investigated next. 
Apart from being the major molecule of the canonical Wnt signalling pathway, !-catenin 
also plays an important role in cell adhesion and control of E-cadherin (Hülsken et al., 
1994). 
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As cell motility requires the involvement of extra-cellular matrix molecules like 
E-cadherin, it seemed logical to examine motility and also invasiveness in our model. 
Although there were no differences in motility found between PC-3v45 and the scrambled 
control, the differences in invasiveness were significant. PC-3v45 cells showed much less 
invasiveness than the control cells in a matrigel invasion assay. 
The observations are in line with other reports where inhibition or modification of the Wnt 
pathway lead to a reduction of invasiveness (Davies et al., 2000). Zi and colleagues 
showed, for example, that treating PC-3 cells with Wnt antagonist sFRP3 (soluble 
Frizzled-related protein 3), resulted in growth reduction and decreased invasiveness. They 
also showed that cell-cell contacts were upregulated upon treatment and the cells 
expressed more epithelial markers. From these observations, it was concluded that 
treatment with a Wnt antagonist reversed epithelial to mesenchymal transition (EMT). In 
accordance with this, lower expression of mesenchymal markers was found (Zi et al., 
2005). Similar observations of a reversal of EMT in prostate cancer have also been 
reported by several other groups (Acevedo et al., 2007, Jiang et al., 2007, Shah et al., 
2009, Yee et al., 2010). 
Invasion assays also showed that there was no significant difference in motility between 
PC-3v45 and control cells. However, measuring motility as well as invasiveness gave us 
the advantage of ruling out any ‘masking’ effects due to incomparable motility of different 
cell lines (3.2.8). Highly motile cells statistically have a higher chance than their less 
motile counterparts to find pores in the invasion assay membrane. Even if the expression 
of matrigel degrading enzymes in those cells was lower than in a more invasive cell line, 
motility would give them some advantage. 
 
5.2.4 Delayed tumour onset in mice and protein expression in xenografts 
Having seen significant changes in growth and invasiveness, an initial, small-scale in vivo 
experiment was carried out. As PC-3 cells readily form subcutaneous tumours in 
immunocompromised mice (Havens et al., 2008), this method was chosen as our next 
experiment, to gather valuable in vivo data for tumour growth. 
After injecting PC-3v45 and control cells (scrambled, uninfected) subcutaneously into 
immunocompromised mice, tumour growth was monitored and tumour size measured. 
Here, a delayed onset of tumour growth in the PC-3v45 mice was seen when compared to 
controls. This was a noteworthy result, as reduced tumour growth in animal studies is 
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often the first step towards future clinical studies for cancer therapies (Fishman et al., 
2003). As each group of mice in our pilot study only consisted of 3 animals, no statistical 
analysis was possible.  
To analyse the amount of !-catenin protein in tumours taken from mice, lysates were 
made of the depleted xenograft cells and subjected to Western Blot. As with the previous 
Western Blot experiments, !-actin was used as a loading control. In two mice tested, no 
!-actin was detected along !-catenin, while in the remaining mice both proteins were 
clearly visible on the blots. This observation raised the question whether downregulation 
of !-catenin was interfering with the actin cytoskeleton in tumour cells. 
Apart from its essential function in canonical Wnt signalling, !-catenin is also part of the 
E-cadherin transmembrane complex in epithelial cells. !-catenin binds to the highly 
phosphorylated intracellular domain of E-cadherin, thus making this region vital to the 
correct functioning of the protein. As part of this complex, !-catenin can also bind 
!-catenin, therefore linking E-cadherin cell-junctions with actin-containing cytoskeletal 
filaments, which are often adjacent to adherens junctions in epithelial cells (Aberle et al., 
1994, Gooding et al., 2004, Hülsken et al., 1994). Loss of function or reduced expression 
of E-cadherin has been shown to contribute to cancer progression and metastasis (Beavon, 
2000, Hazan et al., 2004, Wijnhoven et al., 2000). This has also often been linked to 
genetic alterations of !-catenin, which reduced or abolished interaction with the 
E-cadherin/!-catenin complex (Kawanishi et al., 1995, Oyama et al., 1994). Highly 
metastatic tumour cell lines are known to usually express low levels of E-cadherin 
(Bukholm et al., 1998, Pignatelli et al., 1994) and they also often show a more fibroblast 
like morphology, mostly due to poor differentiation (Wijnhoven et al., 2000). 
Future experiments could therefore include knockdown experiments of !-catenin followed 
by dual or triple IF staining for !-actin/E-cadherin or !-actin/!-catenin/E-cadherin, 
respectively. 
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5.3 Targeting primary prostate cells with shRNA-lentiviruses 
Following the successful !-catenin knockdown experiments in the PC-3 cell line, the last 
aim was to apply the now established protocol to primary prostate cells, which were 
cultured directly from patient tumours. This was done to see whether any effects seen in 
cell lines were applicable or relevant in patients. Accordingly, primary cells were infected 
with commercial lentiviruses. 
 
The integration of lentiviral cDNA into the host cell genome is not only the first step in 
the natural life cycle of retroviruses, it is also one of the most challenging aspects when 
employing lentiviral gene transfer as a therapeutic method. Side effects due to integration 
site position have been reported regularly, since the first human gene therapy trials (Baum 
et al., 2003, Seggewiss et al., 2006). Retroviruses do not select their integration site at 
random. A clear preference has been shown for transcriptionally active sites or regulatory 
regions, which are relevant to cell growth, differentiation and development, thus 
increasing the possibility for unwanted side effects (Felice et al., 2009, Montini et al., 
2009). 
In general, lentiviruses are suitable for infecting and replicating in non-dividing or slowly 
dividing cells, like adult stem cells. However, one of the hurdles of infecting primary 
cells, especially stem cells, with lentiviruses is the tendency of the cells to differentiate 
when placed in culture and also their fragility (Paré and Sherley, 2006). This fragility 
could be enhanced even further through immunomagnetic selection of the CSC 
population. Ideally, the prostate CSCs would be selected from the total tumour population 
and infected to compare the effects of silencing to CB cells. Due to the fragility of the 
cells however, whole populations of primary prostate tumour cells, including CSC and CB 
cells were infected. This mimics the situation in a tumour, when mixed cell populations 
would have to be transduced. 
To overcome any integration site specific effects, various methods have been suggested, 
which were shown to work in haematopoietic stem cells and progenitor cells. These 
include using a ubiquitously acting chromatin opening element, to enhance stable 
transgene expression (Zhang et al., 2007). Compared to CMV promoter containing 
controls, silencing of the transgene was also reduced (Zhang et al., 2007). 
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It has also been reported that external factors, such as media composition with or without 
serum, multiplicity of infection and duration of transduction were important to achieve 
transgene delivery without compromising self-renewal or multipotency of stem cells 
(Millington et al., 2009).  
To receive more consistent results, it is possible to use clonal populations of primary cells 
obtained through serial replating. The behaviour of clonal populations is usually more 
consistent than that of a mixed population (personal communication S. Hager). 
 
5.3.1 Wnt pathway microarray analysis in prostate cancer patients 
The basis for our study of !-catenin in primary cells was the reanalysis of microarray data 
obtained by Birnie and colleagues (Birnie et al., 2008). This led to the hypothesis, that 
Wnt signalling and possible deregulation of !-catenin might play an important part in 
prostate CSC maintenance and growth. In addition, as discussed above, higher amounts of 
!-catenin would also influence cell-cell-contacts and adherence through E-cadherin related 
activity (Gooding et al., 2004), and would therefore influence migration and invasion. 
Furthermore, the large number of !-catenin target genes makes it challenging to study 
individual outcomes and usually prominent examples like Cyclin D1 or cMyc are chosen 
to be examined first. 
A trend for higher expression of !-catenin was observed in the proposed prostate cancer 
stem cell population (CSC; CD133+ phenotype), compared to the malignant committed 
basal population (CB; !2"1low phenotype), although its statistical significance was 
limited by inter-patient variability. To cover prominent components of Wnt signalling, 
expression of APC, AXIN, GSK3B and TCF4 as well as of !-catenin target genes c-Myc 
and Cyclin D1 was also analysed. 
Although consistent differences in expression in both !-catenin and TCF4, which were 
both higher expressed in CSC than CB cells of primary prostate cancer samples, were 
found, no major expression differences in APC, AXIN or the two chosen !-catenin target 
genes were seen. This is in line with the literature, as mutations in APC or AXIN, which 
are very common in colorectal cancer, for example, are rarely detected in prostate cancer 
and these genes might therefore not be differentially expressed. This is especially true 
since !-catenin has been shown to be influenced during EMT and it is still under 
discussion whether this is due to a direct correlation between active Wnt signalling and 
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EMT (Jiang et al., 2007), or due to its interaction with E-cadherin in the adhesion 
complex. 
It has been shown recently, that one of the nuclear transducers of Wnt signalling, Lef-1, 
exists in two different transcripts in pancreatic cancer. On the one hand, transient 
expression of the shorter form resulted in inhibition of E-cadherin expression, which 
happened in a !-catenin independent manner. On the other hand, the full-length protein 
caused the induction of cell-cycle regulators c-Myc and Cyclin D1 (Jesse et al., 2010). 
Expression of Cyclin D1 is not directly affected, even if APC mutations occur, but its 
expression changes at a later stage. However, APC mutations seem to have a more 
imminent effect on Cyclin D2. It has been shown that Cyclin D2 plays an essential role in 
tumourigenesis post APC loss in colon cancer (Cole et al., 2010). It would therefore be 
interesting to follow up gene expression of Cyclin D2 in prostate samples and establish if 
it is affected in CSCs compared to CB cells and determine APC status of the samples at 
the same time. 
For our analysis, we plotted the average expression of 9 different patient samples and 
calculated standard deviation. One technical disadvantage when analysing and comparing 
gene expression from patient samples is, that any statistics applied, like standard 
deviation, will result in high variability, due to the high variation between individual 
patients (Pereira et al., 2010, Sontrop et al., 2009). This has to be taken into account when 
comparing results from a cohort of patients or tissue samples. However, we were still able 
to determine expression trends, especially in genes like !-catenin, where differences were 
high between the different cell populations. To reduce variation and therefore decrease the 
range of standard deviation, a larger cohort of patient samples could be analysed. 
However, depending on the availability of patient samples and the time needed for growth 
and subculturing of primary prostate cancer cells, which often show variable growth, 
further studies would have to be designed on a more long-term scale. Factors which have 
to be taken into account in any future studies, include defining tumour status by Gleason 
Grade, invasive potential of samples (invasion assay) and any pre-treatment patients 
received prior to donating tissue. Another factor which could influence data gathering is 
the low dynamic range of Affymetrix microarray chips, which can lead to small yet 
significant under-representations of fold changes in gene expression (Chang et al., 2000). 
To follow on from the microarray analysis, which only provided mRNA expression data, 
protein arrays or ChIP assays could be performed to enhance and compare data. ChIP 
assays have become a popular tool for Wnt signalling pathway studies (Lee et al., 2010). 
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ChIP would also provide a tool to monitor protein-DNA interactions and could clarify if 
there is more interaction of !-catenin with genes related to E-cadherin rather than cell 
cycle regulators, for example. 
 
5.3.2 Detection of activated !-catenin 
Staal and colleagues have shown dephosphorylation and nuclear localisation of !-catenin, 
which provided a tool for studying Wnt signalling pathway activity (Staal et al., 2002). In 
our study, the detection of nuclear !-catenin was not reliable when using an antibody, 
which has been marketed as detecting ‘active’ !-catenin (anti-ABC, Millipore). The 
present observations are in line with those reported by the manufacturer, that state that the 
antibody has been used for IF to detect !-catenin in the cytosol and membrane. However, 
this is a contradiction of the nuclear localisation of ‘active’ !-catenin. After optimisation 
and application of higher than recommended antibody concentrations with very limited 
success, we decided to omit using this particular antibody. Results were confirmed with 
colleagues from a neighbouring lab, who had discovered the same drawbacks using the 
anti-ABC antibody (personal communication Lisa Kirkwood, Southgate lab, University of 
York). These observations were in contrast to the original publication and the observations 
made by the group who developed the antibody (Staal et al., 2002). 
To overcome the limitations seen with the anti-ABC antibody, colocalisation with nuclear 
DAPI staining was used to visualise how much nuclear !-catenin was present in cells, 
using an antibody for total !-catenin (C2206, Sigma). We showed that although 
colocalisation varies both in the CSC and CB populations, higher levels of colocalisation 
were detected in CSCs. In order to provide statistical analysis for these experiments, larger 
numbers of CSCs would be necessary. The varability observed might reflect that even 
after selection for CSCs, and especially in the CB population, there might still be a mixed 
population present. One reason could be that cells at different stages of differentiation 
might express different levels of total !-catenin, which then in turn increases or decreases 
the percentage found in the nuclear compartment. Following on from this, co-staining for 
Cyclin D1 or D2 as well as staining for an established proliferation marker like Ki67 
(Fiorentino et al., 2010) or a promising new proliferation marker like SOX9 (Thomsen et 
al., 2010), could be employed. This has been shown to point to regions of low 
proliferation in colorectal adenocarcinomas (Jung et al., 2001). 
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5.3.3 Appearance of infected primary colonies 
Observations included a striking difference in appearance between infected cells, which 
expressed the GFP-expressing control lentivirus and those in the same culture, that did 
not. The latter were small and tightly packed, and colonies generally looked healthy and 
undifferentiated. Round, densely packed colonies are suggestive of being derived directly 
from stem cells (Barrandon and Green, 1987, Hudson et al., 2001). In contrast to that, GFP 
expressing cells looked flatter, more spread out and differentiated than their healthy 
looking counterparts. 
This raised the question, if the lentiviral infection itself, the selection using puromycin, or 
the expression of GFP is the reason for this phenomenon. Some cells might switch off the 
expression of GFP or the whole integrated lentiviral genome. 
That the lentivirus itself being solely responsibly for the effect observed, is not likely, as 
the healthy looking, tight colonies survived the selection. This should not have happened 
if they did not carry the resistance transfected as a transgene within the lentiviral genome. 
One medium component, which might influence the appearance of primary epithelial cells 
following lentivirus infection is the serum contained in the viral supernatant. Primary 
cells, which are normally cultured without any serum present, would undergo 
differentiation following exposure. Due to the high titres of commercial lentiviruses and 
therefore the very low amounts of supernatant used per infection, this should not be a 
problem. However, it has to be taken into account when ‘home-made’ lentiviruses are 
produced (see chapter 3.1.6). 
Of course, the expression of GFP alone could be a problem to the cells’ metabolism. 
However, without the aid of fluorescent proteins, there is no possibility to visualise or 
track infected cells. Other fluorescent proteins have been tried on primary prostate cells 
with similar effects of differentiation or growth arrest (Hager et al., 2008). 
Multiplicity of infection could contribute to the problem as well. It might be that one or a 
few integrated lentiviral vectors are enough for transferring resistance to puromycin, but 
that more integrated vectors are needed to microscopically detect GFP expression to a 
sufficient level. In addition to that, multiple integration events might cause cells to switch 
on differentiation or cell death pathways. 
The changing shape of infected cells could also be due to insertion of the lentivirus into 
particular genes or regions, or a potential interaction between !-catenin and E-Cadherin, 
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or the downregulation thereof, which has been reported in the literature (Nelson and 
Nusse, 2004). 
Primary cells infected with sh-!-catenin-lentivirus also displayed heterogeneity in cultured 
colonies. However, as these viruses do not carry a fluorescent reported gene, expression of 
lentiviral genome in different colonies could not be confirmed in the same way. 
Clonal heterogeneity might also be displayed in the culture, resulting in differences in 
GFP expression while maintaining puromycin resistance. This phenomenon has been 
reported in primary cultures of keratinocytes (Barrandon and Green, 1987), but also in 
primary prostate epithelium (Collins et al., 2001, Hudson et al., 2001, Richardson et al., 
2004) and in holoclones formed from potential tumour-initiating cells selected from the 
PC-3 cell line (Li et al., 2008a). 
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5.4 Conclusions and Outlook 
Nuclear !-catenin has been suggested as a prognostic factor in colorectal cancer and as a 
means of identifying tumour initating (stem) cells (Elzagheid et al., 2008, Fodde and 
Brabletz, 2007). This thesis produced some promising results, which indicated that 
!-catenin might also play an important role in prostate cancer. However, improvements 
are needed to develop a more reliable method for a virally transmitted knockdown, 
especially in primary cells. 
Multicistronic cotranscription has been used for some time in lentiviral systems and it has 
been shown that shRNAs expressed within a microRNA context produced efficient 
knockdown as well as providing cotranscription of a reporter gene (Stegmeier et al., 
2005). This could be employed to provide a tool for multiple targets within one transcript. 
Such a method has been developed using adenoviral delivery (Junn et al., 2010). 
One idea for multiple targets is based on a recent report by Shah and colleagues. They 
studied the calcitonin-calcitonin receptor axis in prostate cancer and found correlations 
between nuclear !-catenin accumulation, higher amounts of calcitonin mRNA in higher 
Gleason grade tumours and destabilization of cell-cell junctions, resulting in EMT (Shah 
et al., 2009). Targeting calcitonin and !-catenin together, using a multicistronic vector, 
could therefore provide insight into this interaction and might improve any future 
therapeutic applications. 
As a therapeutic delivery system, lentiviral vectors could be further improved by increased 
viral titres and infection efficiency. Recently, reports suggested that a new envelope 
glycoprotein could help attachment of virions to prostate cells (Sakuma et al., 2010). The 
XMRV (xenotropic murine leukemia virus-related virus) envelope glycoprotein is a 
promising candidate for this approach. While many tissues express XPR1, the virus’ cell 
surface receptor (Battini et al., 1999, Tailor et al., 1999), it has been found to be strongly 
associated with prostate cancer patients with a familial background of the disease 
(Urisman et al., 2006). There is also evidence that XMRV primarily infects malignant 
prostate cells, and is associated with tumours of a high Gleason grade (Schlaberg et al., 
2009). XPR1 is believed to be the most important port of entry for this virus (Bhosle et al., 
2010), making a lentiviral vector pseudoyped with the XMRV envelope an ideal candidate 
for a promising new viral approach. In addition, the association between infections with 
gammaretrovirus XMRV and prostate cancer has major implications on how researchers 
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approach prostate carcinogenesis and could potentially link tumour development to a 
sexually transmitted disease (Trottier and Fleshner, 2010). 
Alternatively, the lentiviral approach could be altered in favour of other viral vectors. 
Oncolytic viruses, such as herpes simplex, have been used to target cells with strong 
!-catenin/TCF-signalling (Kuroda et al., 2006) and a similar approach was used, 
combining oncolysis with shRNA knockdown of IL-8 in breast cancer, which resulted in 
growth reduction and antiangiogenesis (Yoo et al., 2008). 
In addition, the structure of shRNAs used could be improved as recent reports suggest that 
directly delivered shorter shRNAs with minimal length offer a suitable alternative, 
potentially decreasing any side effects during therapeutic use (Ge et al., 2010). 
Furthermore, another Wnt protein, not part of the canonical signalling cascade, Wnt5a, has 
recently had more attention in relation to its importance in prostate cancer. However, 
reports are conflicting, as Wnt5a has been shown to be more highly expressed in the 
potential prostate CSC population, alongside !-catenin (Birnie et al., 2008), while others 
reported exclusive expression of either !-catenin or Wnt5a (Yamamoto et al., 2010). 
Reports are consistent in suggesting an important role for Wnt5a in prostate cancer. 
This is in line with our results, which suggest that although !-catenin probably plays an 
important part in prostate cancer growth and invasiveness, its role in canonical Wnt 
signalling might not be of primary importance. 
 
To summarise, it was shown that !-catenin plays a role in regulating growth and 
invasiveness in the prostate cancer cell line PC-3. A stable knockdown cell line also 
delayed tumour induction in immunocompromised mice. Additionally, experiments 
showed encouraging results as well as some limitations when using shRNA-lentiviruses in 
primary prostate epithelial cell cultures. 
Our results are a promising start to elucidate the role of !-catenin in prostate cancer but 
there is still a lot of work to be done. 
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Appendices 
Appendix 1: Plasmid maps 
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Appendix 2: Composition of buffers and solutions 
General molecular biology 
 
1 x TE buffer  
10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
 
1 x TAE buffer  
40 mM Tris-acetate, 1 mM EDTA, pH 8.0 
 
6 x agarose gel-loading buffer 
0.25 % (w/v) bromophenol blue, 0.25 % (w/v) xylene cyanol FF, 30 % (v/v) glycerol in 
H2O 
 
Magnetic cell separation 
 
MACS buffer 
PBS, pH 7.2, supplemented with 0.5% foetal calf serum and 2 mM EDTA 
 
Flow cytometry 
 
FACS buffer 
2 mM EDTA in phosphate buffered saline, pH 7.2 
 
SDS-Page and Semi-dry transfer 
 
10x SDS running buffer 
250 mM Tris, 1.92 M glycine, 1 % SDS 
 
Transfer buffer A 
300mM Tris, 20 % MeOH 
 
Transfer buffer B 
25mM Tris, 20 % MeOH 
 
Immunocytochemistry 
 
TBS 
50 mM Tris-HCl, 150 mM NaCl 
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TBST 
TBS supplemented with 0.4 % (v/v) Triton X-100 
 
Reagents obtained with commercial kits 
 
! Gateway cloning 
 
Salt solution 
1.2 M NaCl, 0.06 M MgCl2 
 
Proteinase K solution 
2 µg/µl Proteinase K in 10 mM Tris-HCl, pH 7.5, 20 mM CaCl2, 50% (v/v) glycerol 
 
! Restriction buffers 
 
NEBuffer 3 (1x) 
50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, pH 7.9 
 
Promega Buffer D (1x) 
6 mM Tris-HCl, 150 mM NaCl, 6 mM MgCl2, 1 mM DTT, pH 7.9 
 
Promega Buffer H (1x) 
90 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, pH 7.5 
 
! DNA elution and storage 
 
Buffer EB 
10 mM Tris-HCl, pH 8.5 
 
! Ligation 
T4 DNA Ligase Buffer (10x) 
300 mM Tris-HCl (pH 7.8), 100 mM MgCl2, 100 mM DTT, 10 mM ATP 
 
! shRNA annealing 
10 x Oligo Annealing Buffer 
100 mM Tris-HCl (pH 8.0), 10 mM EDTA (pH 8.0), 1 M NaCl 
 
Media and solutions for bacterial work 
 
S.O.C. Medium 
2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose 
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LB medium 
10 g/l bacto-tryptone, 5 g/l bacto-yeast extract, 10 g/l NaCl in ddH2O 
 
LB agar 
10 g/l bacto-tryptone, 5 g/l bacto-yeast extract, 10 g/l NaCl, 15 g/l agar in ddH2O 
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Abbreviations 
AIDS     Acquired immunodeficiency syndrome 
anti-ABC    Anti active !-catenin 
APC     Adenomatous polyposis coli 
AR     Androgen receptor 
AXIN1    Axin 1 
bp     Base pairs 
BPH     Benign prostatic hyperplasia 
CamKII    Ca2+-calmodulin-dependent protein kinase II 
CaP     Carcinoma of the prostate 
CCND1    Cyclin D1 
CE     Convergent extension 
CD     Cluster of differentiation 
ChIP     Chromatin immunoprecipitation 
CMV     Cytomegalovirus 
CRU     Cancer research unit 
CSC     Cancer stem cell 
CSK1A1    Casein kinase 1 alpha 
CTBP1    C terminal binding protein 1 
CTNNB1    !-catenin 
Da     Dalton 
DAPI     4’,6-diamidino-2-phenylindole 
DHT     Dihydrotestosterone 
DMSO     Dimethyl sulfoxide 
DNA     Deoxyribonucleic acid  
DNase     Deoxyribonuclease 
dNTP     Deoxynucleoside triphosphate 
ds     Double stranded 
dT     Deoxythymidine 
dTTP     Deoxythymidine triphosphate 
dUTP     Deoxyuridine triphosphate    
EDTA     Ethylenediaminetetraacetic acid 
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EF1!     Elongation factor 1! 
EGFP     Enhanced green fluorescent protein 
ELISA     Enzyme-linked immunosorbent assay 
ES cell     Embryonic stem cell 
FACS     Fluorescence-activated cell sorting 
FITC     Fluorescein isothiocyanate 
fmol     Femtomole 
FS     Forward scatter 
GAPDH    Glyceraldehyde 3-phosphate dehydrogenase 
GFP     Green fluorescent protein 
GSK3B    Glycogen synthase kinase 3 " 
Hh     Hedgehog 
HIV     Human immunodeficiency virus 
HRP     Horseradish peroxidase 
HSC     Hematopoietic stem cell 
ICM     Inner cell mass 
IF     Immunofluorescence 
IP3     Inositol-1, 4, 5 –triphosphate 
JNK     Jun N-terminal kinase 
kb     Kilobases 
KSFM     Keratinocyte serum-free medium 
LB     Lysogeny broth or Luria-Bertani broth 
LTR     Long terminal repeat 
m     Monomer 
M     Molar 
MHC     Major histocompatibility complex 
MLV     Murine leukaemia virus 
min     Minute 
MOI     Multiplicity of infection 
MOPS     3-(N-morpholino)propanesulfonic acid 
mRFP     Monomeric red fluorescent protein 
mRNA     Messenger ribonucleic acid 
MYC     c-Myc 
NF-#B     Nuclear factor-kappa B 
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NOD/SCID Nonobese diabetic/severe combined 
immunodeficiency 
NSAIDs Nonaspirin nonsteroidal anti-inflammatory drugs 
PAP     Prostatic acid phosphatase 
PBS     Phosphate-buffered saline 
PBS     Primer binding site 
PCP     Planar cell polarity 
PCR     Polymerase chain reaction 
PE     Prostate epithelium 
PET     Polyethylene terephthalate 
PF     Prostate fibroblasts 
PFA     Paraformaldehyde 
PGK     Phosphoglycerate kinase 
p.i.     Post infection 
PIA      Proliferative inflammatory atrophy 
PIN     Prostate intraepithelial neoplasia 
PIC     Preintegration complex 
PIC     Protease inhibitor cocktail 
PIN     Prostate intraepithelial neoplasia 
PKC     Protein kinase C 
PLC     Phopholipase C 
poly(A) signal    Polyadenylation signal 
PPT     Polypurine tract 
PSA     Prostate-specific antigen 
PSCA     Prostate stem cell antigen 
PSEN1 Presenilin 1 
PTEN Phosphatase and tensin homolog deleted on 
chromosome 10 
PVDF     Polyvinylidene fluoride 
RNA     Ribonucleic acid 
RNAi     RNA interference 
RNase     Ribonuclease 
RRE     Rev-responsive element 
rRNA     Ribosomal ribonucleic acid 
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RT-PCR    Reverse-transcription polymerase chain reaction 
Sca     Stem cell antigen 
SCM     Stem cell medium 
SDS     Sodium dodecyl sulfate 
Shh     Sonic hedgehog 
shRNA    Short hairpin ribonucleic acid 
SIN     Self-inactivating 
siRNA     Short interfering ribonucleic acid 
SP     Side population 
SS     Side scatter 
STO SIM (sandos inbred mice) derived embryonic 
fibroblasts resistant to thioguanine and ouabain 
SV40     Simian virus 40 
SVE     Seminal vesicle epithelium 
TBS     Tris-buffered saline 
TBST     Tris-buffered saline Triton-X 100 
TCF4     T cell factor 4 
td      Tandem-dimer 
TF     Technology Facility 
TGF     Transforming growth factor 
UGE     Urogenital sinus epithelium 
UGM     Urogenital sinus mesenchyme 
UGS     Urogenital sinus 
UV     Ultraviolet 
U     Units 
V     Volt 
v/v     Volume per volume 
VSV-G    Vesicular stomatitis virus G-glycoprotein 
WPRE     Woodchuck posttranscriptional regulatory element 
w/v     Weight per volume 
XMRV    Xenotropic murine leukaemia virus-related virus 
XPR1 Xenotropic and polytropic murine leukaemia virus 
receptor 
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